

\$0.04 Estimated cost this search  
\$0.45 Estimated total session cost 0.201 DialUnits

File 6:NTIS 64-2000/Apr W1  
Comp&distr 1998 NTIS, Intl Copyright All Righ

Set Items Description  
---  
? e au=waldmann

Ref	Items	Index-term
E1	3	AU=WALDMAN, S.
E2	7	AU=WALDMAN, W.
E3	0	*AU=WALDMANN
E4	1	AU=WALDMANN, D.
E5	1	AU=WALDMANN, E. R.
E6	8	AU=WALDMANN, H.
E7	1	AU=WALDMANN, M.
E8	4	AU=WALDMANN, R. A.
E9	1	AU=WALDMANN, T.
E10	3	AU=WALDMANN, T. A.
E11	2	AU=WALDMANN, U.
E12	1	AU=WALDMEIER, M.

Enter P or PAGE for more  
? s e9,e10

	1	AU=WALDMANN, T.
	3	AU=WALDMANN, T. A.
S1	4	E9,E10

? t s1/3/all

1/3/1  
DIALOG(R)File 6:NTIS  
Comp&distr 1998 NTIS, Intl Copyright All Righ. All rts. reserv.

1445930 NTIS Accession Number: PB89-200315  
Novel Interleukin 2 Receptor and Applications Thereof  
(Patent Applicatio)  
**Waldmann, T. A.** ; Leonard, W. J.  
Department of Health and Human Services, Washington, DC.  
Corp. Source Codes: 068119000  
Report No.: PAT-APPL-7-165 302  
Filed 8 Mar 88 18p  
Languages: English Document Type: Patent  
Journal Announcement: GRAI8916  
See also PB87-218426.

This Government-owned invention available for U.S. licensing and, possibly, for foreign licensing. Copy of application available NTIS. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)321-8547; and email at orders@ntis.fedworld.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

NTIS Prices: PC A03/MF A01

1/3/2  
DIALOG(R)File 6:NTIS  
Comp&distr 1998 NTIS, Intl Copyright All Righ. All rts. reserv.

1351659 NTIS Accession Number: PB88-140231  
Method for Treating Maligancy and Autoimmune Disorders in Humans  
(Patent Applicatio)  
**Waldmann, T. A.**

Department of Health and Human Services, Washington, DC.

Corp. Source Codes: 068119000

Report No.: PAT-APPL-7-085 707

Filed 17 Aug 87 18p

Languages: English Document Type: Patent

Journal Announcement: GRAI8808

This Government-owned invention available for U.S. licensing and, possibly, for foreign licensing. Copy of application available NTIS. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)321-8547; and email at orders@ntis.fedworld.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

NTIS Prices: PC A03/MF A01

1/3/3

DIALOG(R)File 6:NTIS

Comp&distr 1998 NTIS, Intl Copyright All Righ. All rts. reserv.

1325945 NTIS Accession Number: PB87-224424

Novel Interleukin 2 Receptor and Applications Thereof

(Patent Application)

**Waldmann, T. A.**

Department of Health and Human Services, Washington, DC.

Corp. Source Codes: 068119000

Report No.: PAT-APPL-7-066 989

Filed 29 Jun 87 16p

Languages: English Document Type: Patent

Journal Announcement: GRAI8723

This Government-owned invention available for U.S. licensing and, possibly, for foreign licensing. Copy of application available NTIS. Order this product from NTIS by: phone at 1-800-553-NTIS (U.S. customers); (703)605-6000 (other countries); fax at (703)321-8547; and email at orders@ntis.fedworld.gov. NTIS is located at 5285 Port Royal Road, Springfield, VA, 22161, USA.

NTIS Prices: PC A02/MF A01

1/3/4

DIALOG(R)File 6:NTIS

Comp&distr 1998 NTIS, Intl Copyright All Righ. All rts. reserv.

1320089 NTIS Accession Number: PB87-218426

Novel Interleukin 2 Receptor and Applications Thereof

(Patent Application)

**Waldmann, T.**

Department of Health and Human Services, Washington, DC.

Corp. Source Codes: 068119000

Report No.: PAT-APPL-7-066 989

Filed 29 Jun 87 18p

Languages: English Document Type: Patent

Journal Announcement: GRAI8721

This Government-owned invention available for U.S. licensing and, possibly, for foreign licensing. Copy of application available NTIS.

NTIS Prices: Not available NTIS

? begin medtext

15mar00 08:06:04 User208760 Session D1481.3

\$1.31 0.223 DialUnits File6

\$7.20 4 Type(s) in Format 3

\$7.20 4 Types

\$8.51 Estimated cost File6

\$0.10 TYMNET

\$8.61 Estimated cost this search

\$9.06 Estimated total session cost 0.423 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 442:AMA Journals 1982-2000/Sep W1

(c)2000 Amer Med Assn -FARS/DARS apply

File 444:New England Journal of Med. 1985-2000/Feb W3

(c) 2000 Mass. Med. Soc.

File 457:The Lancet 1986-2000/Mar W1

(c) 2000 The Lancet, Ltd.

Set	Items	Description
---	-----	-----
? s		(leukemia? or lymphoma?) and tac
	4878	LEUKEMIA?
	5632	LYMPHOMA?
	194	TAC
S1	78	(LEUKEMIA? OR LYMPHOMA?) AND TAC
? s s1		and (dose? or dosing or mg)
	78	S1
	31691	DOSE?
	2214	DOSING
	32314	MG
S2	55	S1 AND (DOSE? OR DOSING OR MG)
? t s2/3/all		

2/3/1 (Item 1 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00107152

COPYRIGHT American Medical Association 1998

Cutaneous Graft-versus-Host Disease (ARTICLE)

ARACTINGI, SELIM; CHOSIDOW, OLIVIER

Archives of Dermatology

May, 1998; Review: tzd602

LINE COUNT: 00989

2/3/2 (Item 2 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00100896

COPYRIGHT American Medical Association 1996

Detection of Human T-Cell Lymphotropic Virus Type I in Archival Tissue Specimens (ARTICLE)

WOOD, GARY S.; RUFFO, ALICE; SALVEKAR, ANUPAMA; HENGHOLD, WILL;

TAKESHITA, MORISHIGE; KIKUCHI, MASAHIRO

Archives of Dermatology

Nov, 1996; Study: tzd1339

LINE COUNT: 00413

2/3/3 (Item 3 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00100597

COPYRIGHT American Medical Association 1996

Circulating Skin-Homing T Cells in Atopic Dermatitis Selective

Up-regulation of HLA-DR, Interleukin-2R, and CD30 and Decrease After  
Combined UV-A and UV-B Phototherapy (ARTICLE)

PILETTA, PIERRE A.; WIRTH, SUSANNE; HOMMEL, LUCETTE; SAURAT, JEAN H.;  
HAUSER, CONRAD  
Archives of Dermatology  
Oct, 1996; Study: tzdl171  
LINE COUNT: 00464

2/3/4 (Item 4 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00094516  
COPYRIGHT American Medical Association 1995

Peering at the Dermatology Literature (ARTICLE)

Archives of Dermatology  
May, 1995; Editorials: de\_602  
LINE COUNT: 00366

2/3/5 (Item 5 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00093606  
COPYRIGHT American Medical Association 1995

Human T-Cell Lymphotropic Virus Type I-Associated Adult T-Cell  
**Leukemia** The Joseph Goldberger Clinical Investigator Lecture (ARTICLE  
)

WALDMANN, THOMAS A.  
JAMA, The Journal of the American Medical Association  
March 1, 1995; 9 of Health: tzj735  
LINE COUNT: 00348

2/3/6 (Item 6 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00090827  
COPYRIGHT American Medical Association 1994

Recurrence of Pemphigus Vulgaris Associated With Interleukin 2 Therapy (ARTICLE)

PRUSSICK, RONALD; PLOTT, R. TODD; STANLEY, JOHN R.  
Archives of Dermatology  
July, 1994; Observation: de\_890  
LINE COUNT: 00266

2/3/7 (Item 7 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00090215  
COPYRIGHT American Medical Association 1994

Primary Gastric T-Cell **Lymphoma** Morphological and Immunohistochemical  
Studies of Two Cases (ARTICLE)

Archives of Pathology and Laboratory Medicine  
May, 1994; Original Article: p547  
LINE COUNT: 00257

2/3/8 (Item 8 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00087400  
COPYRIGHT American Medical Association 1992  
(ARTICLE)  
GOLDMAN, BARRY D.; OH, SE-KYUNG; DAVIS, BRET E.; KADIN, MARSHALL E.;  
POIESZ, BERNARD J.; KOH, HOWARD K.  
Archives of Dermatology  
Sep, 1993; OBSERVATION: p1166  
LINE COUNT: 00294

2/3/9 (Item 9 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00081309  
COPYRIGHT American Medical Association 1992  
Use and Interpretation of Diagnostic Immunologic Laboratory Tests (ARTICLE)  
LOPEZ, MANUEL; FLEISHER, THOMAS; DESHAZO, RICHARD D.  
JAMA, The Journal of the American Medical Association  
November 25, 1992; 20: p2970  
LINE COUNT: 01953

2/3/10 (Item 10 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00055691  
Administration of a Prostaglandin Synthetase Inhibitor Associated With an  
Increased Immune Cell Infiltrate in Squamous Cell Carcinoma of the Head and  
Neck (Article)  
Shikani, Alan H. MD; Richtsmeier, William J. MD, Klein, Jerry L.  
PhD;Kopher, Kenneth A. MS  
Archives of Otolaryngology-Head & Neck Surgery  
1992; 118: 526 (3)

2/3/11 (Item 11 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00055031  
Interleukin 2 and Granulocyte-Macrophage Colony-Stimulating Factor Induce a  
Perivascular Lymphocytic Infiltrate in a Skin Explant Model (Article)  
Horn, Thomas D., MD; Rest, Ellen B., MD; Karp, Judith E., MD; Burke,  
Philip J., MD; Vogelsang, Georgia B., MD; Boucher, Correne L.; Hood,  
Antoinette F., MD  
Archives of General Psychiatry  
1991; 48: 1789 (5)

2/3/12 (Item 12 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00050927

Large-cell Anaplastic (Ki-1-Positive) **Lymphoma** Complicated by  
Disseminated Intravascular Coagulation (Article)

Arber, Daniel, MD; Bilbao, Jorge, MD; Bassion, Susan, PhD  
Archives of Pathology & Laboratory Medicine  
1991; 115: 188 (5)

2/3/13 (Item 13 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00050311

Intravenous Administration of Recombinant Human Granulocyte-Macrophage  
Colony-Stimulating Factor Causes a Cutaneous Eruption (Article)

Horn, Thomas D., MD; Burke, Philip J., MD; Karp, Judith E., MD; Hood,  
Antoinette F., MD  
Archives of Dermatology  
1991; 127: 49 (4)

2/3/14 (Item 14 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00049917

Human T-cell **Leukemia/Lymphoma** Viruses: Life Cycle,  
Pathogenicity, Epidemiology, and Diagnosis (Article)

Hjelle, Brian, MD  
Archives of Pathology & Laboratory Medicine  
1991; 115: 440 (11)

2/3/15 (Item 15 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00046690

Copyright (C) 1989 American Medical Association

Childhood Ki-1 **Lymphoma**; A Report of Two Cases (ORIGINAL ARTICLES)

OKA, KUNIYUKI; MORI, NAOYOSHI; KOJIMA, MIZU; IIJIMA, TATSUO; HANADA,  
TAKASHI; TSUCHIDA, MASAHIRO  
Archives of Pathology and Laboratory Medicine  
September, 1989; 113: 998-1002  
LINE COUNT: 00166 WORD COUNT: 02302

2/3/16 (Item 16 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00040278

Copyright (C) 1988 American Medical Association

Cutaneous-Type Adult T-Cell **Leukemia/Lymphoma**; A Unique  
Clinical Feature With Monoclonal T-Cell Proliferation Detected by Southern  
Blot Analysis (OBSERVATIONS)

TAKAHASHI, KENZO; TANAKA, TOSHIHIRO; FUJITA, MAYUMI; HORIGUCHI, YUJI;  
MIYACHI, YOSHIKI; IMAMURA, SADA O  
Archives of Dermatology  
March, 1988; 124: 399-404  
LINE COUNT: 00225 WORD COUNT: 03115

2/3/17 (Item 17 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00038322  
Copyright (C) 1987 American Medical Association

Human T-Cell Lymphotropic Virus Type I-Associated Adult T-Cell  
**Leukemia/Lymphoma** in an Atypical Host (ORIGINAL ARTICLE)

GOLDMAN-LEIKIN, ROBIN E.; HERST, C. V.; KIES, MERRILL S.; MARDER, ROBERT  
J.; ROSEN, STEVEN T.  
Archives of Pathology and Laboratory Medicine  
November, 1987; 111: 1054-1056  
LINE COUNT: 00122 WORD COUNT: 01684

2/3/18 (Item 18 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00037960  
Copyright (C) 1986 American Medical Association

Coexisting Hodgkin's Disease and Mycosis Fungoides; Immunohistochemical  
Proof of Its Existence (ORIGINAL ARTICLE)

SIMRELL, CHARLES R.; BOCCIA, RALPH V.; JAFFE, ELAINE S.  
Archives of Pathology and Laboratory Medicine  
November, 1986; 110: 1029-1034  
LINE COUNT: 00223 WORD COUNT: 03078

2/3/19 (Item 19 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00029473  
Copyright (C) 1986 American Medical Association

Nephrotic Syndrome Associated With a Clonal T-Cell **Leukemia** of Large  
Granular Lymphocytes With Cytotoxic Function (CLINICAL OBSERVATION)

ORMAN, STEPHEN V.; SCHECHTER, GERALDINE P.; WHANG-PENG, JACQUELINE;  
GUCCION, JOHN; CHAN, CLARA; SCHULOF, RICHARD S.; SHALHOUB, ROBERT J.  
Archives of Internal Medicine  
September, 1986; 146: 1827-1829  
LINE COUNT: 00157 WORD COUNT: 02170

2/3/20 (Item 20 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00025675

Copyright (C) 1987 American Medical Association

Sezary-like Syndrome in a 10-Year-Old Girl With Serologic Evidence of Human T-Cell Lymphotropic Virus Type I Infection (OBSERVATIONS)

IKAI, KOUICHI; UCHIYAMA, TAKASHI; MAEDA, MICHIIYUKI; TAKIGAWA, MASAHIRO  
Archives of Dermatology  
October, 1987; 123: 1351-1355  
LINE COUNT: 00149 WORD COUNT: 02069

2/3/21 (Item 21 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00025435

Copyright (C) 1987 American Medical Association

Actinic Reticuloid: An Immunohistochemical Study (CORRESPONDENCE; Vignettes )

TAKIGAWA, MASAHIRO  
Archives of Dermatology  
March, 1987; 123: 296-297  
LINE COUNT: 00045 WORD COUNT: 00624

2/3/22 (Item 22 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00025414

Copyright (C) 1987 American Medical Association

New Therapies for Cutaneous T-Cell **Lymphoma** (EDITORIALS)

HEALD, PETER W.  
Archives of Dermatology  
February, 1987; 123: 189-191  
LINE COUNT: 00122 WORD COUNT: 01697

2/3/23 (Item 23 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00025360

Copyright (C) 1986 American Medical Association

**Lymphomatoid** Papulosis; Histologic and Immunohistochemical Studies in a Patient With a Scaly Pigmented Eruption (STUDIES)

TOKURA, YOSHIKI; TAKIGAWA, MASAHIRO; OKU, TOMOZO; YAMADA, MIZUHO  
Archives of Dermatology  
December, 1986; 122: 1400-1405  
LINE COUNT: 00215 WORD COUNT: 02972

2/3/24 (Item 24 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00017385

Copyright (C) 1988 American Medical Association

Positron Emission Tomography in Oncology; Council on Scientific Affairs;  
Report of the Positron Emission Tomography Panel (Topics in  
Radiology/Council Report)

JACOBSON, HAROLD G.

JAMA, The Journal of the American Medical Association

April 8, 1988; 259: 2126-2131

LINE COUNT: 00216 WORD COUNT: 02988

2/3/25 (Item 25 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00016139

Copyright (C) 1987 American Medical Association  
(FROM THE NIH)

WYNGAARDEN, BY JAMES B.

JAMA, The Journal of the American Medical Association

October 2, 1987; 258: 1707

LINE COUNT: 00076 WORD COUNT: 01052

2/3/26 (Item 26 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00012709

Copyright (C) 1986 American Medical Association

Antitumor Strategies Based on Enhancing -- and Blocking -- Effects of  
Interleukin-2 (MEDICAL NEWS & PERSPECTIVES)

MERZ, BY BEVERLY

JAMA, The Journal of the American Medical Association

September 12, 1986; 256: 1241, 1244

LINE COUNT: 00114 WORD COUNT: 01577

2/3/27 (Item 1 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00120088

Copyright 2000 by the Massachusetts Medical Society

Prevention of Rejection in Cardiac Transplantation by Blockade of the  
Interleukin-2 Receptor with a Monoclonal Antibody (Original Articles)

Beniaminovitz, Ainat; Itescu, Silviu; Lietz, Katherine; Donovan, Mary;  
Burke, Elizabeth M.; Groff, Barbara D.; Edwards, Niloo; Mancini,  
Donna M.

The New England Journal of Medicine

Mar 2, 2000; 342 (9),pp 613-619

LINE COUNT: 00418 WORD COUNT: 05780

2/3/28 (Item 2 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00118604

Copyright 1998 by the Massachusetts Medical Society

Bone Marrow Involvement in Acute **Leukemia** (Images in Clinical  
Medicine)

Junghans, R.P.  
The New England Journal of Medicine  
Nov 5, 1998; 339 (19),p 1375  
LINE COUNT: 00074            WORD COUNT: 01028

2/3/29        (Item 3 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00117715  
Copyright 1998 by the Massachusetts Medical Society

Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection  
in Renal Transplantation (Original Articles)

Vincenti, Flavio; Kirkman, Robert; Light, Susan; Bumgardner, Ginny;  
Pescovitz, Mark; Halloran, Philip; Neylan, John; Wilkinson, Alan;  
Ekberg, Henrik; Gaston, Robert; Backman, Lars; Burdick, James; for  
the Daclizumab Triple Therapy Study Group.  
The New England Journal of Medicine  
Jan 15, 1998; 338 (3),pp 161-165  
LINE COUNT: 00291            WORD COUNT: 04020

2/3/30        (Item 4 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00114651  
Copyright 1995 by the Massachusetts Medical Society

Treatment of Adult T-Cell **Leukemia-Lymphoma** with a Combination  
of Interferon Alfa and Zidovudine (Original Articles)

Gill, Parkash S.; Harrington, William, Jr.; Kaplan, Mark H.; Ribeiro,  
Raul C.; Bennett, John M.; Liebman, Howard A.; Bernstein-Singer,  
Marjorie; Espina, Byron M.; Cabral, Lisa; Allen, Steven; Kornblau,  
Steven; Pike, Malcolm C.; Levine, Alexandra M.  
The New England Journal of Medicine  
Jun 29, 1995; 332 (26),pp 1744-1748  
LINE COUNT: 00357            WORD COUNT: 04935

2/3/31        (Item 5 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00113528  
Copyright 1994 by the Massachusetts Medical Society

Medical Progress: Renal Transplantation (Review Articles)

Suthanthiran, Manikkam; Strom, Terry B.  
The New England Journal of Medicine  
Aug 11, 1994; 331 (6),pp 365-376  
LINE COUNT: 00629            WORD COUNT: 08682

2/3/32        (Item 6 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00113464  
Copyright 1990 by the Massachusetts Medical Society

Current Concepts: Designer And Catalytic Antibodies (Review Article)

Mayforth, Ruth D.; Quintans, Jose.  
The New England Journal of Medicine  
Jul 19, 1990; 323 (3),pp 173-178  
LINE COUNT: 00486 WORD COUNT: 06710

2/3/33 (Item 7 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00113334  
Copyright 1990 by the Massachusetts Medical Society

Current Concepts: Designer And Catalytic Antibodies (Review Article)

Mayforth, Ruth D.; Quintans, Jose.  
The New England Journal of Medicine  
Jul 19, 1990; 323 (3),pp 173-178  
LINE COUNT: 00486 WORD COUNT: 06710

2/3/34 (Item 8 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00112704  
Copyright 1994 by the Massachusetts Medical Society

Seminars in Medicine of the Beth Israel Hospital, Boston: Cytokine Receptors In Congenital Hematopoietic Disease (Review Article)

D'Andrea, Alan D.  
The New England Journal of Medicine  
Mar 24, 1994; 330 (12),pp 839-846  
LINE COUNT: 00579 WORD COUNT: 08002

2/3/35 (Item 9 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00111325  
Copyright 1993 by the Massachusetts Medical Society

Seminars in Medicine of the Beth Israel Hospital, Boston: Pathogenesis Of Diseases Induced By Human Lymphotropic Virus Type I Infection (Review Articles)

Hollenberg, Per; Hafler, David A.  
The New England Journal of Medicine  
Apr 22, 1993; 328 (16),pp 1173-1182  
LINE COUNT: 00561 WORD COUNT: 07742

2/3/36 (Item 10 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00109977  
Copyright 1992 by the Massachusetts Medical Society

Hodgkin's Disease, **Lymphomatoid** Papulosis, And Cutaneous T-Cell **Lymphoma** Derived From A Common T-Cell Clone (Original Articles)

Davis, Thomas H.; Morton, Cynthia C.; Miller-Cassman, Robert; Balk,  
Steven P.; Kadin, Marshall E.  
The New England Journal of Medicine  
Apr 23, 1992; 326 (17),pp 1115-1122  
LINE COUNT: 00421 WORD COUNT: 05813

2/3/37 (Item 11 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00108296  
Copyright 1991 by the Massachusetts Medical Society

A Cluster Of Pneumocystis Carinii Pneumonia In Adults Without Predisposing  
Illnesses (Brief Report)

Jacobs, Jonathan L.; Libby, Daniel M.; Winters, Robert A.; Gelmont,  
David M.; Fried, Ethan D.; Hartman, Barry J.; Laurence, Jeffrey.  
The New England Journal of Medicine  
Jan 24, 1991; 324 (4),pp 246-250  
LINE COUNT: 00467 WORD COUNT: 06445

2/3/38 (Item 12 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00107833  
Copyright 1990 by the Massachusetts Medical Society

Current Concepts: Designer And Catalytic Antibodies (Review Article)

Mayforth, Ruth D.; Quintas, Jose.  
The New England Journal of Medicine  
Jul 19, 1990; 323 (3),pp 173-178  
LINE COUNT: 00487 WORD COUNT: 06722

2/3/39 (Item 13 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00107419  
Copyright 1990 by the Massachusetts Medical Society

Severe Combined Immunodeficiency Due To A Specific Defect In The Production  
Of Interleukin-2 (Brief Reports)

Weinberg, Kenneth; Parkman, Robertson.  
The New England Journal of Medicine  
Jun 14, 1990; 322 (24),pp 1718-1723  
LINE COUNT: 00466 WORD COUNT: 06442

2/3/40 (Item 14 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00106381  
Copyright 1989 by the Massachusetts Medical Society

Weekly Clinicopathological Exercises: Case 36-1989: A 34-Year-Old Jamaican  
Man With Fever, Hepatic Failure, Diarrhea, And A Progressive Gait Disorder  
(Case Records of the Massachusetts General Hospital)

Groopman, Jerome E.; Ferry, Judith A.  
The New England Journal of Medicine  
Sep 7, 1989; 321 (10),pp 663-675  
LINE COUNT: 01042                      WORD COUNT: 14379

2/3/41            (Item 15 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00106327  
Copyright 1989 by the Massachusetts Medical Society

Pure Red-Cell Aplasia Of 10 Years' Duration Due To Persistent Parvovirus  
B19 Infection And Its Cure With Immunoglobulin Therapy (Medical  
Intelligence)

Kurtzman, Gary; Frickhofen, Norbert; Kimball, Janice; Jenkins, Douglas  
W.; Nienhuis, Arthur W.; Young, Neal S.  
The New England Journal of Medicine  
Aug 24, 1989; 321 (8),pp 519-523  
LINE COUNT: 00393                      WORD COUNT: 05426

2/3/42            (Item 16 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00104190  
Copyright 1988 by the Massachusetts Medical Society

Pathogenic Human Retroviruses (Editorial)

Broder, Samuel  
The New England Journal of Medicine  
January 28, 1988; 318 (4),pp 243-245  
LINE COUNT: 00301                      WORD COUNT: 04164

2/3/43            (Item 17 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00102985  
Copyright 1987 by the Massachusetts Medical Society

Remissions            In            Hairy-Cell            **Leukemia**            With            Pentostatin  
(2'-Deoxycoformycin) (Original Article)

Spiers, Alexander S.D., T.D., Ph.D.; Moore, Dirk, Ph.D., Cassileth,  
Peter A., Harrington, David P., Ph.D., Cummings, Frank J.; Neiman,  
Richard S., Bennett, John M.; O'Connell, Michael J.  
The New England Journal of Medicine  
April 2, 1987; 316 (14),pp 825-830  
LINE COUNT: 00439                      WORD COUNT: 06069

2/3/44            (Item 18 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00102420  
Copyright 1986 by the Massachusetts Medical Society

Concomitant Infection with HTLV-I and HTLV-III In A Patient with T8

Lymphoproliferative Disease (Medical Intelligence)

Harper, Mary E., Ph.D.; Kaplan, Mark H.; Marselle, Lisa M., B.A.;  
Pahwa, Savita G.; Chayt, Karen J.; Sarngadharan, M.G., Ph.D.;  
Wong-Staal, Flossie, Ph.D.; Gallo, Robert C.  
The New England Journal of Medicine  
October 23, 1986; 315 (17), pp 1073-1078  
LINE COUNT: 00408 WORD COUNT: 05641

2/3/45 (Item 19 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00102091  
Copyright 1986 by the Massachusetts Medical Society

A Second Isolate of HTLV-II Associated with Atypical Hairy-Cell  
**Leukemia** (Medical Intelligence)

Ronseblatt, Joseph D.; Golde, David W.; Wachsman, William, Ph.D.;  
Giorgi, Janis V., Ph.D.; Jacobs, Andrew; Schmidt, Gerhard M.; Quan,  
Shirley; Gasson, Judith C., Ph.D.; Chen, Irvin S.Y., Ph.D.  
The New England Journal of Medicine  
August 7, 1986; 315 (6), pp 372-377  
LINE COUNT: 00564 WORD COUNT: 07793

2/3/46 (Item 20 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00101373  
Copyright 1986 by the Massachusetts Medical Society

A Second Isolate of HTLV-II Associated with Atypical Hairy-Cell  
**Leukemia** (Medical Intelligence)

Ronseblatt, Joseph D.; Golde, David W.; Wachsman, William, Ph.D.;  
Giorgi, Janis V., Ph.D.; Jacobs, Andrew; Schmidt, Gerhard M.; Quan,  
Shirley; Gasson, Judith C., Ph.D.; Chen, Irvin S.Y., Ph.D.  
The New England Journal of Medicine  
August 7, 1986; 315 (6), pp 372-377  
LINE COUNT: 00564 WORD COUNT: 07793

2/3/47 (Item 21 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00100709  
Copyright 1985 by the Massachusetts Medical Society

T-Cell Receptor Gene Rearrangements as Clinical Markers of Human T-Cell  
**Lymphomas** (Original Article)

Bertness, Virginia, B.S.; Kirsch, Ilan; Hollis, Gregory, Ph.D.;  
Johnson, Bruce; Bunn, Paul A., Jr.  
The New England Journal of Medicine  
August 29, 1985; 313 (9), pp 534-538  
LINE COUNT: 00579 WORD COUNT: 07994

2/3/48 (Item 22 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00100384

Copyright 1985 by the Massachusetts Medical Society

Subsets of Patients with Aplastic Anemia Identified by Flow  
Microfluorometry (Original Article)

Torok-Storb, Beverly, Ph.D.; Doney, Kristine; Sale, George; Thomas, E.  
Donnall; Storb, Rainer

The New England Journal of Medicine

April 18, 1985; 312 (16), pp 1015-1022

LINE COUNT: 00484

WORD COUNT: 06684

2/3/49 (Item 1 from file: 457)

DIALOG(R)File 457:The Lancet

(c) 2000 The Lancet, Ltd. All rts. reserv.

00118363 (USE FORMAT 7 OR 9 FOR FULLTEXT)

TITLE: Human T-lymphotropic virus type I infection

Manns, Angela ; Hisada, Michie ; La Grenade, Lois

Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics,

National Cancer Institute, Bethesda, MD, USA; Department of Medicine,

University of the West Indies, Kingston, Jamaica

The Lancet, v353, n9168, pp 1951-1958

June 5, 1999

DOCUMENT TYPE: Journal; Seminar LANGUAGE: English RECORD TYPE:

Fulltext

WORD COUNT: 5001

2/3/50 (Item 2 from file: 457)

DIALOG(R)File 457:The Lancet

(c) 2000 The Lancet, Ltd. All rts. reserv.

00117541 (USE FORMAT 7 OR 9 FOR FULLTEXT)

TITLE: Immunosuppressive strategies in transplantation

Denton, Mark D ; Magee, Colm C ; Sayegh, Mohamed H

Laboratory of Immunogenetics and Transplantation, Renal Division,

Department of Medicine, Brigham and Women's Hospital, Harvard Medical

School, Boston, MA 02115, USA

The Lancet, v353, n9158, pp 1083-1091

March 27, 1999

DOCUMENT TYPE: Journal; Review LANGUAGE: English RECORD TYPE: Fulltext

WORD COUNT: 5609

2/3/51 (Item 3 from file: 457)

DIALOG(R)File 457:The Lancet

(c) 2000 The Lancet, Ltd. All rts. reserv.

00104852 (USE FORMAT 7 OR 9 FOR FULLTEXT)

TITLE: Cutaneous T-cell **lymphoma** (mycosis fungoides)

Lorincz, Allan L

Section of Dermatology, University of Chicago, 5841 South Maryland, MC

5067, Chicago, IL 60637, USA

The Lancet, v347, n9005, pp 871-876

March 30, 1996

DOCUMENT TYPE: Journal; Skin cancer quartet LANGUAGE: English

RECORD TYPE: Fulltext

WORD COUNT: 3304

2/3/52 (Item 4 from file: 457)  
DIALOG(R)File 457:The Lancet  
(c) 2000 The Lancet, Ltd. All rts. reserv.

00101288 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
TITLE: Impairment of leukaemia-free survival by addition of interleukin-2-  
receptor antibody to standard graft-versus-host prophylaxis  
Blaise, Didier ; Olive, Daniel ; Michallet, Mauricette ; Marit, Gerald ;  
Leblond, Veronique ; Maraninchi, Dominique  
Institut Paoli Calmettes and Inserm U119, Marseille; Hopital Edouard  
Herriot, Lyon; Hopital Haut Leveque, Bordeaux, Hopital Pitie-  
Salpetriere, Paris, France.  
The Lancet, v345, n8958, pp 1144-1146  
May 6, 1995

DOCUMENT TYPE: Journal; Articles LANGUAGE: English RECORD TYPE:  
Fulltext  
WORD COUNT: 1856

2/3/53 (Item 5 from file: 457)  
DIALOG(R)File 457:The Lancet  
(c) 2000 The Lancet, Ltd. All rts. reserv.

00088561 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
TITLE: Short Reports: Therapeutic effects of genetically engineered toxin  
(DAB sub 486 IL-2) in patient with chronic lymphocytic leukaemia  
LeMaistre, Charles F|Rosenblum, Michael G|Reuben, James M|Parkinson, David  
R|Meneghetti, Carole M|Parker, Karen|Shaw, Jill P|Deisseroth, Albert  
B|Woodworth, Thasia  
Department of Medicine/Hematology, University of Texas Health Science  
Center, San Antonio. Department of Hematology, Department of Clinical  
Immunology and Biological Therapy and Department of Laboratory Medicine,  
University of Texas MD Anderson Cancer Centre, Houston, Texas. National  
Cancer Institute, Bethesda, Maryland. Seragen, Inc., Hopkinton,  
Massachusetts, USA. Correspondence: Dr C. F. LeMaistre, University of  
Texas Health Science Center, Department of Medicine/Hematology, 7703  
Floyd Curl Drive, San Antonio, Texas 78284-7880, USA.  
The Lancet, v337, n8750, pp 1124-1125  
1991 May 11

DOCUMENT TYPE: Journal; Report (REP) LANGUAGE: English RECORD TYPE:  
Fulltext  
WORD COUNT: 993

2/3/54 (Item 6 from file: 457)  
DIALOG(R)File 457:The Lancet  
(c) 2000 The Lancet, Ltd. All rts. reserv.

00082387 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
TITLE: Original Article: Effects of intradermal gamma-interferon in  
cutaneous leishmaniasis  
Harms, G|Zwingenberger, K|Chehade, A K|Talhari, S|Racz, P|Mouakeh, A|Douba,  
M|Nakel, L|Naiff, R D|Kremsner, P G|Feldmeier, H|Bienzle, U  
Landesinstitut fur Tropenmedizin, Berlin, Federal Republic of Germany.  
Departement de Dermato-Venereologie, Faculte de Medecine, Universite  
d'Alep, Syria. Centro de Dermatologia Tropical e Venereologia "Alfredo  
da Matta", Manaus, Brazil. Bernhard-Nocht-Institut fur Tropenmedizin,  
Abteilung fur Pathologie, Hamburg, Federal Republic of Germany.  
Instituto Nacional de Pesquisa da Amazonia, Departamento de Leishmaniose,  
Manaus, Brazil. Correspondence: G. H., Landesinstitut fur Tropenmedizin,  
Koenigin-Elisabeth-Strasse 32, 1 Berlin 19, FRG.  
The Lancet, v333, n8650, pp 1287-1292  
1989 Jun 10

DOCUMENT TYPE: Journal; Article (ART) LANGUAGE: English RECORD TYPE:  
Fulltext  
WORD COUNT: 3343

2/3/55 (Item 7 from file: 457)  
DIALOG(R)File 457:The Lancet  
(c) 2000 The Lancet, Ltd. All rts. reserv.

00075191 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
TITLE: Original Articles: Serum reactivity to human T-cell leukaemia/  
lymphoma virus type I proteins in patients with large granular  
lymphocytic leukaemia  
Starkebaum, Gordon|Loughran, Thomas P Jr|Kalyanaraman, V S|Kadin, Marshall  
E|Kidd, Pamela G|Singer, Jack W|Ruscetti, Francis W  
Department of Medicine, Veterans Administration Medical Center, Seattle,  
Washington. Fred Hutchinson Cancer Research Center, Seattle. Centers  
for Disease Control, Atlanta, Georgia. Department of Pathology and  
Charles A. Dana Research Laboratory, Beth Israel Hospital and Harvard  
Medical School, Boston, Massachusetts. Department of Medicine and  
Laboratory Medicine, University of Washington, Seattle. National Cancer  
Institute, Frederick Cancer Research Facility, Frederick, Maryland, USA.  
Correspondence: G. S., Medical Service (111), VA Medical Center, 1660 S.  
Columbian Way, Seattle, Washington 98108, USA.  
The Lancet, v329, n8533, pp 596-598  
1987 Mar 14

DOCUMENT TYPE: Journal; Article (ART) LANGUAGE: English RECORD TYPE:  
Fulltext  
WORD COUNT: 1984  
? s sl and py=1993

78 S1  
9725 PY=1993  
S3 2 S1 AND PY=1993  
? t s3/3/all

3/3/1 (Item 1 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00087400  
COPYRIGHT American Medical Association 1992  
(ARTICLE)  
GOLDMAN, BARRY D.; OH, SE-KYUNG; DAVIS, BRET E.; KADIN, MARSHALL E.;  
POIESZ, BERNARD J.; KOH, HOWARD K.  
Archives of Dermatology  
Sep, 1993; OBSERVATION: p1166  
LINE COUNT: 00294

3/3/2 (Item 1 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00111325  
Copyright 1993 by the Massachusetts Medical Society

Seminars in Medicine of the Beth Israel Hospital, Boston: Pathogenesis Of  
Diseases Induced By Human Lymphotropic Virus Type I Infection (Review  
Articles)

Hollsberg, Per; Hafler, David A.  
The New England Journal of Medicine  
Apr 22, 1993; 328 (16),pp 1173-1182

LINE COUNT: 00561                      WORD COUNT: 07742  
? s s1 and py=1994

78 S1  
9636 PY=1994  
S4 4 S1 AND PY=1994  
? t s4/3/all

4/3/1 (Item 1 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00090827  
COPYRIGHT American Medical Association 1994

Recurrence of Pemphigus Vulgaris Associated With Interleukin 2 Therapy (ARTICLE)

PRUSSICK, RONALD; PLOTT, R. TODD; STANLEY, JOHN R.  
Archives of Dermatology  
July, 1994; Observation: de\_890  
LINE COUNT: 00266

4/3/2 (Item 2 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2000 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00090215  
COPYRIGHT American Medical Association 1994

Primary Gastric T-Cell **Lymphoma** Morphological and Immunohistochemical Studies of Two Cases (ARTICLE)

Archives of Pathology and Laboratory Medicine  
May, 1994; Original Article: p547  
LINE COUNT: 00257

4/3/3 (Item 1 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00113528  
Copyright 1994 by the Massachusetts Medical Society

Medical Progress: Renal Transplantation (Review Articles)

Suthanthiran, Manikkam; Strom, Terry B.  
The New England Journal of Medicine  
Aug 11, 1994; 331 (6),pp 365-376  
LINE COUNT: 00629                      WORD COUNT: 08682

4/3/4 (Item 2 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2000 Mass. Med. Soc. All rts. reserv.

00112704  
Copyright 1994 by the Massachusetts Medical Society

Seminars in Medicine of the Beth Israel Hospital, Boston: Cytokine Receptors In Congenital Hematopoietic Disease (Review Article)

D'Andrea, Alan D.

The New England Journal of Medicine  
Mar 24, 1994; 330 (12),pp 839-846  
LINE COUNT: 00579 WORD COUNT: 08002  
? begin 159

15mar00 08:11:08 User208760 Session D1481.4  
\$1.81 0.398 DialUnits File442  
\$63.80 29 Type(s) in Format 3  
\$63.80 29 Types  
\$65.61 Estimated cost File442  
\$1.18 0.247 DialUnits File444  
\$55.00 25 Type(s) in Format 3  
\$55.00 25 Types  
\$56.18 Estimated cost File444  
\$0.97 0.202 DialUnits File457  
\$15.05 7 Type(s) in Format 3  
\$15.05 7 Types  
\$16.02 Estimated cost File457  
OneSearch, 3 files, 0.847 DialUnits FileOS  
\$0.30 TYMNET  
\$138.11 Estimated cost this search  
\$147.17 Estimated total session cost 1.270 DialUnits

File 159:Cancerlit 1975-2000/Mar  
(c) format only 2000 Dialog Corporation

Set Items Description  
--- -----  
? e au=waldmann

Ref	Items	Index-term
E1	4	AU=WALDMAN TA
E2	11	AU=WALDMAN WJ
E3	0	*AU=WALDMANN
E4	1	AU=WALDMANN A
E5	1	AU=WALDMANN AT
E6	3	AU=WALDMANN C
E7	7	AU=WALDMANN D
E8	2	AU=WALDMANN E
E9	7	AU=WALDMANN G
E10	101	AU=WALDMANN H
E11	1	AU=WALDMANN HJ
E12	1	AU=WALDMANN K

Enter P or PAGE for more  
? p

Ref	Items	Index-term
E13	1	AU=WALDMANN KD
E14	1	AU=WALDMANN KH
E15	3	AU=WALDMANN P
E16	7	AU=WALDMANN R
E17	2	AU=WALDMANN RA
E18	8	AU=WALDMANN T
E19	250	AU=WALDMANN TA
E20	1	AU=WALDMANN U
E21	17	AU=WALDMANN V
E22	3	AU=WALDMANN W
E23	1	AU=WALDMANN WJ
E24	1	AU=WALDMEIER P

Enter P or PAGE for more  
? s e1,e19

```

      4 AU=WALDMAN TA
    250 AU=WALDMANN TA
  S1    254 E1,E19
? s s1 and tac

      254 S1
    1376 TAC
  S2    72 S1 AND TAC
? s s2 and py=1993

      72 S2
    80574 PY=1993
  S3    6 S2 AND PY=1993
? s s2 and py=1994

      72 S2
    83740 PY=1994
  S4    4 S2 AND PY=1994
? t s3/3/all

```

3/3/1  
 DIALOG(R)File 159:Cancerlit  
 (c) format only 2000 Dialog Corporation. All rts. reserv.

01034122 94003208 MEDL/94003208  
 The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia.  
**Waldmann TA**; White JD; Goldman CK; Top L; Grant A; Bamford R; Roessler E; Horak ID; Zaknoen S; Kasten-Sportes C; et al  
 Metabolism Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.  
 Blood; 82(6):1701-12 1993 ISSN 0006-4971 Journal Code: A8G  
 Languages: ENGLISH  
 Document Type: JOURNAL ARTICLE

3/3/2  
 DIALOG(R)File 159:Cancerlit  
 (c) format only 2000 Dialog Corporation. All rts. reserv.

01029144 93368196 MEDL/93368196  
 1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.  
**Waldmann TA**  
 Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.  
 Leukemia; 7 Suppl 2:S151-6 1993 ISSN 0887-6924 Journal Code: LEU  
 Languages: ENGLISH  
 Document Type: JOURNAL ARTICLE

3/3/3  
 DIALOG(R)File 159:Cancerlit  
 (c) format only 2000 Dialog Corporation. All rts. reserv.

01022892 93329041 MEDL/93329041  
 Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-**TAC**.  
 Hakimi J; Ha VC; Lin P; Campbell E; Gately MK; Tsudo M; Payne PW;  
**Waldmann TA**; Grant AJ; Tsien WH; et al  
 Roche Research Center, Hoffmann-LaRoche, Inc., Nutley, NJ 07110.  
 J Immunol; 151(2):1075-85 1993 ISSN 0022-1767 Journal Code: IFB  
 Languages: ENGLISH  
 Document Type: JOURNAL ARTICLE

3/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01004177 93218273 MEDL/93218273

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.

Kreitman RJ; Chaudhary VK; **Waldmann TA**; Hanchard B; Cranston B; FitzGerald DJ; Pastan I

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leukemia; 7(4):553-62 1993 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

3/3/5

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00991310 95606931 ICDB/95606931

Lymphokine receptors: a target for immunotherapy of lymphomas (Meeting abstract).

**Waldmann TA**

NCI, Bethesda, MD 20892

Non-serial; Fifth International Conference on Malignant Lymphoma, June 9-12, 1993, Lugano, Switzerland, p. 46, 1993.: 1993

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

3/3/6

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00985141 93693792 ICDB/93693792

Towards optimal anti-**Tac** antibody dosing in the presence of antigenemia in adult T-cell leukemia-lymphoma (Meeting abstract).

Junghans RP; Goldman CK; Carrasquillo J; Reynolds J; Nelson DL;

**Waldmann TA**

New England Deaconess Hosp., Boston, MA 02215

Proc Annu Meet Am Assoc Cancer Res; 34:A2849 1993 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

? t s4/3/all

4/3/1

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01102643 94325579 MEDL/94325579

Treatment of acute graft-versus-host disease with humanized anti-**Tac**: an antibody that binds to the interleukin-2 receptor.

Anasetti C; Hansen JA; **Waldmann TA**; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R; et al

Clinical Research Division, Fred Hutchinson Cancer Research Center 98104.

Blood; 84(4):1320-7 1994 ISSN 0006-4971 Journal Code: A8G

Contract/Grant No.: CA 18029, SS, CA, SS, NCI; CA 18221, SS, CA, SS, NCI; HL36444, SS, HL, SS, NHLBI; +

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

4/3/2

DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

01092742 94266289 MEDL/94266289

Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of  
T-cell lymphoma.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, Bethesda, Maryland.

Important Adv Oncol; :131-41 1994 ISSN 0883-5896 Journal Code: GG9

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

4/3/3

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01086036 94226936 MEDL/94226936

Lymphokine receptors: a target for immunotherapy of lymphomas.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of  
Health, Bethesda, Maryland.

Ann Oncol; 5 Suppl 1:13-7 1994 ISSN 0923-7534 Journal Code: AYF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

4/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01083831 94211860 MEDL/94211860

Cooperative interactions between the interleukin 2 receptor alpha and  
beta chains alter the interleukin 2-binding affinity of the receptor  
subunits.

Roessler E; Grant A; Ju G; Tsudo M; Sugamura K; **Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of  
Health, Bethesda, MD 20892.

Proc Natl Acad Sci U S A; 91(8):3344-7 1994 ISSN 0027-8424

Journal Code: PV3

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

? ds

Set	Items	Description
S1	254	E1,E19
S2	72	S1 AND TAC
S3	6	S2 AND PY=1993
S4	4	S2 AND PY=1994

? rd s2

...examined 50 records (50)

...completed examining records

S5 69 RD S2 (unique items)

? t s5/3/all

5/3/1

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01559550 20021681 MEDL/20021681

Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M;

**Waldmann TA**; Pastan I

Laboratory of Molecular Biology, the Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Blood; 94(10):3340-8 1999 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: CLINICAL TRIAL; CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE

5/3/2

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01516566 99251477 MEDL/99251477

Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment.

Kobayashi H; Kim IS; Drumm D; Kim MK; Paik DS; Le N; **Waldmann TA**; Carrasquillo JA; Paik CH

Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1180, USA.

J Nucl Med; 40(5):837-45 1999 ISSN 0161-5505 Journal Code: JEC

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/3

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01479275 99066764 MEDL/99066764

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.

Lehky TJ; Levin MC; Kubota R; Bamford RN; Flerlage AN; Soldan SS; Leist TP; Xavier A; White JD; Brown M; Fleisher TA; Top LE; Light S; McFarland HF; **Waldmann TA**; Jacobson S

Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

Ann Neurol; 44(6):942-7 1998 ISSN 0364-5134 Journal Code: 6AE

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01441042 98301301 MEDL/98301301

Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.

Kingsbury GA; **Waldmann TA**; Junghans RP

Biotherapeutics Development Lab, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.

Leukemia; 12(6):982-91 1998 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/5

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01436925 98280344 MEDL/98280344

Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.

Kobayashi H; Sun BF; Han ES; Kim MK; Le N; Wang QC; Nelson DL; Pastan I;

Waldmann TA; Paik CH; Carrasquillo JA  
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center,  
National Cancer Institute, National Institutes of Health, Bethesda, MD  
20892-1180, USA.

Jpn J Cancer Res; 89(4):436-44 1998 ISSN 0910-5050 Journal Code: HBA  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/6

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01414399 98132664 MEDL/98132664

Impact of antigenemia on the bioactivity of infused anti-**Tac**  
antibody: implications for dose selection in antibody immunotherapies.

Junghans RP; Carrasquillo JA; **Waldmann TA**

Biotherapeutics Development Lab, Harvard Medical School, Division of  
Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA  
02115, USA. junghans@warren.med.harvard.edu

Proc Natl Acad Sci U S A; 95(4):1752-7 1998 ISSN 0027-8424  
Journal Code: PV3

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/7

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01353147 97301590 MEDL/97301590

Improved biodistribution of 125I-labeled anti-**Tac**  
disulfide-stabilized Fv fragment by blocking its binding to the alpha  
subunit of the interleukin 2 receptor in the circulation with preinjected  
humanized anti-**Tac** IgG.

Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I;  
**Waldmann TA**; Paik CH; Carrasquillo JA

Department of Nuclear Medicine, National Cancer Institute, NIH, Bethesda,  
Maryland 20892-1180, USA.

Cancer Res; 57(10):1955-61 1997 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/8

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01326403 98641089 ICDB/98641089

Phase I clinical trial with recombinant immunotoxin anti-**Tac**  
(Fv)-PE38 (LMB-2) in patients with hematologic malignancies (Meeting  
abstract).

Kreitman RJ; White JD; Pearson D; Top LE; **Waldmann TA**; Pastan I

National Cancer Institute, National Institutes of Health, Bethesda, MD  
20892-4255

Proc Annu Meet Am Assoc Cancer Res; 38:A4089 1997 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS; CLINICAL TRIAL; CLINICAL TRIAL, PHASE I

5/3/9

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01281441 96390748 MEDL/96390748

The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of

HTLV-I-associated disorders.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

J Acquir Immune Defic Syndr Hum Retrovirol; 13 Suppl 1:S179-85 1996

ISSN 1077-9450 Journal Code: B7J

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/10

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01261511 96261660 MEDL/96261660

Metabolism of **Tac** (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.

Junghans RP; **Waldmann TA**

Division of Hematology-Oncology, Harvard Medical School, New England Deaconess Hospital, Boston, MA 02215, USA.

J Exp Med; 183(4):1587-602 1996 ISSN 0022-1007 Journal Code: I2V

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/11

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01213309 96082159 MEDL/96082159

Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-**Tac** [see comments]

**Waldmann TA**; White JD; Carrasquillo JA; Reynolds JC; Paik CH; Gansow OA; Brechbiel MW; Jaffe ES; Fleisher TA; Goldman CK; et al

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Blood; 86(11):4063-75 1995 ISSN 0006-4971 Journal Code: A8G

Comment in SS Blood SS 1996 Jun 15;87(12):5379-80

Languages: ENGLISH

Document Type: CLINICAL TRIAL; CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE

5/3/12

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01170001 95241460 MEDL/95241460

Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.

Richardson JH; Sodroski JG; **Waldmann TA**; Marasco WA

Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Proc Natl Acad Sci U S A; 92(8):3137-41 1995 ISSN 0027-8424  
Journal Code: PV3

Contract/Grant No.: P30 AI28691, SS, AI, SS, NIAID; P30 CA06516, SS, CA, SS, NCI; AI28785, SS, AI, SS, NIAID; +

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/13

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01156141 97609760 ICDB/97609760

The promiscuous IL-2 receptor: a target for immunotherapy of HTLV-I-associated diseases (Meeting abstract).

**Waldmann TA**

Metabolism Branch, NCI, NIH Bethesda, MD 20892

Int J Oncol; 7(Suppl):980 1995 ISSN 1019-6439

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

5/3/14

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01102643 94325579 MEDL/94325579

Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.

Anasetti C; Hansen JA; **Waldmann TA**; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R; et al

Clinical Research Division, Fred Hutchinson Cancer Research Center 98104.

Blood; 84(4):1320-7 1994 ISSN 0006-4971 Journal Code: A8G

Contract/Grant No.: CA 18029, SS, CA, SS, NCI; CA 18221, SS, CA, SS, NCI; HL36444, SS, HL, SS, NHLBI; +

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/15

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01092742 94266289 MEDL/94266289

Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, Bethesda, Maryland.

Important Adv Oncol; :131-41 1994 ISSN 0883-5896 Journal Code: GG9

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

5/3/16

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01086036 94226936 MEDL/94226936

Lymphokine receptors: a target for immunotherapy of lymphomas.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Ann Oncol; 5 Suppl 1:13-7 1994 ISSN 0923-7534 Journal Code: AYF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/17

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01083831 94211860 MEDL/94211860

Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits.

Roessler E; Grant A; Ju G; Tsudo M; Sugamura K; **Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

5/3/18

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01034122 94003208 MEDL/94003208

The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia.

**Waldmann TA**; White JD; Goldman CK; Top L; Grant A; Bamford R; Roessler E; Horak ID; Zaknoen S; Kasten-Sportes C; et al

Metabolism Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Blood; 82(6):1701-12 1993 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/19

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01029144 93368196 MEDL/93368196

1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leukemia; 7 Suppl 2:S151-6 1993 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/20

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01022892 93329041 MEDL/93329041

Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC.

Hakimi J; Ha VC; Lin P; Campbell E; Gately MK; Tsudo M; Payne PW; **Waldmann TA**; Grant AJ; Tsien WH; et al

Roche Research Center, Hoffmann-LaRoche, Inc., Nutley, NJ 07110.

J Immunol; 151(2):1075-85 1993 ISSN 0022-1767 Journal Code: IFB

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/21

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01004177 93218273 MEDL/93218273

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.

Kreitman RJ; Chaudhary VK; **Waldmann TA**; Hanchard B; Cranston B; FitzGerald DJ; Pastan I

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leukemia; 7(4):553-62 1993 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/22

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00985141 93693792 ICDB/93693792

Towards optimal anti-**Tac** antibody dosing in the presence of antigenemia in adult T-cell leukemia-lymphoma (Meeting abstract).

Junghans RP; Goldman CK; Carrasquillo J; Reynolds J; Nelson DL; **Waldmann TA**

New England Deaconess Hosp., Boston, MA 02215

Proc Annu Meet Am Assoc Cancer Res; 34:A2849 1993 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

5/3/23

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00970994 93102188 MEDL/93102188

Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-**Tac** in conjunction with granulocyte colony-stimulating factor.

Parenteau GL; Dirbas FM; Garmestani K; Brechbiel MW; Bukowski MA; Goldman CK; Clark R; Gansow OA; **Waldmann TA**

Surgery Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.

Transplantation; 54(6):963-8 1992 ISSN 0041-1337 Journal Code: WEJ

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/24

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00961028 93043351 MEDL/93043351

Recombinant toxins containing the variable domains of the anti-**Tac** monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.

Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; **Waldman TA**; Pastan I

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Blood; 80(9):2344-52 1992 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/25

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00889798 92035744 MEDL/92035744

Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Clin Immunol Immunopathol; 61(2 Pt 2):S37-46 1991 ISSN 0090-1229  
Journal Code: DEA

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/26

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00847429 92678733 ICDB/92678733

ADULT T-CELL LEUKEMIA: PROSPECTS FOR IMMUNOTHERAPY

**Waldmann TA**

Metabolism Branch, NCI, Bethesda, MD 20892

Non-serial; The Human Retroviruses. Gallo RC and Jay G, eds. San Diego, Academic Press, p. 319-32, 1991.: 1991

Languages: ENGLISH

Document Type: MONOGRAPH; REVIEW

5/3/27

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00792675 90205200 MEDL/90205200

Human B lymphocytes express the p75 component of the interleukin 2 receptor.

Begley CG; Burton JD; Tsudo M; Brownstein BH; Ambrus JL Jr; **Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leuk Res; 14(3):263-71 1990 ISSN 0145-2126 Journal Code: K9M

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/28

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00787046 90150108 MEDL/90150108

Anti-**Tac**-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.

Junghans RP; **Waldmann TA**; Landolfi NF; Avdalovic NM; Schneider WP; Queen C

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Cancer Res; 50(5):1495-502 1990 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/29

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00778698 90367069 MEDL/90367069

IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Cancer Surv; 8(4):891-903 1989 ISSN 0261-2429 Journal Code: CNG

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/30

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00762583 90053574 MEDL/90053574

The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.

**Waldmann TA**; Goldman CK

Metabolism Branch National Cancer Institute, Bethesda, MD 20892.

Am J Kidney Dis; 14(5 Suppl 2):45-53 1989 ISSN 0272-6386

Journal Code: 3H5

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/31

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00758904 90028731 MEDL/90028731

Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia.

Hege KM; Daleke DL; **Waldmann TA**; Matthay KK

Department of Pediatrics, University of California, San Francisco 94143.

Blood; 74(6):2043-52 1989 ISSN 0006-4971 Journal Code: A8G

Contract/Grant No.: CA39448, SS, CA, SS, NCI

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/32

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00746870 89337215 MEDL/89337215

The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro.

Oh-Ishi T; Goldman CK; Misiti J; **Waldmann TA**

Metabolism Branch, National Cancer Institute, Bethesda, Maryland 20892.

Clin Immunol Immunopathol; 52(3):447-59 1989 ISSN 0090-1229

Journal Code: DEA

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/33

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00738209 89279941 MEDL/89279941

Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.

**Waldmann TA**

Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.

J Natl Cancer Inst; 81(12):914-23 1989 ISSN 0027-8874 Journal Code: J9J

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

5/3/34

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00732036 89230284 MEDL/89230284

Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.

Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghaus R; Gansow OA;

**Waldmann TA**

Division of Cytokine Biology, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland.

Cancer Res; 49(10):2639-44 1989 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/35

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00731058 89223365 MEDL/89223365

Early experience with anti-**Tac** in clinical renal transplantation.

Kirkman RL; Shapiro ME; Carpenter CB; Milford EL; Ramos EL; Tilney NL;

**Waldmann TA**; Zimmerman CE; Strom TB

Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115.

Transplant Proc; 21(1 Pt 2):1766-8 1989 ISSN 0041-1345 Journal Code: WE9

Languages: ENGLISH

Document Type: CLINICAL TRIAL; JOURNAL ARTICLE

5/3/36

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00729030 89203989 MEDL/89203989

Anti-**TAC** MOAB prolongs renal allografts in cynomolgus monkeys.

Reed MH; Shapiro ME; Strom TB; Carpenter CB; Letvin NL; Reimann K; Weinberg DS; **Waldmann TA**; Kirkman RL

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

Transplant Proc; 21(1 Pt 1):1028-30 1989 ISSN 0041-1345 Journal Code: WE9

Contract/Grant No.: N01-AI-52587, SS, AI, SS, NIAID; P01-AI-19414, SS, AI, SS, NIAID; RR-01032, SS, RR, SS, NCRR

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/37

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00694691 89027118 MEDL/89027118

Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-**Tac**, a monoclonal antibody to the receptor for interleukin-2.

**Waldmann TA**; Goldman CK; Bongiovanni KF; Sharrow SO; Davey MP; Cease KB; Greenberg SJ; Longo DL

Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.

Blood; 72(5):1805-16 1988 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/38

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00687973 88320464 MEDL/88320464

Blockade of the interleukin-2 receptor by anti-**Tac** antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro.

Oh-Ishi T; Goldman CK; Misiti J; **Waldmann TA**

Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.  
Proc Natl Acad Sci U S A; 85(17):6478-82 1988 ISSN 0027-8424  
Journal Code: PV3  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/39  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00682917 88285731 MEDL/88285731  
Lateral diffusion measurements give evidence for association of the **Tac** peptide of the IL-2 receptor with the T27 peptide in the plasma membrane of HUT-102-B2 T cells.  
Edidin M; Aszalos A; Damjanovich S; **Waldmann TA**  
Department of Biology, Johns Hopkins University, Baltimore, MD 21218.  
J Immunol; 141(4):1206-10 1988 ISSN 0022-1767 Journal Code: IFB  
Contract/Grant No.: AI-14584, SS, AI, SS, NIAID; AI-19814, SS, AI, SS, NIAID  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/40  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00665767 88151572 MEDL/88151572  
Prolongation of primate renal allografts with anti-**Tac** monoclonal antibody.  
Reed MH; Shapiro ME; Strom TB; Milford EL; Carpenter CB; Letvin NL; **Waldmann TA**; Kirkman RL  
Curr Surg; 45(1):28-30 1988 ISSN 0149-7944 Journal Code: DWP  
Contract/Grant No.: N01-AI-52587, SS, AI, SS, NIAID  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/41  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00647210 88082577 MEDL/88082577  
The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation.  
**Waldmann TA**  
National Cancer Institute, Bethesda, MD 20892.  
Environ Health Perspect; 75:11-5 1987 ISSN 0091-6765 Journal Code: EIO  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

5/3/42  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00641017 88041084 MEDL/88041084  
Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa **Tac** peptide.  
Szollosi J; Damjanovich S; Goldman CK; Fulwyler MJ; Aszalos AA; Goldstein G; Rao P; Talle MA; **Waldmann TA**  
Department of Biophysics, Medical University School of Debrecen, Hungary.  
Proc Natl Acad Sci U S A; 84(20):7246-50 1987 ISSN 0027-8424  
Journal Code: PV3

Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/43

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00634465 87322693 MEDL/87322693

The interleukin-2 receptor on normal and malignant lymphocytes.

**Waldmann TA**

Adv Exp Med Biol; 213:129-37 1987 ISSN 0065-2598 Journal Code: 2LU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/44

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00625742 87260992 MEDL/87260992

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

Tsuda M; Goldman CK; Bongiovanni KF; Chan WC; Winton EF; Yagita M; Grimm EA; **Waldmann TA**

Proc Natl Acad Sci U S A; 84(15):5394-8 1987 ISSN 0027-8424  
Journal Code: PV3

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/45

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00621664 87231976 MEDL/87231976

Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex.

Tsuda M; Kozak RW; Goldman CK; **Waldmann TA**

Proc Natl Acad Sci U S A; 84(12):4215-8 1987 ISSN 0027-8424  
Journal Code: PV3

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/46

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00617179 87196414 MEDL/87196414

Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes.

Holter W; Goldman CK; Casabo L; Nelson DL; Greene WC; **Waldmann TA**

J Immunol; 138(9):2917-22 1987 ISSN 0022-1767 Journal Code: IFB

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/47

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00596064 87092314 MEDL/87092314

Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Tsuda M; Kozak RW; Goldman CK; **Waldmann TA**  
Proc Natl Acad Sci U S A; 83(24):9694-8 1986 ISSN 0027-8424  
Journal Code: PV3  
Contract/Grant No.: 1F32 CA07974-01, SS, CA, SS, NCI  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/48  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00583605 87002626 MEDL/87002626  
The interleukin-2 receptor on malignant cells: a target for diagnosis and therapy.  
**Waldmann TA**  
Cell Immunol; 99(1):53-60 1986 ISSN 0008-8749 Journal Code: CQ9  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/49  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.  
00581940 86315189 MEDL/86315189  
The arrangement of immunoglobulin, T cell antigen receptor, and interleukin 2 receptor genes in human lymphoid neoplasms.  
**Waldmann TA**; Korsmeyer SJ; Greene WC  
Symp Fundam Cancer Res; 38:63-78 1986 ISSN 0190-1214 Journal Code: SFC  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/50  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.  
00567958 86217733 MEDL/86217733  
Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin.  
Kronke M; Schlick E; **Waldmann TA**; Vitetta ES; Greene WC  
Cancer Res; 46(7):3295-8 1986 ISSN 0008-5472 Journal Code: CNF  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/51  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.  
00559918 86149324 MEDL/86149324  
Only high-affinity receptors for interleukin 2 mediate internalization of ligand.  
Weissman AM; Harford JB; Svetlik PB; Leonard WL; Depper JM; **Waldmann TA**; Greene WC; Klausner RD  
Proc Natl Acad Sci U S A; 83(5):1463-6 1986 ISSN 0027-8424  
Journal Code: PV3  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/52  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00555671 86094413 MEDL/86094413  
Bismuth-212-labeled anti-Tac monoclonal antibody:  
alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.  
Kozak RW; Atcher RW; Gansow OA; Friedman AM; Hines JJ; **Waldmann TA**  
Proc Natl Acad Sci U S A; 83(2):474-8 1986 ISSN 0027-8424  
Journal Code: PV3  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/53  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00554462 88640034 ICDB/88640034  
ROLE AND MOLECULAR BIOLOGY OF THE INTERLEUKIN-2-INTERLEUKIN-2 RECEPTOR  
SYSTEM IN HEALTH AND DISEASE  
**Waldmann TA**; Kozak RW; Tsudo M; Oh-ishi T; Bongiovanni KF; Goldman  
CK  
Metabolism Branch, NCI, Bethesda, MD 20892  
Non-serial; Progress in Immunology VI. Sixth International Congress of  
Immunology. Cinader B, Miller RG, eds. New York, Academic Press, p. 553-62,  
1986.: 1986  
Languages: ENGLISH  
Document Type: MEETING PAPER

5/3/54  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00522623 85254471 MEDL/85254471  
Isolation and expression of complementary DNAs encoding the human  
interleukin 2 receptor.  
Greene WC; Depper JM; Crabtree GR; Rudikoff S; Pumphrey J; Robb RJ;  
Kronke M; Svetlik P; Peffer NJ; **Waldmann TA**; et al  
Cancer Res; 45(9 Suppl):4563s-4567s 1985 ISSN 0008-5472 Journal Code:  
CNF  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/55  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00522622 85254470 MEDL/85254470  
Interleukin 2 receptor (**Tac** antigen) expression in  
HTLV-I-associated adult T-cell leukemia.  
**Waldmann TA**; Longo DL; Leonard WJ; Depper JM; Thompson CB; Kronke M  
; Goldman CK; Sharrow S; Bongiovanni K; Greene WC  
Cancer Res; 45(9 Suppl):4559s-4562s 1985 ISSN 0008-5472 Journal Code:  
CNF  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/56  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00514976 85200298 MEDL/85200298  
Adult T cell leukemia: a potential target for ricin A chain immunotoxins.  
Kronke M; Depper JM; Leonard WJ; Vitetta ES; **Waldmann TA**; Greene WC  
Blood; 65(6):1416-21 1985 ISSN 0006-4971 Journal Code: A8G

Contract/Grant No.: CA-28149, SS, CA, SS, NCI  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/57

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00499850 86111567 MEDL/86111567

Interleukin-2 receptor expression in retrovirus associated adult T-cell leukemia.

**Waldmann TA**; Leonard WJ; Depper JM; Kronke M; Goldman CK; Oh T; Greene WC

Princess Takamatsu Symp; 15:259-68 1984 Journal Code: HHI

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/58

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00489169 85061621 MEDL/85061621

Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells.

Mingari MC; Gerosa F; Carra G; Accolla RS; Moretta A; Zubler RH; **Waldmann TA**; Moretta L

Nature; 312(5995):641-3 1984 ISSN 0028-0836 Journal Code: NSC

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/59

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00484993 85032518 MEDL/85032518

Expression of interleukin 2 receptors on activated human B cells.

**Waldmann TA**; Goldman CK; Robb RJ; Depper JM; Leonard WJ; Sharrow SO; Bongiovanni KF; Korsmeyer SJ; Greene WC

J Exp Med; 160(5):1450-66 1984 ISSN 0022-1007 Journal Code: I2V

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/60

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00484844 85031785 MEDL/85031785

Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen.

Depper JM; Leonard WJ; Kronke M; Noguchi PD; Cunningham RE; **Waldmann TA**; Greene WC

J Immunol; 133(6):3054-61 1984 ISSN 0022-1767 Journal Code: IFB

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/61

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00478032 84289961 MEDL/84289961

Pseudomonas exotoxin-anti-**TAC** . Cell-specific immunotoxin active

against cells expressing the human T cell growth factor receptor.  
FitzGerald DJ; **Waldmann TA**; Willingham MC; Pastan I  
J Clin Invest; 74(3):966-71 1984 ISSN 0021-9738 Journal Code: HS7  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/62  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00471239 84241073 MEDL/84241073  
Phorbol diester induces expression of **Tac** antigen on human acute T lymphocytic leukemic cells.  
Greene WC; Robb RJ; Depper JM; Leonard WJ; Drogula C; Svetlik PB; Wong-Staal F; Gallo RC; **Waldmann TA**  
J Immunol; 133(2):1042-7 1984 ISSN 0022-1767 Journal Code: IFB  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/63  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00467497 84213140 MEDL/84213140  
Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-**Tac**. Monoclonal antibody identifying the human receptor for T cell growth factor.  
**Waldmann TA**; Greene WC; Sarin PS; Saxinger C; Blayney DW; Blattner WA; Goldman CK; Bongiovanni K; Sharrow S; Depper JM; et al  
J Clin Invest; 73(6):1711-8 1984 ISSN 0021-9738 Journal Code: HS7  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/64  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00441769 84070747 MEDL/84070747  
Characterization of the human receptor for T-cell growth factor.  
Leonard WJ; Depper JM; Robb RJ; **Waldmann TA**; Greene WC  
Proc Natl Acad Sci U S A; 80(22):6957-61 1983 ISSN 0027-8424  
Journal Code: PV3  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/65  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00437919 84039776 MEDL/84039776  
Association of human T-cell leukaemia/lymphoma virus with the **Tac** antigen marker for the human T-cell growth factor receptor.  
Lando Z; Sarin P; Megson M; Greene WC; **Waldman TA**; Gallo RC; Broder S  
Nature; 305(5936):733-6 1983 ISSN 0028-0836 Journal Code: NSC  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

5/3/66

DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

00428272 83273653 MEDL/83273653

Rearrangement and expression of immunoglobulin genes and expression of **Tac** antigen in hairy cell leukemia.

Korsmeyer SJ; Greene WC; Cossman J; Hsu SM; Jensen JP; Neckers LM; Marshall SL; Bakhshi A; Depper JM; Leonard WJ; Jaffe ES; **Waldmann TA**

Proc Natl Acad Sci U S A; 80(14):4522-6 1983 ISSN 0027-8424  
Journal Code: PV3

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/67

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00357793 83601683 ICDB/83601683

A MONOCLONAL ANTIBODY THAT APPEARS TO RECOGNIZE THE RECEPTOR FOR HUMAN T-CELL GROWTH FACTOR; PARTIAL CHARACTERIZATION OF THE RECEPTOR

Leonard WJ; Depper JM; Uchiyama T; Smith KA; **Waldmann TA**; Greene WC

Metabolism Branch, NCI, NIH, Bethesda, MD, 20205

Nature; 300(5889):267-269 1982

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/68

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00304399 81197499 MEDL/81197499

Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells.

Broder S; Uchiyama T; Muul LM; Goldman C; Sharrow S; Poplack DG; **Waldmann TA**

N Engl J Med; 304(23):1382-7 1981 ISSN 0028-4793 Journal Code: NOW

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

5/3/69

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00299993 81143481 MEDL/81143481

A monoclonal antibody (anti-**Tac**) reactive with activated and functionally mature human T cells. I. Production of anti-**Tac** monoclonal antibody and distribution of **Tac** (+) cells.

Uchiyama T; Broder S; **Waldmann TA**

J Immunol; 126(4):1393-7 1981 ISSN 0022-1767 Journal Code: IFB

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

11/3/2

DIALOG(R) File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00889575 92034763 MEDL/92034763

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

Hanninen EL; Korfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J

Department of Hematology and Oncology, Medizinische Hochschule Hanover, Germany.

Cancer Res; 51(23 Pt 1):6312-6 1991 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

s tac and lymphoma?

1376 TAC  
79436 LYMPHOMA?  
S6 168 TAC AND LYMPHOMA?  
? s s6 and py=1993

168 S6  
80574 PY=1993  
S7 12 S6 AND PY=1993  
? rd s7

...completed examining records  
S8 12 RD S7 (unique items)  
? s s6 and py=1994

168 S6  
83740 PY=1994  
S9 10 S6 AND PY=1994  
? t s7/3/all

7/3/1  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

01040145 94036762 MEDL/94036762  
Alternative splicing of the p53 tumor suppressor gene in the Molt-4  
T-lymphoblastic leukemia cell line.  
Chow VT; Quek HH; Tock EP  
Department of Microbiology, Faculty of Medicine, National University of  
Singapore, Kent Ridge.  
Cancer Lett; 73(2-3):141-8 1993 ISSN 0304-3835 Journal Code: CMX  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

7/3/2  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

01034122 94003208 MEDL/94003208  
The interleukin-2 receptor: a target for monoclonal antibody treatment of  
human T-cell lymphotropic virus I-induced adult T-cell leukemia.  
Waldmann TA; White JD; Goldman CK; Top L; Grant A; Bamford R; Roessler E;  
Horak ID; Zaknoen S; Kasten-Sportes C; et al  
Metabolism Branch and Laboratory of Pathology, National Cancer Institute,  
National Institutes of Health, Bethesda, MD 20892.  
Blood; 82(6):1701-12 1993 ISSN 0006-4971 Journal Code: A8G  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

7/3/3  
DIALOG(R)File 159:Cancerlit  
(c) format only 2000 Dialog Corporation. All rts. reserv.

01029144 93368196 MEDL/93368196  
1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.  
Waldmann TA

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leukemia; 7 Suppl 2:S151-6 1993 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

7/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01021107 93318559 MEDL/93318559

Ki-1-positive large cell anaplastic **lymphoma** diagnosed by urinary cytology. A case report.

Tanaka T; Yoshimi N; Sawada K; Takami T; Sugie S; Etori F; Kachi H; Mori H

Department of Pathology, Gifu University School of Medicine, Japan.

Acta Cytol; 37(4):520-4 1993 ISSN 0001-5547 Journal Code: OLi

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

7/3/5

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01019871 93311229 MEDL/93311229

Clinicopathologic, enzyme and histochemical studies of centrocytic (mantle cell) **lymphoma** : comparison with other types of low-grade B cell **lymphoma** based on the updated Kiel classification.

Takeshita M; Masuda Y; Sumiyoshi Y; Ohshima K; Kikuchi M; Kimura N; Okamura T; Nishimura J; Kozuru M

Department of Pathology, School of Medicine, Fukuoka University, Japan.

Acta Pathol Jpn; 43(5):244-52 1993 ISSN 0001-6632 Journal Code: lNE

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

7/3/6

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01004177 93218273 MEDL/93218273

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.

Kreitman RJ; Chaudhary VK; Waldmann TA; Hanchard B; Cranston B; FitzGerald DJ; Pastan I

Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Leukemia; 7(4):553-62 1993 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

7/3/7

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00991310 95606931 ICDB/95606931

Lymphokine receptors: a target for immunotherapy of **lymphomas** (Meeting abstract).

Waldmann TA

NCI, Bethesda, MD 20892

Non-serial; Fifth International Conference on Malignant Lymphoma, June 9-12, 1993, Lugano, Switzerland, p. 46, 1993.: 1993

Languages: ENGLISH  
Document Type: MEETING ABSTRACTS

7/3/8

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00990752 95605905 ICDB/95605905

Progress in radioimmunotherapy (Meeting abstract).

Carrasquillo JA

Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892

Non-serial; International Congress of Radiation Oncology 1993. June 21-25, 1993, Kyoto, Japan, p. 149, 1993.: 1993

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

7/3/9

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00986602 94690741 ICDB/94690741

Value of lymphography in the study of **lymphomas**

Valor de la linfografia en el estudio de los linfomas.

Jimenez Cazorla AD

Universidad de Sevilla, Spain

Diss Abstr Int [C]; 54(1):245 1993 ISSN 0419-4217

Languages: SPANISH

Document Type: THESIS

7/3/10

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00985732 93694384 ICDB/93694384

Recombinant toxins for cancer treatment (Meeting abstract).

Pastan I; FitzGerald DJ

Lab. of Molecular Biology, NCI, Bethesda, MD 20892

Proc Annu Meet Am Assoc Cancer Res; 34:622-3 1993 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

7/3/11

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00985141 93693792 ICDB/93693792

Towards optimal anti-**Tac** antibody dosing in the presence of antigenemia in adult T-cell leukemia-**lymphoma** (Meeting abstract).

Junghans RP; Goldman CK; Carrasquillo J; Reynolds J; Nelson DL; Waldmann TA

New England Deaconess Hosp., Boston, MA 02215

Proc Annu Meet Am Assoc Cancer Res; 34:A2849 1993 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

7/3/12

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00983622 93692207 ICDB/93692207

Pilot Phase II study of a DAB486IL-2 fusion toxin in cutaneous T-cell lymphoma (Meeting abstract).

Foss F; Borkowski T; Tompkins A; Gilliom M; Cooper M; Udey M; Stetler-Stevenson M; Jaffe E; Woodworth T; Sausville E

NCI, Bethesda, MD

Proc Annu Meet Am Assoc Cancer Res; 34:A1236 1993 ISSN 0197-016X

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

? t s9/3/all

9/3/1

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01138480 95182475 MEDL/95182475

Experimental study on anti-tumor effect of splenocytes induced by anti-CD3 McAb, PHA and IL-2.

Shen GX; Wang XL; Zhu HF; Zhang Y; Shao JF

Department of Immunology, Tongji Medical University, Wuhan.

J Tongji Med Univ; 14(1):12-5 1994 ISSN 0257-716X Journal Code: KAJ

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

9/3/2

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01109205 94362224 MEDL/94362224

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.

Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T; et al

US Naval Hospital, Bethesda, MD.

Blood; 84(6):1765-74 1994 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE

9/3/3

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01102721 94325831 MEDL/94325831

Down-regulation of CD3 antigen on adult T cell leukemia cells.

Maeda Y; Matsuda M; Irimajiri K; Horiuchi A

Third Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.

Leuk Lymphoma; 13(3-4):249-56 1994 ISSN 1042-8194 Journal Code: BNQ

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

9/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01102643 94325579 MEDL/94325579

Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor.

Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R; et al

Clinical Research Division, Fred Hutchinson Cancer Research Center 98104.

Blood; 84(4):1320-7 1994 ISSN 0006-4971 Journal Code: A8G

Contract/Grant No.: CA 18029, SS, CA, SS, NCI; CA 18221, SS, CA, SS, NCI;  
HL36444, SS, HL, SS, NHLBI; +  
Languages: ENGLISH  
Document Type: JOURNAL ARTICLE

9/3/5

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01101755 94320068 MEDL/94320068

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor  
alpha-expressing **lymphoma** utilizing the alpha-emitting  
radionuclide-conjugated monoclonal antibody 212Bi-anti-**Tac**.

Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J;  
Kosteiny SA; Gansow OA; Nelson DL; et al

Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland  
20892.

Cancer Res; 54(16):4362-70 1994 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

9/3/6

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01097860 94297519 MEDL/94297519

Recombinant single-chain immunotoxins against T and B cell leukemias.

Kreitman RJ; Pastan I

Laboratory of Molecular Biology, National Cancer Institute, National  
Institutes of Health, Bethesda, Maryland 20892.

Leuk Lymphoma; 13(1-2):1-10 1994 ISSN 1042-8194 Journal Code: BNQ

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

9/3/7

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01092742 94266289 MEDL/94266289

Anti-IL-2 receptor monoclonal antibody (anti-**Tac**) treatment of  
T-cell **lymphoma**.

Waldmann TA

Metabolism Branch, National Cancer Institute, Bethesda, Maryland.

Important Adv Oncol; :131-41 1994 ISSN 0883-5896 Journal Code: GG9

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC

9/3/8

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01089877 94249675 MEDL/94249675

Differential expression of interleukin-2 receptors (alpha and beta chain)  
in mature lymphoid neoplasms.

Nakase K; Kita K; Nasu K; Ueda T; Tanaka I; Shirakawa S; Tsudo M

Department of Internal Medicine, Yamada Red Cross Hospital, Misono,  
Japan.

Am J Hematol; 46(3):179-83 1994 ISSN 0361-8609 Journal Code: 3H4

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

9/3/9

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01086036 94226936 MEDL/94226936

Lymphokine receptors: a target for immunotherapy of **lymphomas**.

Waldmann TA

Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Ann Oncol; 5 Suppl 1:13-7 1994 ISSN 0923-7534 Journal Code: AYF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

9/3/10

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01071386 96605013 ICDB/96605013

Effectiveness of bcl-2 antisense oligodeoxy-nucleotides (AS-ODN) against human follicular small-cleaved cell **lymphoma** (FSCCL)-SCID mice xenograft model (Meeting abstract).

Abubakr YA; Mohammad R; Maki A; Dan M; Du W; Smith MR; Al-Katib A

Division of Hematology/Oncology and Department of Pathology, Wayne State University, Detroit, MI

Blood; 84(10, Suppl 1):374a 1994 ISSN 0903-1936

Languages: ENGLISH

Document Type: MEETING ABSTRACTS

? ds

Set	Items	Description
S1	254	E1,E19
S2	72	S1 AND TAC
S3	6	S2 AND PY=1993
S4	4	S2 AND PY=1994
S5	69	RD S2 (unique items)
S6	168	TAC AND LYMPHOMA?
S7	12	S6 AND PY=1993
S8	12	RD S7 (unique items)
S9	10	S6 AND PY=1994

? s s6 and soluble(10n) (IL(w)2 or IL(w)2R)

	168	S6
	20463	SOLUBLE
	61351	IL
	499237	2
	21778	IL(W)2
	61351	IL
	3103	2R
	2251	IL(W)2R
	826	SOLUBLE(10N) (IL(W)2 OR IL(W)2R)
S10	5	S6 AND SOLUBLE(10N) (IL(W)2 OR IL(W)2R)

? rd s10

...completed examining records

S11 5 RD S10 (unique items)

s soluble(30n) (IL(w)2 or IL(w)2R or IL(w)2(w)receptor?) and tac

```
20463 SOLUBLE
61351 IL
499237 2
21778 IL(W)2
61351 IL
3103 2R
2251 IL(W)2R
61351 IL
499237 2
122702 RECEPTOR?
3467 IL(W)2(W)RECEPTOR?
1164 SOLUBLE(30N)((IL(W)2 OR IL(W)2R) OR IL(W)2(W)RECEPTOR?)
1376 TAC
S12 43 SOLUBLE(30N)(IL(W)2 OR IL(W)2R OR IL(W)2(W)RECEPTOR?) AND
TAC
```

? rd s12

...completed examining records

```
S13 43 RD S12 (unique items)
? t s13/3/all
```

13/3/1

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01095932 94286643 MEDL/94286643

Targeting human IL-2 receptors for diagnosis and therapy.

Nelson DL; Kurman CC

Immunophysiology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Proc Soc Exp Biol Med; 206(3):309-11 1994 ISSN 0037-9727

Journal Code: PXZ

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

13/3/2

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01075134 94139113 MEDL/94139113

Follow up of **soluble IL-2 receptor** level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Soubrane C; Mouawad R; Ichen M; Suissa J; Borel C; Vuillemin E; Benhammouda A; Bizzari JP; Weil M; Khayat D

Department of Medical Oncology, Salpetriere Hospital, Paris, France.

Clin Exp Immunol; 95(2):232-6 1994 ISSN 0009-9104 Journal Code: DD7

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/3

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01073616 94118567 MEDL/94118567

Does IL-2 receptor expression and secretion in chronic B-cell leukemia

have a role in down-regulation of the immune system?

Burton J; Kay NE

Metabolism Branch, National Institute of Health, Bethesda, MD.

Leukemia; 8(1):92-6 1994 ISSN 0887-6924 Journal Code: LEU

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

13/3/4

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01049259 94092956 MEDL/94092956

Human T lymphocyte activation by pokeweed mitogen induces production of TNF-alpha and GM-CSF and helper signaling by IL-1 and IL-6 results in IL-2-dependent T cell growth.

Wallays G; Ceuppens JL

Department of Medicine and Pathophysiology, University of Leuven, Belgium.

Eur Cytokine Netw; 4(4):269-77 1993 ISSN 1148-5493 Journal Code: A56

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/5

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

01034189 94003317 MEDL/94003317

A model of in vivo cell proliferation of adult T-cell leukemia.

Kondo A; Imada K; Hattori T; Yamabe H; Tanaka T; Miyasaka M; Okuma M; Uchiyama T

First Department of Internal Medicine and Laboratory of Anatomic Pathology, Kyoto University, Japan.

Blood; 82(8):2501-9 1993 ISSN 0006-4971 Journal Code: A8G

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/6

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00966791 93077183 MEDL/93077183

Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.

Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR; et al

Department of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Immunol Lett; 33(2):127-34 1992 ISSN 0165-2478 Journal Code: GIH

Languages: ENGLISH

Document Type: CLINICAL TRIAL; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY

13/3/7

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00950624 92388287 MEDL/92388287

Membrane-based receptor affinity chromatography.

Nachman M; Azad AR; Bailon P

Protein Biochemistry Department, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110.

13/3/8

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00930410 92256201 MEDL/92256201

Diagnostic and clinical importance of interleukin-2 receptor alpha chain expression on non-T-cell acute leukaemia cells.

Nakase K; Kita K; Otsuji A; Anazawa H; Hoshino K; Sekine T; Shirakawa S; Tanaka I; Nasu K; Tsutani H; et al

Second Department of Internal Medicine, Faculty of Medicine, Mie University, Tsu, Japan.

Br J Haematol; 80(3):317-26 1992 ISSN 0007-1048 Journal Code: AXC

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/9

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00924210 92208969 MEDL/92208969

Highly concentrated urine-purified **Tac** peptide fails to inhibit IL-2-dependent cell proliferation in vitro.

Pizzolo G; Vincenzi C; Vinante F; Rigo A; Veneri D; Chilosì M; Dusi S; Poli G; Zambello R; Semenzato G; et al

Cattedra di Ematologia, Istituto di Patologia Generale, Verona, Italy.

Cell Immunol; 141(1):253-9 1992 ISSN 0008-8749 Journal Code: CQ9

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/10

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00923445 92201878 MEDL/92201878

The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes.

Kniep EM; Strelow I; Lohmann-Matthes ML

Abteilung für Immunobiologie, Fraunhofer Institut für Toxikologie, Hannover, Germany.

Immunology; 75(2):299-304 1992 ISSN 0019-2805 Journal Code: GH7

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/11

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00914263 93689708 ICDB/93689708

Combination of rIFN alpha-2a and IL-2 in melanoma patients: what are effective doses? (Meeting abstract).

Castello G; Comella P; Napolitano M; Manzo T; Leonardi E; Galati MG; Casaretti R; Daponte A; Comella G

Natl. Cancer Inst. of Naples, Naples, Italy

Ann Oncol; 3(Suppl 5):141 1992 ISSN 0923-7534

Languages: ENGLISH

Document Type: MEETING ABSTRACTS; CLINICAL TRIAL

13/3/12

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00903052 92136003 MEDL/92136003

The cytokine receptor superfamily.

Kaczmariski RS; Mufti GJ

Department of Haematological Medicine, King's College School of Medicine and Dentistry, London, UK.

Blood Rev; 5(3):193-203 1991 ISSN 0268-960X Journal Code: BLR

Languages: ENGLISH

Document Type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

13/3/13

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00889575 92034763 MEDL/92034763

Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.

Hanninen EL; Korfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J

Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.

Cancer Res; 51(23 Pt 1):6312-6 1991 ISSN 0008-5472 Journal Code: CNF

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

13/3/14

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00881013 91360958 MEDL/91360958

[The interleukin-2 receptor (editorial)]

Il recettore dell'interleukina-2.

Marino P; Preatoni A

Recenti Prog Med; 82(5):291-3 1991 ISSN 0034-1193 Journal Code: R1T

Languages: ITALIAN

Document Type: EDITORIAL English Abstract

13/3/15

DIALOG(R)File 159:Cancerlit

(c) format only 2000 Dialog Corporation. All rts. reserv.

00819435 91002416 MEDL/91002416

Increased serum levels of **soluble IL-2 receptor**, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms.

Pizzolo G; Stein H; Josimovic-Alasevic O; Vinante F; Zanotti R; Chilosi M; Feller AC; Diamantstein T

Department of Hematology, Verona University, Italy.

Br J Haematol; 75(4):485-8 1990 ISSN 0007-1048 Journal Code: AXC

Languages: ENGLISH

Document Type: JOURNAL ARTICLE

# ADONIS - Electronic Journal Services

Requested by

Adonis

Article title                      The use of antibodies against the IL-2 receptor in transplantation

Article identifier                0952791598003542

Authors                          Waldmann\_T\_A O'Shea\_J

Journal title                    Current Opinion in Immunology

ISSN                              0952-7915

Publisher                        Current Biology

Year of publication            1998

Volume                          10

Issue                             5

Supplement                    0

Page range                     507-512

Number of pages              6

User name                       Adonis

Cost centre                      Development

PCC                               \$20.00

Date and time                  Thursday, March 09, 2000 12:35:16 AM

Copyright © 1991-1999 ADONIS and/or licensors.

The use of this system and its contents is restricted to the terms and conditions laid down in the Journal Delivery and User Agreement. Whilst the information contained on each CD-ROM has been obtained from sources believed to be reliable, no liability shall attach to ADONIS or the publisher in respect of any of its contents or in respect of any use of the system.

2/3/53 (Item 4 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

111005761 CA: 111(1)5761u PATENT  
Monoclonal antibody to Tac receptor for treatment of malignancy and  
autoimmune disorders in humans  
INVENTOR(AUTHOR): Waldmann, T. A.  
LOCATION: USA  
ASSIGNEE: United States Dept. of Health and Human Services  
PATENT: U.S. Pat. Appl. ; US 85707 A0 DATE: 880415  
APPLICATION: US 85707 (870817)  
PAGES: 18 pp. Avail. NTIS Order No. PAT-APPL-7-85707. CODEN: XAXXAV

2/3/52 (Item 3 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

117190132 CA: 117(19)190132z PATENT  
Antibody composition directed against human or animal interleukin-2  
(IL-2) receptor, and therapeutic uses thereof  
INVENTOR(AUTHOR): Jacques, Yannick; Soulillou, Jean Paul; Audrain, Marie;  
Francois-Bendahou, Christine  
LOCATION: Fr.  
ASSIGNEE: Institut National de la Sante et de la Recherche Medicale  
(INSERM)  
PATENT: PCT International ; WO 9213886 A1 DATE: 920820  
APPLICATION: WO 92FR75 (920128) \*FR 911102 (910131)  
PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: French CLASS: C07K-015/00A  
DESIGNATED COUNTRIES: AU; CA; JP; KR; US DESIGNATED REGIONAL: AT; BE; CH  
; DE; DK; ES; FR; GB; GR; IT; LU; MC; NL; SE

2/3/53 (Item 4 from file: 399)

2/3/29  
DIALOG(R)Fi  
(c) 2000 El

n 1 from file: 73)  
3:EMBASE  
Science B.V. All rts. reserv.

10828958  
Successful  
receptor) o  
**antibody** to  
Krueger J  
S.; Sherr A  
Dr. J.G.  
Investiga  
States  
AUTHOR EM  
Journal o  
(United Sta  
CODEN: JA  
DOCUMENT  
LANGUAGE:

ASE No: 2000309668  
vivo blockade of CD25 (high-affinity interleukin 2  
cells by administration of humanized anti-Tac  
patients with psoriasis  
Walters I.B.; Miyazawa M.; Gilleaudeau P.; Hakimi J.; Light  
Stlief A.B.  
er, Laboratory Head, Rockefeller University, Lab. for  
Dermatology, 1230 York Ave, New York, NY 10021-6399 United  
kruegej@rockvax.rockefeller.edu  
American Academy of Dermatology ( J. AM. ACAD. DERMATOL. )  
2000, 43/3 (448-458)  
ISSN: 0190-9622  
Journal; Article  
[SH SUMMARY LANGUAGE: ENGLISH

10828958 EMBASE  
Successful in vivo  
receptor) on T cells  
**antibody** to patients  
Krueger J.G.; Walt  
S.; Sherr A.; Gottli  
Dr. J.G. Krueger,  
Investigative Derm  
States  
AUTHOR EMAIL: krue  
Journal of the Ame  
(United States) 200  
CODEN: JAADD ISS  
DOCUMENT TYPE: Jou  
LANGUAGE: ENGLISH  
NUMBER OF REFERENC

Background: Dacliz  
(CD25) of the interl  
normal IL-2 binding  
T-cell growth, **block**  
be useful in treatin  
Objective: Our purpo  
**antibody** were achiev  
lesions to saturate  
effect and safety of  
immunosuppressive dr  
psoriasis in two cer  
then 1 mg/kg at week  
blocked in vivo, flo  
CD3sup + T cells der  
of CD25sup + cells d  
Patients were follow  
and Severity Index s  
of CD25 in periphera  
while the dosing was  
began after 4 weeks,  
improvement. Patient  
score of less than 3  
(P = .02). During th  
of the IL-2 receptor  
were calculated and  
study No significant  
study. Conclusion: W  
well-tolerated agent  
skin. Furthermore, i

00309668  
ade of CD25 (high-affinity interleukin 2  
ministration of humanized anti-**Tac**  
psoriasis  
B.; Miyazawa M.; Gilleaudeau P.; Hakimi J.; Light  
ory Head, Rockefeller University, Lab. for  
7, 1230 York Ave, New York, NY 10021-6399 United  
skvax.rockefeller.edu  
Academy of Dermatology ( J. AM. ACAD. DERMATOL. )  
(448-458)  
-9622  
article  
RY LANGUAGE: ENGLISH

a humanized **antibody** to the alpha-subunit  
(**IL-2 receptor**) that blocks  
receptor. Because IL-2 is a major stimulus for  
the **IL-2 receptor** could  
l-mediated (**autoimmune**) diseases.  
to determine whether adequate concentrations of  
circulating blood and in psoriatic skin  
receptors. We also intended to measure clinical  
agent when used alone (without other  
psoriasis. Methods: Nineteen patients with  
ceived daclizumab at an initial dose of 2 mg/kg,  
8, and 12. To determine whether CD25 was  
metric studies measured (1) expression of CD25 on  
om blood and (2) immunohistochemistry measures  
pretreatment and posttreatment biopsy specimens.  
clinically with photographs and Psoriasis Area  
Results: This study showed a consistent blockade  
and tissue during the first 4 weeks of therapy  
2 weeks. Variable desaturation of receptors  
correlated with a reversal in disease  
a pretreatment Psoriasis Area and Severity Index  
ed a mean reduction in severity by 30% at 8 weeks  
eks of treatment, a 44.8% decrease in expression  
subunit was found. The absolute T-cell counts  
no significant changes during the course of the  
e events were produced by daclizumab during this  
efore conclude that daclizumab is a  
blocks CD25 expression in peripheral blood and  
be useful in treating psoriasis in some patients.

53 RD S1 (uni  
? s s2 and (soluble)

ns)  
(w)2R or receptor?)

53 S2  
326299 SO  
256953 IL  
21117 2R  
8771 IL  
1948284 RE  
19857 SO  
S3 0 S2

N) (IL(W)2R OR RECEPTOR?)  
OLUBLE) (5N) (IL(W)2R OR RECEPTOR?)

S - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2001/Jul W1  
(c) 2001 BIOSIS

File 73:EMBASE 1974-2001/Jun W4  
(c) 2001 Elsevier Science B.V.

\*File 73: For information about Explode feature please  
see Help News73.

File 155:MEDLINE(R) 1966-2001/Jul W2  
(c) format only 2001 Dialog Corporation

\*File 155: This file has been reloaded. Accession numbers have changed.  
Please see Help News155 for further details.

File 399:CA SEARCH(R) 1967-2001/UD=13501  
(c) 2001 AMERICAN CHEMICAL SOCIETY

\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see HELP RATES 399.

Set Items Description

? e au=waldmann thomas ?

Ref	Items	Index-term
E1	3	AU=WALDMANN TH.
E2	12	AU=WALDMANN THOMAS
E3	0	*AU=WALDMANN THOMAS ?
E4	65	AU=WALDMANN THOMAS A
E5	1	AU=WALDMANN THOMAS ALEXANDER
E6	1	AU=WALDMANN THOMAS W
E7	1	AU=WALDMANN TODD B
E8	2	AU=WALDMANN TODD M
E9	1	AU=WALDMANN TS
E10	15	AU=WALDMANN U
E11	7	AU=WALDMANN U.
E12	1	AU=WALDMANN ULRICH

Enter P or PAGE for more

? s e1-e5

3	AU=WALDMANN TH.
12	AU=WALDMANN THOMAS
0	AU=WALDMANN THOMAS ?
65	AU=WALDMANN THOMAS A
1	AU=WALDMANN THOMAS ALEXANDER
S1	81 E1-E5

? rd s1

...examined 50 records (50)

...completed examining records

S2 79 RD S1 (unique items)  
? s s2 and tac

79	S2
9383	TAC
S3	25 S2 AND TAC

? t s3/7/all

3/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

13107907 BIOSIS NO.: 200100315056

Pretargeting radioimmunotherapy with the alpha emitter, Bi-213, in the treatment of adult T cell leukemia (ATL).

AUTHOR: Zhang Meili(a); Yao Zhengsheng; Garmestani Kayhan; Axworthy Donald B; Mallett Robert W; Fritzberg Alan R; Brechbiel Martin W; Carrasquillo Jorge A; **Waldmann Thomas A**(a)

AUTHOR ADDRESS: (a)Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD\*\*USA

JOURNAL: Blood 96 (11 Part 1):p721a November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

**ABSTRACT:** Adult T-cell leukemia (ATL) consists of an overabundance of activated T cells which are characterized by the expression of CD25 or IL-2Ralpha on the cell surface. Presently, there is no accepted curative therapy for ATL. In this study, we investigated the use of a pretargeting technique with the alpha-emitter, Bi-213, to treat ATL. DOTA-biotin was labeled with Bi-213 at a specific activity of >1 mCi/mug. Humanized anti-**Tac** antibody (HAT), which recognizes CD25, was conjugated to streptavidin (SA) forming HAT-SA. A tumor model was established by i.p. injection of 20X106 tumor cells from human ATL-tumor bearing mice into NOD/SCID mice. The therapy study was performed at two weeks after the inoculation. Before therapy and every two weeks thereafter, serum soluble **Tac** (sIL-2Ralpha) levels were measured in order to monitor tumor growth. HAT-SA (140 mug) was used allowing pretargeting for 24 hours. Then, 100 mug of synthetic clearing agent (sCA), containing biotin and galactose arms, developed by NeoRx, was used to clear unbound conjugate from the circulation. Four hours later, 0.3 mug of Bi-213 labeled DOTA-biotin was given for therapy. Groups of 5 mice each were treated with 0, 50, 150, 250 or 350 muCi of Bi-213 and one group without any treatment served as a control. Complete blood count (CBC) was monitored for toxicity weekly. Results: The tumor growth was inhibited by using 250 or 350 muCi of Bi-213 labeled biotin in the pretargeting technique as indicated by the significant reduction of sIL-2Ralpha levels ( $p < 0.005$ , t test) compared with the control group on day 28. Furthermore, there was a significant prolongation of the survival of the mice treated with either 250 or 350 muCi of Bi-213 as compared with the control group ( $p < 0.02$ , rank test). The median survival duration of the control group was 52 days, whereas it increased to >75.6 and >67 days in 250 and 350 muCi Bi-213 treated groups, respectively. The CBC results revealed a dose dependant decrease of platelet and white blood cell count one week after therapy, with recovery three weeks later. Conclusion: Bi-213 labeled biotin used with the pretargeting technique proved to be an effective therapeutic for ATL without unacceptable toxicity.

3/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

12862062 BIOSIS NO.: 200100069211

IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.

AUTHOR: Phillips Kathleen E; Herring Bert; Wilson Latresia A; Rickford Marc S; Zhang Meili; Goldman Carolyn K; Tso J Yun; **Waldmann Thomas A**(a)

AUTHOR ADDRESS: (a)Metabolism Branch, National Cancer Institute, NIH, 10 Center Drive, Building 10, Room 4N-115, Bethesda, MD, 20892-1374\*\*USA

JOURNAL: Cancer Research 60 (24):p6977-6984 December 15, 2000

MEDIUM: print  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

ABSTRACT: Adult T-cell leukemia (ATL) develops in a small proportion of human T-cell lymphotropic virus-I infected individuals. The leukemia consists of an overabundance of activated T cells, which are characterized by the expression of CD25, or IL-2Ralpha, on their cell surface. Presently, there is not an accepted curative therapy for ATL. We developed an in vivo model of ATL in non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice by introducing cells from an ATL patient (MET-1) into the mice. The leukemic cells proliferated in these mice that lack functional T, B, and natural killer (NK) cells. The MET-1 leukemic cells could be monitored by measurements of both serum soluble **Tac** (IL-2Ralpha) and soluble human beta2-microglobulin (beta2mu) by ELISA. The disease progressed to death in the mice after approx 4-6 weeks. The mice developed grossly enlarged spleens and a leukemia involving ATL cells that retained the phenotype and the T-cell receptor rearrangement and human T-cell lymphotropic virus-I integration pattern of the patient's ATL leukemia cells. This model is of value for testing the efficacy of novel therapeutic agents for ATL. The administration of humanized anti-**Tac** (HAT), murine anti-**Tac** (MAT), and 7G7/B6, all of which target IL-2Ralpha, significantly delayed the progression of the leukemia and prolonged the survival of the tumor-bearing mice. In particular, HAT induced complete remissions in 4 of 19 mice and partial remissions in the remainder. It appears that the antibodies act by a mechanism that had not been anticipated. The prevailing view is that antibodies to the IL-2Ralpha receptor have their effective action by blocking the interaction of IL-2 with its growth factor receptor, thereby inducing cytokine deprivation apoptosis. However, although both HAT and MAT block the binding of IL-2 to IL-2Ralpha of the high affinity receptor, the 7G7/B6 monoclonal antibody binds to a different epitope on the IL-2Ralpha receptor, one that is not involved in IL-2 binding. This suggested that the antibodies provide an effective therapy by a mechanism other than induction of cytokine deprivation. In accord with this view, the MET-1 cells obtained from the spleens of leukemic mice did not produce IL-2, nor did they express IL-2 mRNA as assessed by reverse transcription-PCR. Another possible conventional mechanism of action involves complement-mediated killing. However, although MAT and 7G7/B6 fix rabbit complement, HAT does not do so. Furthermore, in the presence of NOD/SCID mouse serum, there was no complement-mediated lysis of MET-1 cells. In addition, the antibodies did not manifest antibody-dependent cellular cytotoxicity with NOD/SCID splenocytes that virtually lack NK cells as the effector cells as assessed in an in vitro chromium-release assay. However, in contrast to the efficacy of intact HAT, the F(ab')<sub>2</sub> version of this antibody was not effective in prolonging the survival of mice injected with MET-1 ATL cells. In conclusion, in our murine model of ATL, monoclonal antibodies, HAT, MAT, and 7G7/B6, appear to delay progression of the leukemia by a mechanism of action that is different from the accepted mechanism of IL-2 deprivation leading to cell death. We consider two alternatives: the first, antibody-dependent cellular cytotoxicity mediated by FcRI- or FcRIII-expressing cells other than NK cells, such as monocytes or polymorphonuclear leukocytes. The second alternative we consider involves direct induction of apoptosis by the anti-IL-2R antibodies in vivo. It has been shown that the IL-2R is a critical element in the peripheral self-tolerance T-cell suicide mechanism involved in the phenomenon of activation-induced cell death.

3/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

12831477 BIOSIS NO.: 200100038626

Advances in interleukin 2 receptor targeted treatment.

AUTHOR: Morris John C(a); **Waldmann Thomas A**

AUTHOR ADDRESS: (a)Metabolism Branch, Division of Clinical Sciences,  
National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Rm 4N115,  
Bethesda, MD, 20892-1374: jmorris@mail.nih.gov\*\*USA

JOURNAL: Annals of the Rheumatic Diseases 59 (Supplement 1):pi109-i114  
November, 2000

MEDIUM: print

ISSN: 0003-4967

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: T cell activation and cellular immune responses are modulated by interleukin 2 (IL2) through binding to its corresponding cell surface receptor. Three forms of the receptor are recognised based on IL2 binding affinity. The high affinity receptor is a heterotrimer composed of alpha, beta, and gamma-polypeptide chains. The 55 kDa alpha-chain also known as the **Tac** (T cell activation) antigen or CD-25 is a unique subunit of the high affinity IL2 receptor (IL2Ralpha). Resting T cells express few IL2Ralpha, however, when activated, the expression of IL2Ralpha rapidly increases. The IL2Ralpha is shed from the cell surface and is measurable in the serum as a 45 kDa soluble form (s-**Tac** or s-IL2Ralpha). Serum concentrations of s-**Tac** can be used as a surrogate marker for T cell activation and IL2Ralpha expression. IL2Ralpha is over expressed by T cells in a number of autoimmune diseases, allograft rejection and a variety of lymphoid neoplasms. IL2 induced proliferation of T cells can be inhibited by the murine monoclonal antibody (anti-**Tac**) directed against the alpha-chain of the IL2R. Through molecular engineering, murine anti-**Tac** has been humanised reducing its immunogenicity without changing its specificity. Humanised anti-**Tac** (HAT) has been shown to reduce the incidence of renal and cardiac allograft rejection as well as decrease the severity of graft versus host disease in patients undergoing HLA matched allogeneic bone marrow transplantation. IL2Ralpha targeted treatment with radioimmunoconjugates of anti-**Tac** and immunotoxins has shown promise in the treatment of CD25 expressing lymphomas.

3/7/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

12482143 BIOSIS NO.: 200000235645

Phase I trial of recombinant immunotoxin anti-**Tac**(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

AUTHOR: Kreitman Robert J; Wilson Wyndham H; White Jeffrey D;  
Stetler-Stevenson Maryalice; Jaffe Elaine S; Giardina Steven; **Waldmann Thomas A**; Pastan Ira(a)

AUTHOR ADDRESS: (a)Laboratory of Molecular Biology, National Cancer  
Institute, National Institute of Health, 9000 Rockville Pike, Building  
37/4E16, Bethesda, MD, 20892\*\*USA

JOURNAL: Journal of Clinical Oncology 18 (8):p1622-1636 April, 2000

ISSN: 0732-183X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: Purpose: To evaluate the toxicity, pharmacokinetics, immunogenicity, and antitumor activity of anti-**Tac**(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an antibody Fv fragment fused to truncated Pseudomonas exotoxin. Patients and Methods: Patients with CD25+ hematologic malignancies for whom standard

and salvage therapies failed were treated with LMB-2 at dose levels that ranged from 2 to 63 mug/kg administered intravenously over 30 minutes on alternate days for three doses (QOD X 3). Results: LMB-2 was administered to 35 patients for a total of 59 cycles. Dose-limiting toxicity at the 63 mug/kg level was reversible and included transaminase elevations in one patient and diarrhea and cardiomyopathy in another. LMB-2 was well tolerated in nine patients at the maximum-tolerated dose (40 mug/kg QOD X 3); toxicity was transient and most commonly included transaminase elevations (eight patients) and fever (seven patients). Only six of 35 patients developed significant neutralizing antibodies after the first cycle. The median half-life was 4 hours. One hairy cell leukemia (HCL) patient achieved a complete remission, which is ongoing at 20 months. Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three patients), chronic lymphocytic leukemia (one patient), Hodgkin's disease (one patient), and adult T-cell leukemia (one patient). Responding patients had 2 to 5 log reductions of circulating malignant cells, improvement in skin lesions, and regression of lymphomatous masses and splenomegaly. All four patients with HCL responded to treatment. Conclusion: LMB-2 has clinical activity in CD25+ hematologic malignancies and is relatively nonimmunogenic. It is the first recombinant immunotoxin to induce major responses in cancer. LMB-2 and similar agents that target other cancer antigens merit further clinical development.

BIOSIS. All rts. reserv.

12831477 BIOSIS NO.: 200100038626

Advances in interleukin 2 receptor targeted treatment.

AUTHOR: Morris John C(a); **Waldmann Thomas A**

AUTHOR ADDRESS: (a)Metabolism Branch, Division of Clinical Sciences,  
National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Rm 4N115,  
Bethesda, MD, 20892-1374: jmorris@mail.nih.gov\*\*USA

JOURNAL: Annals of the Rheumatic Diseases 59 (Supplement 1):pi109-i114  
November, 2000

MEDIUM: print

ISSN: 0003-4967

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: T cell activation and cellular immune responses are modulated by interleukin 2 (IL2) through binding to its corresponding cell surface receptor. Three forms of the receptor are recognised based on IL2 binding affinity. The high affinity receptor is a heterotrimer composed of alpha, beta, and gamma-polypeptide chains. The 55 kDa alpha-chain also known as the **Tac** (T cell activation) antigen or CD-25 is a unique subunit of the high affinity IL2 receptor (IL2Ralpha). Resting T cells express few IL2Ralpha, however, when activated, the expression of IL2Ralpha rapidly increases. The IL2Ralpha is shed from the cell surface and is measurable in the serum as a 45 kDa soluble form (s-**Tac** or s-IL2Ralpha). Serum concentrations of s-**Tac** can be used as a surrogate marker for T cell activation and IL2Ralpha expression. IL2Ralpha is over expressed by T cells in a number of autoimmune diseases, allograft rejection and a variety of lymphoid neoplasms. IL2 induced proliferation of T cells can be inhibited by the murine monoclonal antibody (anti-**Tac**) directed against the alpha-chain of the IL2R. Through molecular engineering, murine anti-**Tac** has been humanised reducing its immunogenicity without changing its specificity. Humanised anti-**Tac** (HAT) has been shown to reduce the incidence of renal and cardiac allograft rejection as well as decrease the severity of graft versus host disease in patients undergoing HLA matched allogeneic bone marrow transplantation. IL2Ralpha targeted treatment with radioimmunoconjugates of anti-**Tac** and immunotoxins has shown promise in the treatment of CD25 expressing lymphomas.

-----  
? s (tac) (10n) (antibod?) (30n) (radiolabel? or yttrium? or  
90Y) (40n) (mg) (40n) (treat? or therap? or administ?)

Processing

Processing

Processing

	8865	TAC
	1537832	ANTIBOD?
	92472	RADIOLABEL?
	81886	YTTRIUM?
	1178	90Y
	1234664	MG
	4863111	TREAT?
	4576406	THERAP?
	2662304	ADMINIST?
S1	8	(TAC) (10N) (ANTIBOD?) (30N) (RADIOLABEL? OR YTTRIUM? OR 90Y) (40N) (MG) (40N) (TREAT? OR THERAP? OR ADMINIST?)

? rd s1

...completed examining records

S2 3 RD S1 (unique items)

? t s2/7/all

2/7/1 (Item 1 from file: 5)  
DIALOG(R) File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

12458362 BIOSIS NO.: 200000211864

Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv  
recombinant immunotoxin.

AUTHOR: Kobayashi Hisataka; Kao Chih-Hao K; Kreitman Robert J; Le Nhat; Kim  
Meyoung-Kon; Brechbiel Martin W; Paik Chang H; Pastan Ira; Carrasquillo  
Jorge A(a)

AUTHOR ADDRESS: (a) Department of Nuclear Medicine, National Institutes of  
Health, 10 Center Dr., Bldg. 10, Rm. 1C496, Bethesda, MD, 20892-1180\*\*USA

JOURNAL: Journal of Nuclear Medicine 41 (4):p755-762 April, 2000

ISSN: 0161-5505

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT: The use of immunotoxins for cancer **therapy** is an attractive strategy that exploits the targeting specificity of monoclonal **antibodies** and their fragments as well as the exquisite toxicity of the toxins. However, few studies of immunotoxins have evaluated their biodistribution in vivo. Previous studies have used 125I for tracing immunotoxin biodistribution in mice. Because the immunotoxin works only when it is internalized and because of known problems with quick dehalogenation after internalization of **antibodies**, we decided to use 111In, which has greater intracellular retention than iodine. Methods: To trace the in vivo pharmacokinetics of the immunotoxin in mice, we labeled the antiTac(Fv)-PE38 with 111In and compared it with 125I-labeled antiTac(Fv)-PE38. We successfully labeled antiTac(Fv)-PE38 with 111In at up to 2.96 GBq/mg. A 3- to 4-fold decrease in cytotoxicity was observed for both **radiolabeled** preparations. We evaluated the internalization of 111In- and 125I-labeled antiTac(Fv)-PE38 into ATAC4 cells (**Tac**-positive) as well as their biodistribution

and pharmacokinetics in vivo in mice. In addition, some mice receiving these reagents were co-infused with 30 mg L-lysine to inhibit renal accumulation. Results: Significantly more 111In- than 125I-labeled antiTac(Fv)-PE38 accumulated in the ATAC4 cells (20% versus 5% of initial surface-bound radioactivity;  $P < 0.001$ ). In vivo, significantly more 111In- than 125I-labeled antiTac(Fv)-PE38 accumulated in the kidney (119 versus 31 percentage injected dose per gram (%ID/g);  $P < 0.001$ ). The tumor accumulation of 111In-labeled antiTac(Fv)-PE38 at 96 h was 13-fold greater than that of 125I-labeled antiTac(Fv)-PE38 (1.4 versus 0.1 %ID/g;  $P < 0.001$ ). No antiTac(Fv)-PE38 was excreted into the urine in its intact form unless lysine was co-infused. Co-injected lysine reduced the renal accumulation of 111In-labeled antiTac(Fv)-PE38 by 62%. Conclusion: We evaluated the biodistribution, pharmacokinetics, and catabolism of 111In-labeled antiTac(Fv)-PE38 and found that it differed from 125I-labeled antiTac(Fv)-PE38. These studies suggest that 111In-labeled antiTac(Fv)-PE38 can be used to trace the fate of antiTac(Fv)-PE38 in humans.

2/7/2 (Item 2 from file: 5)  
DIALOG(R) File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08785022 BIOSIS NO.: 199395074373

Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor.

AUTHOR: Parenteau Gary L; Dirbas Frederick M; Garmestani Kayhan; Brechbiel Martin W; Bukowski Maria A; Goldman Carolyn K; Clark Richard; Gansow Otto A; Waldmann Thomas A(a)

AUTHOR ADDRESS: (a) Metabolism Branch, National Cancer Inst., Bldg. 10, Room 4N115, National Inst. Health, Bethesda,

JOURNAL: Transplantation (Baltimore) 54 (6):p963-968 1992

ISSN: 0041-1337

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: High-affinity IL-2 receptors are expressed by T cells activated in response to foreign histocompatibility antigens but not by normal resting T cells. To exploit this difference in IL-2R expression, anti-Tac, a murine monoclonal antibody specific for the IL-2R-alpha subunit, was used to inhibit organ allograft rejection. To enhance its effector function, anti-Tac was armed by chelation with yttrium-90, a pure beta-emitting radionuclide. Animals received no immunosuppression (n=5, group I, controls), unmodified anti-Tac (n=5, 1 mg/kg, q.o.d., group II), or 90Y-anti-tac (n=5, 1.6 mCi/kg divided into four doses, group III). The animals in group IV (n=4) were treated identically to those in group III with the exception that 5 mu-g/kg/dose of granulocyte colony-stimulating factor was administered intramuscularly on the days when the yttrium-90 was given and on postoperative days 12 through 35 in order to reduce hematopoietic toxicity. Mean graft survival  $\pm$  S.E.M. for the control group was 8.2 $\pm$ 0.5 days as compared with 13.8 $\pm$ 2.1 days ( $P < 0.05$ ) for those monkeys treated with unmodified anti-Tac. Graft survival was further prolonged in animals of group III that received 90Y-anti-Tac, with a mean graft survival of 45.0 $\pm$ 11.8 days; however, three of the five monkeys retained viable grafts within this group but died secondary to bone marrow suppression. In comparison, the monkeys in group IV that were treated with G-CSF in combination with 90Y-anti-Tac had a mean graft survival of 49.2 $\pm$ 2.9 days. In contrast to group III there were no deaths in the group (IV) receiving G-CSF. Furthermore, animals in group IV had a reduced magnitude and shortened duration of irradiation-induced neutropenia when compared with that observed in group III animals that did not receive G-CSF. Thus, treatment with 90Y-anti-tac in conjunction with G-CSF may have

102022586 CA: 102(3)22586x JOURNAL  
Expression of interleukin 2 receptors on activated human B cells  
AUTHOR(S): Waldmann, Thomas A.; Goldmah, Carolyn K.; Robb, Richard J.;  
Depper, Joel M.; Leonard, Warren J.; Sharrow, Susan O.; Bongiovanni,  
Kathleen F.; Korsmeyer, Stanley J.; Greene, Warner C.  
LOCATION: Metab. Branch, Natl. Cancer Inst., Bethesda, MD, 20205, USA  
JOURNAL: J. Exp. Med. DATE: 1984 VOLUME: 160 NUMBER: 5 PAGES: 1450-66  
CODEN: JEMEAV ISSN: 0022-1007 LANGUAGE: English

8/3/22 (Item 22 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 1999 American Chemical Society. All rts. reserv.

101205721 CA: 101(23)205721m JOURNAL  
Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against  
cells expressing the human T-cell growth factor receptor  
AUTHOR(S): FitzGerald, David J. P.; Waldmann, Thomas A.; Willingham, Mark  
C.; Pastan, Ira  
LOCATION: Lab. Mol. Biol., Natl. Cancer Inst., Bethesda, MD, 20205, USA  
JOURNAL: J. Clin. Invest. DATE: 1984 VOLUME: 74 NUMBER: 3 PAGES:  
966-71 CODEN: JCINAO ISSN: 0021-9738 LANGUAGE: English

8/3/23 (Item 23 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 1999 American Chemical Society. All rts. reserv.

101105569 CA: 101(13)105569z JOURNAL  
Phorbol diester induces expression of Tac antigen on human acute T  
lymphocytic leukemic cells  
AUTHOR(S): Greene, Warner C.; Robb, Richard J.; Depper, Joel M.; Leonard,  
Warren J.; Drogula, Cynthia; Svetlik, Penny B.; Wong-Staal, Flossie; Gallo,  
Robert C.; Waldmann, Thomas A.  
LOCATION: Lab. Tumor Cell Biol., Natl. Cancer Inst., Bethesda, MD, USA  
JOURNAL: J. Immunol. DATE: 1984 VOLUME: 133 NUMBER: 2 PAGES: 1042-7  
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English

8/3/24 (Item 24 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 1999 American Chemical Society. All rts. reserv.

100083564 CA: 100(11)83564u JOURNAL  
Hairy cell leukemia: a malignant expansion of B cells which express Tac  
antigen  
AUTHOR(S): Greene, Warner C.; Waldmann, Thomas A.; Cossman, Jeffrey; Hsu,  
Su Ming; Neckers, Leonard M.; Marshall, Sandra L.; Jensen, Jane P.;  
Bakhshi, Ajay; Leonard, Warren J.; et al.  
LOCATION: Metab. Branch, Natl. Cancer Inst., Bethesda, MD, 20205, USA  
JOURNAL: UCLA Symp. Mol. Cell. Biol., New Ser. DATE: 1983 VOLUME: 9  
NUMBER: Norm. Neoplast. Hematopoiesis PAGES: 501-11 CODEN: USMBD6  
LANGUAGE: English

8/3/25 (Item 25 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 1999 American Chemical Society. All rts. reserv.

100004419 CA: 100(1)4419z CONFERENCE PROCEEDING  
Monoclonal anti-Tac blocks the action and membrane binding of human  
interleukin-2  
AUTHOR(S): Depper, Joel M.; Leonard, Warren J.; Smith, Kendall A.;  
Waldmann, Thomas A.; Greene, Warner C.

LOCATION: Metab. Branch, Natl. Cancer Inst., Bethesda, MD, USA  
JOURNAL: Interleukins, Lymphokines, Cytokines, Proc. Int. Lymphokine  
Workshop, 3rd EDITOR: Oppenheim, Joost J. (Ed), Cohen, Stanley (Ed),  
Landy, Maurice (Ed), DATE: 1983 PAGES: 19-26 CODEN: 50OPAC LANGUAGE:  
English MEETING DATE: 820000 PUBLISHER: Academic, New York, N. Y

8/3/26 (Item 26 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 1999 American Chemical Society. All rts. reserv.

99086331 CA: 99(11)86331n JOURNAL  
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition  
of human lymphocyte activation  
AUTHOR(S): Depper, Joel M.; Leonard, Warren J.; Robb, Richard J.;  
Waldmann, Thomas A.; Greene, Warner C.  
LOCATION: Metab. Branch, Natl. Cancer Inst., Bethesda, MD, 20205, USA  
JOURNAL: J. Immunol. DATE: 1983 VOLUME: 131 NUMBER: 2 PAGES: 690-6  
CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE: English

s3/k/1,21,47,50,54,62,68,70,71

3/K/1 (Item 1 from file: 653)  
DIALOG(R)File 653:(c) format only 2000 The Dialog Corp. All rts. reserv.

... specific for tumor cells. With the possible exception of the antigens associated with B-cell **lymphoma** against which anti-idiotypic antibodies are directed, no tumor-specific antigens suitable as targets for ...

... possible exceptions are anti-idiotypic antibodies, but any such antibody is specific for the B-**lymphoma** cells of only one individual, and thus must be separately developed and isolated for each...e.g., cancer cells) in vivo have been developed. Examples of such MAbs are anti-**TAC**, or other interleukin-2 receptor **antibodies**; 9.2.27 and NR-ML-05 to a 250 kilodalton human melanoma associated proteoglycan...flow of inert gas.

The chelate is then conjugated to a Fab fragment of monoclonal **antibody** TFS-2 and a Fab fragment of TFS-4 in separate reaction mixtures. The Fab fragments are generated by papain **treatment** according to conventional procedures.

A buffered solution of the **antibody** fragment (5 mg/mL, 0.5 mL) is added to the purified sup 188 Re-labeled chelate, followed...

3/K/21 (Item 19 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... AIDS, Meningitis, Arthritis) and therapy of tumors expressing IL-2 receptor such as T-cell **leukemia**.

In fact, the administration of B-B10 on the graft-versus-host reaction as produced... present some other examples in addition to those as hereinabove mentioned. For instance, an anti-**Tac antibody** is humanized by transplantation of nine amino acid residues on the framework in addition to ...  
...activated human T cell as illustrated in Examples 11 and 14.

The humanized B-B10 **antibody** of the invention is parenterally **administered** with a dosage of about 0.05-500 mg for **treatment** and prevention of diseases caused by graft-versus-host reaction or host-versus-graft reaction...

... AIDS, meningitis, arthritis), and therapy of tumors expressing IL-2 receptor such as T-cell **leukemia**.

#### ADVANTAGEOUS EFFECT OF THE INVENTION

1) Half-life of mouse Mab in blood is about...

3/K/47 (Item 45 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

...Statton, New York, pp. 283-301 (1986).

Hale et al., "Remission Induction in Non-Hodgkin **Lymphoma** with

Reshaped Human Monoclonal Antibody CAMPATH-1H," Lancet, Dec. 17, 1988, pp. 1394-1399.

Hieter...virus infection in vivo," Bio/Technology, 9:26-271 (1991).

Uchiyama et al., "A monoclonal **antibody** (anti-Tac) reactive with activated and functionally mature human T-cells," J. Immunol., 126:1393-1397 (1981)...

...heavy chain (B) (SEQ ID NOS:3 and 4) variable regions of the mouse anti-Tac **antibody** (upper lines), compared with the human Eu **antibody** (lower lines), not including signal sequences. The three CDR's in each chain are underlined... FIG. 7A through FIG. 7D. Fluorocytometry of HUT-102 and Jurkat cells stained with anti-Tac **antibody** or humanized anti-Tac **antibody** followed respectively by fluorescein-conjugated goat anti-mouse Ig **antibody** or goat anti-human Ig **antibody**, as labeled. In each panel, the dotted curve shows...

... then with phycoerythrin-conjugated avidin. (B) Fluorocytometry of HUT-102 cells stained with the indicated **antibody**, then with biotinylated anti-Tac, and then with phycoerythrin-conjugated avidin.

FIG. 9A and FIG. 9B. Schematic diagram of the...NOS:7 and 8) chain variable regions of the PDL and CDR-only humanized anti-Tac **antibodies**. The PDL sequence is shown on the upper line, the CDR-only sequence below. Amino...

... light (B) (SEQ ID NO:10) chain variable regions of the CDR-only humanized anti-Tac **antibody** including signal sequences. Oligonucleotides used for gene synthesis are marked by solid lines: above, for...

... 12. FACS analysis of HUT-102 cells stained with PDL and CDR-only humanized anti-Tac **antibodies** and negative control **antibody** Fd79.

FIG. 13. Competition by mouse, PDL humanized, and CDR-only humanized anti-Tac **antibodies** with binding of radioiodinated mouse anti-Tac **antibody** to HUT-102 cells.

FIG. 14. Scheme for anchored polymerase chain reaction (PCR) cloning of ...IL-2 stimulated proliferation of human PHA blasts by humanized mik-beta 1+humanized anti-Tac **antibodies**. No **antibody** added (quadrature), 2 ug each of humanized mik-beta 1 and humanized anti-Tac added...

...human **antibody** (e.g., A.T.C.C. Accession No. CRL 9688 secretes an anti-Tac chimeric **antibody**), although other mammalian species may be used.

As used herein, the term "humanized" immunoglobulin refers...2 receptor's structure and function is due to the development of specifically reactive monoclonal **antibodies**. In particular, one mouse monoclonal **antibody**, known as anti-Tac (Uchiyama, et al., J. Immunol. 126, 1393 (1981)) has been used to show that IL...

...the IL-2 receptor (Herrmann, et al., J. Exp. Med. 162, 1111 (1985)).

The anti-Tac monoclonal **antibody** has also been used to define lymphocyte functions that require IL-2 interaction, and has...

... of cytotoxic and suppressor T lymphocytes in cell culture. Also, based on studies with anti-Tac and other **antibodies**, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.

More recently, the IL-2 receptor has been shown to be an ideal ... approaches to T-cell mediated diseases. It has been proposed that IL-2 receptor specific **antibodies**, such as the anti-Tac monoclonal **antibody**, can be used either alone or as an immunoconjugate (e.g., with Ricin A, isotopes...

... the IL-2 receptor. These agents can, for example, theoretically eliminate IL-2 receptor-expressing **leukemic** cells, certain B-cells, or activated T-cells involved in a disease state, yet allow...

... response by activated T-cells. Indeed, clinical trials have been initiated using, e.g., anti-Tac **antibodies** (see, generally, Waldmann, T., et al., Cancer Res. 45, 625 (1985), Waldmann, T., Science 232 herein by reference).

Unfortunately, the use of the anti-Tac and other non-human monoclonal **antibodies** have certain drawbacks, particularly in repeated therapeutic regimens as explained below. Mouse monoclonal antibodies, for...

... and lack other important immunoglobulin functional characteristics when used in humans.

Perhaps more importantly, anti-Tac and other non-human monoclonal **antibodies** contain substantial stretches of amino acid sequences that will be immunogenic when injected into a...binding to a desired epitope on the human IL-2 receptor, such as the anti-Tac monoclonal **antibody**. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate...selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of **administration** selected.

Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1 to 50 **mg** of **antibody**. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 **mg** of **antibody**. Actual methods for preparing parenterally **administrable** compositions will be known or apparent to those skilled in the art and are described...

... 15th ed., Mack Publishing Company, Easton, Pa. (1980), which is incorporated herein by reference.

The **antibodies** of this invention can be frozen or lyophilized for storage and reconstituted in a suitable... the disease and its complications. An amount adequate to accomplish this is defined as a "**therapeutically** effective dose." Amounts effective for this use will depend upon the severity of the infection...

... the patient's own immune system, but generally range from about 1 to about 200 **mg** of **antibody** per dose, with dosages of from 5 to 25 **mg** being more commonly used. It...of health and general level of immunity, but generally range from 0.1 to 25 **mg** per dose, especially 0.5 to 2.5 **mg** per dose. A preferred prophylactic use is for the prevention of kidney transplant rejection.

Single or multiple **administrations** of the compositions can be carried out with dose levels and pattern being selected by the **treating** physician. In any event, the pharmaceutical formulations should provide a quantity of the **antibody**(ies) of this invention sufficient to effectively **treat** the patient.

Human-like **antibodies** of the present invention can further find a wide variety of utilities in vitro. By way of example, the **antibodies** can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells... human-like antibody binding to p75 of the IL-2 receptor,

i.e., humanized anti-Tac plus humanized mik- beta 1.

Human-like **antibodies** of the present invention can further find a wide variety of utilities in vitro. By... cell type, such as cells expressing an HSV epitope.

The compositions containing the present humanized **antibodies** or a cocktail thereof can be **administered** for prophylactic and/or **therapeutic treatments**. In **therapeutic** application, compositions are **administered** to a patient already suffering from HSV infection, in an amount sufficient to cure or...

...the disease and its complications. An amount adequate to accomplish this is defined as a "**therapeutically** effective dose." Amounts effective for this use will depend upon the severity of the infection...

... the patient's own immune system, but generally range from about 1 to about 200 **mg** of **antibody** per dose, with dosages of from 5 to 25 **mg** being more commonly used. It must be kept in mind that the materials of this... humanized immunoglobulins of this invention, it is possible and may be felt desirable by the **treating** physician to **administer** substantial excesses of these **antibodies**.

In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are **administered** to a patient not already in a disease state to enhance the patient's resistance...

...of health and general level of immunity, but generally range from 0.1 to 25 **mg** per dose. A preferred prophylactic use is for the prevention of herpes in immunocompromised patients, such as organ transplant recipients.

Single or multiple **administrations** of the compositions can be carried out with dose levels and pattern being selected by the **treating** physician. In any event, the pharmaceutical formulations should provide a quantity of the **antibody(ies)** of this invention sufficient to effectively **treat** the patient.

Humanized **antibodies** of the present invention can further find a wide variety of utilities in vitro. By way of example, the **antibodies** can be utilized for detection ...about 10,000-15,000 new cases of myeloid (also called non-lymphocytic or granulocytic) **leukemia** in the U.S. per year (Cancer Facts & Figures, American Cancer Society, 1987). There are two major forms of myeloid **leukemia**: acute myelogenous **leukemia** (AML) and chronic myelogenous **leukemia** (CML). Despite treatment with chemotherapy, long-term survival in patients with AML is less than...  
... Hematology 4, 221 (1986)), and survival with CML and related diseases such as chronic myelomonocytic **leukemia** (CMML), chronic monocytic **leukemia** (CMMOL) and myelodysplastic syndrome (MDS) is even lower.

The p67 protein or CD33 antigen is found on the surface of progenitors of myeloid cells and of the **leukemic** cells of most cases of AML, but not on lymphoid cells or non-hematopoietic cells<sup>124</sup> (1983) and Griffin et al., **Leukemia** Research 8, 521 (1984), both of which are incorporated herein by reference).

Another antibody that binds to CD33 is M195 (Tanimoto et al., **Leukemia** 3, 339 (1989) and Scheinberg et al., **Leukemia** 3, 440 (1989), both of which are incorporated herein by reference). The reactivity of M195...

... 9, 207 (1990)). M195 radiolabeled with iodine-131 was found to rapidly and specifically target **leukemic** cells in both the blood and bone marrow.

Unfortunately, the use of non-human monoclonal...needs.

The present invention provides novel compositions useful, for example, in

the treatment of myeloid **leukemia** -related human disorders, the compositions containing humanized immunoglobulins specifically capable of binding to CD33 antigen...form, or together with a chemotherapeutic agent such as cytosine arabinoside or daunorubicin active against **leukemia** cells, or complexed with a radionuclide such as iodine-131. All of these compounds will be particularly useful in treating **leukemia** and myeloid cell-mediated disorders. The humanized immunoglobulins or their complexes can be prepared in...

...to  $10^5$  M or stronger, are capable of, e.g., destroying **leukemia** cells. The humanized immunoglobulins will have a human framework and will have one or ...additional agents (e.g., 6-thioguanine) well-known to those skilled in the art for **leukemia** treatment may also be utilized (see, Hoffbrund & Pettit., op. cit.).

A preferred pharmaceutical composition of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill **leukemia** cells. ...examples are offered by way of illustration, not by limitation.

## EXPERIMENTAL

### Example 1

#### Humanized anti-Tac Antibody

##### Design of Genes for Humanized anti-Tac Light and Heavy Chains

The sequence of the human **antibody** Eu (Sequences of Proteins of Immunological Interest, E. Kabat et al., U.S. Dept. of...

... humanized antibody, because the amino acid sequence of the heavy chain variable region of anti-Tac is more homologous to the heavy chain of this **antibody** than to any other complete heavy chain variable region sequence in the National Biomedical Foundation...heavy chain (amino acids 30 and 67); or

(4) 3-dimensional modeling of the anti-Tac **antibody** suggested that the amino acid was physically close to the antigen binding region (amino acids...do not express the IL-2 receptor (FIG. 7D). As controls, the original mouse anti-Tac **antibody** was also used to stain these cells, giving similar results.

For the next experiments, cells...Laboratories, Inc., Richmond, Calif.) according to standard techniques. To determine the affinity of the humanized **antibody** relative to the original anti-Tac **antibody**, a competitive binding experiment was performed. About  $5 \times 10^5$  HUT-102 cells were incubated with known quantities (10-40 ng) of the anti-Tac **antibody** and the humanized anti-Tac **antibody** for 10 min at 4 degree(s) C. Then 100 ng of biotinylated anti-Tac of increasing amounts (10-40 ng) of the anti-Tac **antibody** as competitor in the first step decreased the amount of biotinylated anti-Tac that could...

...with the biotinylated anti-Tac, thus decreasing fluorescence more.

### Example 2

#### A Second Humanized anti-Tac Antibody

##### Higher Level Expression of the Humanized anti-Tac Antibody

Three new plasmid vectors were prepared for expression of the humanized antibodies. The plasmid pVg1...Xba I sites of the plasmid vectors pVk and pVg1. To express the humanized anti-Tac **antibody**, the light chain encoding plasmid was introduced by electroporation into SP2/0 mouse

myeloma cells...

...supernatant of transfected cells by protein A sepharose chromatography.

### Construction of the Second Humanized anti-Tac Antibody

To determine whether it was actually necessary to use the mouse anti-Tac amino acids in categories (2)-(4) in the humanized anti-Tac antibody to retain binding affinity, a second humanized anti-Tac antibody was constructed. In the second antibody, only mouse anti-Tac amino acids in Category (1), i.e., in the CDR's themselves, were used, with...

...coming from the human Eu framework. For purposes of this discussion, the original humanized anti-Tac antibody will be called the "PDL humanized antibody," and the second humanized antibody will be called the "CDR-only humanized antibody." The amino...detectably bind the IL-2 receptor.

Binding of the PDL and CDR-only humanized anti-Tac antibodies to the IL-2 receptor were also compared in a competitive binding assay. Approximately  $4 \times 10^5$  HUT-102 cells were incubated with 1.5 ng of radioiodinated mouse anti-Tac antibody ( $7 \times 10^6$  cpm/ $\mu$ g) and varying amounts of each humanized antibody (4 to 512...were collected by centrifugation and radioactivity was measured. The relative binding by the two humanized antibodies and by mouse anti-Tac is shown in a plot of bound/free labelled antibody versus competitor concentration (FIG. 13). The PDL humanized anti-Tac antibody affinity for IL-2 receptor is essentially equal to that of the mouse anti-Tac antibody, because it competes about equally well. But competition by the CDR-only humanized anti-Tac antibody to IL-2 receptor was undetectable at the antibody concentrations used, indicating a binding affinity reduction of at least 100-fold as compared to the PDL humanized anti-Tac antibody. Because the sequences of the PDL and CDR humanized anti-Tac antibodies differ only at positions where mouse framework residues in categories (2)-(4) were used in...of herpes simplex virus (Metcalf et al., Intervirology 29, 39 (1988)), M195 (Tanimoto et al., Leukemia 3, 339 (1989)) which binds to the CD33 antigen, mik-beta 1 (Tusdo et al...of the humanized antibody, because the amino acid sequence of the heavy chain of anti-Tac is more homologous to the heavy chain of this antibody than to any other heavy chain sequence in the National Biomedical Foundation Protein Identification Resource amino acids 30 and 67).

(4) 3-dimensional modeling of the anti-Tac antibody suggested that the amino acid was physically close to the antigen binding region (amino acids...do not express the IL-2 receptor (FIG. 7D). As controls, the original mouse anti-Tac antibody was also used to stain these cells (FIG. 7B and FIG. 7C), giving similar results. To determine the affinity of the humanized antibody relative to the original anti-Tac antibody, a competitive binding experiment was performed. About  $5 \times 10^5$  HUT-102 cells were incubated with known quantities (10-40 ng) of the anti-Tac antibody and the humanized anti-Tac antibody for 10 min at 4 degree(s) C. Then 100 ng of biotinylated anti-Tac...

...fluorescence on a FACSCAN cytofluorometer.

Use of increasing amounts (10-40 ng) of the anti-Tac antibody as competitor in the first step decreased the amount of biotinylated anti... if one had greater affinity, it would have more effectively competed with the biotinylated anti-Tac, thus decreasing fluorescence more.

### Biological Properties of the Humanized Antibody

For optimal use in treatment of human disease, the humanized antibody should be able to...

...cell such as a macrophage that can lyse the target. To determine whether the humanized **antibody** and the original mouse anti-**Tac antibody** can mediate ADCC, a chromium release assay was performed by standard methods. Specifically, human **leukemia** HUT-102 cells, which express the IL-2 receptor, were incubated with sup 51 Cr...

... this radionuclide. The HUT-102 cells were then incubated with an excess of either anti-**Tac** or humanized anti-**Tac antibody**. The HUT-102 cells were next incubated for 4 hrs with either a 30:1...

... is likely to be more efficacious than the original mouse antibody in treating T-cell **leukemia** or other T-cell mediated diseases.

#### TABLE 3 Higher Level Expression of the Humanized anti-**Tac Antibody**

Two new plasmid vectors were prepared for expression of the humanized antibody. The plasmid pVg1... Xba I sites of the plasmid vectors pVk and pVG1. To express the humanized anti-**Tac antibody**, the light chain encoding plasmid was introduced by electroporation into SP2/0 mouse myeloma cells...

... immunoglobulins of the present invention offer numerous advantages of other human IL-2 receptor-specific **antibodies**. In comparison to anti-**Tac** mouse monoclonal **antibodies**, the present human-like immunoglobulin can be more economically produced and contain substantially less foreign... antibody was within about 2-fold of the affinity of the mouse mik- beta 1 **antibody**.

The ability of humanized mik- beta 1 plus humanized anti-**Tac antibody** to inhibit IL-2 stimulated proliferation of human lymphocytes was determined. Human mononuclear cells, collected... of the antibodies will have strong immunosuppressive properties. Humanized mik- beta 1 plus humanized anti-**Tac** inhibited proliferation much more strongly than did either **antibody** alone.

From the foregoing, it will be appreciated that the humanized immunoglobulins of the present...

...First and second polynucleotides according to claim 1, wherein the donor immunoglobulin is the anti-**Tac antibody** or the M195 **antibody**.

5. First and second polynucleotides according to claim 1 wherein the acceptor immunoglobulin heavy and... second polynucleotides according to claim 10 or 11, wherein the donor immunoglobulin is the anti-**Tac antibody** or the M195 **antibody**.

15. A vector comprising first and second polynucleotides according to claim 10.

16. A vector...

3/K/50 (Item 48 from file: 654)  
DIALOG(R) File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...for dividing cells.

Chemotherapy for cancer has improved survival in some cancers such as childhood **leukemia** but the survival rate for advanced (metastatic) solid tumors has not dramatically increased in over... cell division. (Cancer, Edited by V. T. Devita et al. 1985 p50 supra).

A monoclonal **antibody Tac** has been reported (Uchiyama et al. J. Immunol. 1981, 126 1393-1397). It appears to...

... interleukin 2 receptor present on activated T lymphocytes but not present on the majority of **leukemia** cells. However CBL1 has a different antigenic specificity to the **Tac antibody**. CBL1 reacts with **leukemia** cell lines but **Tac** does not. The molecular weight of the CBL1 antigenic determinant is 15,000 daltons. This... antibodies will also find use in detection of malignant cells and in immunological classification of **leukemia**. **Leukemias** can be divided into immunological subsets depending on the particular surface antigens displayed by the...

... CBL1 antibody is reactive with three out of the four generally recognised morphological types of **leukemia**, being nonreactive with chronic lymphocytic **leukemia** (CLL). CBL1 would thus be useful, in combination with other antibodies having different specificities, in clinical diagnosis of a patient having **leukemia**. Malignant lymphocyte cells which are incapable of reacting with CBL1 would be presumed to be... old female Balb/c mice (Simonsen Labs) were immunised intravenously with 2X10<sup>6</sup> acute **leukemia** cells weekly for 3 weeks. Three days after the final injection the spleens were removed...by exclusion gel filtration on S300 (Sephadex sup R). Materials used in characterisation of CBL1.

#### **Leukemia Cells:**

Heparinised peripheral blood samples were drawn from children and adults with active **leukemia**. The acute lymphocytic **leukemia** (ALL,) and acute myelocytic **leukemia** (AML) patients had peripheral blood blast counts greater than 90%. **Leukemia** cells from patients and peripheral blood lymphocytes from healthy donors were isolated by Ficoll-Hypaque sup R density gradient centrifugation. **Leukemia** cells were stored in liquid nitrogen.

Cell lines were grown in suspension cultures in RPMI... of human cell types. The cells that were highly positive were cultured solid tumor cells, **leukemia** cells, activated lymphocytes and monocytes. Most normal non-dividing tissue cells were not reactive. Therefore...blood monocytes

	15	>80%
Peripheral blood activated	6	>60%
lymphocytes		
Malignant cells - Type		
Acute myeloid <b>leukemias</b>	25	>95%
Acute lymphoid <b>leukemias</b>	28	>95%
Chronic myeloid blast crisis	10	>95%
Chronic lymphocytic <b>leukemias</b>	20	<2%
Cultured <b>leukemia</b> cell lines,	10	>95%
Reh, CEM, HSB2, Daudi,		
Raji, HL60, KG, JM, Molt 4,		
BJABE. Human Studies		

Nineteen patients with severe steroid resistant kidney graft rejections were **treated** with the monoclonal **antibody**. Five **mg** in 200 ml of saline ...was given intravenously on 9 successive days. None of the 19 patients developed fever, vomiting, **treatment** created infections or other side effects. All patients had previously been immunosuppressed with conventional antirejection...abdomen causing a large tumor abscess on the left groin and protruding rectal tumor was **treated** with CBL1 purified monoclonal **antibody**. Following ten daily **treatments** of 20 **mg** per day the tumor abscess healed completely and the protruding rectal tumor receded.

Case 4...

3/K/54 (Item 52 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

... therapy is further discussed in the two articles; Kozak et al, "Bismuth-212-labeled anti-Tac monoclonal **antibody** : Alpha-particle-emitting Radionuclides ... diseases, cardiovascular diseases, inflammatory conditions and other pathological conditions.

The cancer states include carcinomas, sarcomas, **leukemias**, **lymphomas**, myelomas and neural tumors.

The infectious diseases include those caused by invading microbes or parasites...Respiratory syncytial virus

Varicella-Zoster virus  
Hepatitis B virus  
Measles virus  
Adenovirus  
Human T-cell **leukemia** viruses  
Epstein-Barr virus  
Murine **leukemia** virus\*  
Mumps virus  
Vesicular stomatitis virus  
Sindbis virus  
Lymphocytic choriomeningitis virus  
Wart virus  
Blue tongue virus  
Sendai virus  
Feline **leukemia** virus\*  
Reo virus  
Polio virus  
Simian virus 40\*  
Mouse mammary tumor virus\*  
Dengue virus  
Rubella...

... antibody fragments reactive with a tumor associated antigens present on carcinoma or sarcoma cells or **lymphomas** . Such antibodies are disclosed, e.g., in Goldenberg et al., Journal of Clinical Oncology, Vol... in vivo with a wide variety of other radiometals of use in cancer detection and **therapy**. Thus, a patient could be imaged with the In-111 **antibody** conjugate of the ligand and thereafter **treated** with the yttrium complex of the same **antibody** chelate conjugate, thus facilitating calculation of the dose of radioactivity transported to the patient's tumor and so increasing likelihood of the effective application of the **therapy**.

The metal chelate conjugated **antibodies** of this invention can be **administered** in vivo in any suitable pharmaceutical carrier. As noted earlier, a physiologic normal saline solution...

...include a minor amount of carrier protein such as human serum albumin to stabilize the **antibody**. The concentration of metal chelate ... conjugated antibodies within the solution will be a matter of choice. Levels of 0.5 **mg** per ml are readily attainable but the concentrations may vary considerably depending upon the specifics...

... addition to these located at the site, the circulating antigens can be removed prior to **treatment** . Such removal of antigens can be accomplished, of example, by the use of unlabeled **antibodies**, or by plasmapheresis in which the patient's serum is **treated** to removed antigens.

A physiological solution of the protein conjugate is advantageously

metered into sterile metal free vials, e.g., at a unit dosage of about 0.1-100 **mg** protein conjugate/vial, and the vials are either stoppered, sealed and stored at low temperature...

... claim 1, wherein said antibody or antibody fragment specifically binds to an antigen associated with **lymphomas**, carcinomas, sarcomas, **leukemias**, myelomas or neural tumors.

4. The conjugate of claim 1, wherein said marker is a...

... antibody or F(ab') sub 2 antibody fragment specifically binds to an antigen associated with **lymphomas**, carcinomas, sarcomas, **leukemias**, myelomas or neural tumors.

16. A method for preparing a precursor conjugate of a therapeutic...

3/K/62 (Item 60 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

...a mouse", Nature 321:522-525 (1986).

Hale et al., "Remission Induction in Non-Hodgkin **Lymphoma** with Reshaped Human Monoclonal Antibody CAMPATH-1H", Lancet Dec. 17, 1988, pp. 1394-1399.

Chothia...

...heavy chain (B) [SEQ ID NOS:3 and 4] variable regions of the mouse anti-**Tac antibody** (upper lines), compared with the human Eu **antibody** (lower lines), not including signal sequences. The three CDR's in each chain are underlined...

... FIG. 7A through FIG. 7D. Fluorocytometry of HUT-102 and Jurkat cells stained with anti-**Tac antibody** or humanized anti-**Tac antibody** followed respectively by fluorescein-conjugated goat anti-mouse Ig **antibody** or goat anti-human Ig antibody, as labeled. In each panel, the dotted curve shows...

... then with phycoerythrin-conjugated avidin. (B) Fluorocytometry of HUT-102 cells stained with the indicated **antibody**, then with biotinylated anti-**Tac**, and then with phycoerythrin-conjugated avidin.

FIG. ... NOS:7 and 8] chain variable regions of the PDL and CDR-only humanized anti-**Tac antibodies**. The PDL sequence is shown on the upper line, the CDR-only sequence below. Amino...

... light (B) [SEQ ID NO:10] chain variable regions of the CDR-only humanized anti-**Tac antibody** including signal sequences. Oligonucleotides used for gene synthesis are marked by solid lines: above, for...

... 12. FACS analysis of HUT-102 cells stained with PDL and CDR-only humanized anti-**Tac antibodies** and negative control **antibody** Fd79.

FIG. 13. Competition by mouse, PDL humanized, and CDR-only humanized anti-**Tac antibodies** with binding of radioiodinated mouse anti-**Tac antibody** to HUT-102 cells.

FIG. 14. Scheme for anchored polymerase chain reaction (PCR) cloning of ...IL-2 stimulated proliferation of human PHA blasts by humanized mik- beta 1+humanized anti-**Tac antibodies**. No **antibody** added (quadrature), 2 ug each of humanized mik- beta 1 and humanized anti-Tac added...

...human antibody (e.g., A.T.C.C. Accession No. CRL 9688 secretes an anti-**Tac** chimeric **antibody**), although other mammalian species may be used.

As used herein, the term "humanized" immunoglobulin refers...2 receptor's structure and function is due to the development of specifically reactive monoclonal **antibodies**. In particular, one mouse monoclonal **antibody**, known as anti-**Tac** (Uchiyama, et al., J. Immunol. 126, 1393 (1981)) has been used to show that IL...

...the IL-2 receptor (Herrmann, et al., J. Exp. Med. 162, 1111 (1985)).

The anti-**Tac** monoclonal **antibody** has also been used to define lymphocyte functions that require IL-2 interaction, and has...

... of cytotoxic and suppressor T lymphocytes in cell culture. Also, based on studies with anti-**Tac** and other **antibodies**, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell **leukemia**.

More recently, the IL-2 receptor has been shown to be an ideal target for ...  
... approaches to T-cell mediated diseases. It has been proposed that IL-2 receptor specific **antibodies**, such as the anti-**Tac** monoclonal **antibody**, can be used either alone or as an immunoconjugate (e.g., with Ricin A, isotopes...

... the IL-2 receptor. These agents can, for example, theoretically eliminate IL-2 receptor-expressing **leukemic** cells, certain B-cells, or activated T-cells involved in a disease state, yet allow...

... response by activated T-cells. Indeed, clinical trials have been initiated using, e.g., anti-**Tac** **antibodies** (see, generally, Waldmann, T., et al., Cancer Res. 45, 625 (1985), Waldmann, T., Science 232 ...

...1989), all of which are incorporated herein by reference).

Unfortunately, the use of the anti-**Tac** and other non-human monoclonal **antibodies** have certain drawbacks, particularly in repeated therapeutic regimens as explained below. Mouse monoclonal antibodies, for...

... and lack other important immunoglobulin functional characteristics when used in humans.

Perhaps more importantly, anti-**Tac** and other non-human monoclonal **antibodies** contain substantial stretches of amino acid sequences that will be immunogenic when injected into a...binding to a desired epitope on the human IL-2 receptor, such as the anti-**Tac** monoclonal **antibody**. The DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate...selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of **administration** selected.

Thus, a typical pharmaceutical composition for injection could be made up to contain 1 ml sterile buffered water, and 1 to 50 **mg** of **antibody**. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 **mg** of **antibody**. Actual methods for preparing parenterally **administrable** compositions will be known or apparent to those skilled in the art and are described...

... 15th ed., Mack Publishing Company, Easton, Pa. (1980), which is incorporated herein by reference.

The **antibodies** of this invention can be frozen or lyophilized for

storage and reconstituted in a suitable...

...the disease and its complications. An amount adequate to accomplish this is defined as a "**therapeutically** effective dose." Amounts effective for this use will depend upon the severity of the infection...

... the patient's own immune system, but generally range from about 1 to about 200 **mg** of **antibody** per dose, with dosages of from 5 to 25 **mg** being more commonly used. It...

...of health and general level of immunity, but generally range from 0.1 to 25 **mg** per dose, especially 0.5 to 2.5 **mg** per dose. A preferred prophylactic use is for the prevention of kidney transplant rejection.

Single or multiple **administrations** of the compositions can be carried out with dose levels and pattern being selected by the **treating** physician. In any event, the pharmaceutical formulations should provide a quantity of the **antibody**(ies) of this invention sufficient to effectively **treat** the patient.

Human-like **antibodies** of the present invention can further find a wide variety of utilities in vitro. By way of example, the **antibodies** can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells... human-like antibody binding to p75 of the IL-2 receptor, i.e., humanized anti-Tac plus humanized mik- beta 1.

Human-like **antibodies** of the present invention can further find a wide variety of utilities in vitro. By... cell type, such as cells expressing an HSV epitope.

The compositions containing the present humanized **antibodies** or a cocktail thereof can be **administered** for prophylactic and/or **therapeutic treatments**. In **therapeutic** application, compositions are **administered** to a patient already suffering from HSV infection, in an amount sufficient to cure or...

...the disease and its complications. An amount adequate to accomplish this is defined as a "**therapeutically** effective dose." Amounts effective for this use will depend upon the severity of the infection...

... the patient's own immune system, but generally range from about 1 to about 200 **mg** of **antibody** per dose, with dosages of from 5 to 25 **mg** being more commonly used. It must be kept in mind that the materials of this... humanized immunoglobulins of this invention, it is possible and may be felt desirable by the **treating** physician to **administer** substantial excesses of these **antibodies**.

In prophylactic applications, compositions containing the present immunoglobulins or a cocktail thereof are **administered** to a patient not already in a disease state to enhance the patient's resistance...

...of health and general level of immunity, but generally range from 0.1 to 25 **mg** per dose. A preferred prophylactic use is for the prevention of herpes in immunocompromised patients, such as organ transplant recipients.

Single or multiple **administrations** of the compositions can be carried out with dose levels and pattern being selected by the **treating** physician. In any event, the pharmaceutical formulations should provide a quantity of the **antibody**(ies) of this invention sufficient to effectively **treat** the patient.

Humanized **antibodies** of the present invention can further find a wide variety of utilities in vitro. By way of example, the **antibodies** can be utilized for detection of HSV antigens, for isolating specific HSV infected cells or...

...about 10,000-15,000 new cases of myeloid (also called non-lymphocytic or

granulocytic) **leukemia** in the U.S. per year (Cancer Facts & Figures, American Cancer Society, 1987). There are two major forms of myeloid **leukemia**: acute myelogenous **leukemia** (AML) and chronic myelogenous **leukemia** (CML). Despite treatment with chemotherapy, long-term survival in patients with AML is less than...

... Hematology 4, 221 (1986)), and survival with CML and related diseases such as chronic myelomonocytic **leukemia** (CMML), chronic monocytic **leukemia** (CMMOL) and myelodysplastic syndrome (MDS) is even lower.

The p67 protein or CD33 antigen is found on the surface of progenitors of myeloid cells and of the **leukemic** cells of most cases of AML, but not on lymphoid cells or non-hematopoietic cells...

... L4B3, L1B2 and MY9 (Andrews et al., Blood 62, 124 (1983) and Griffin et al., **Leukemia** Research 8, 521 (1984), both of which are incorporated herein by reference).

Another antibody that binds to CD33 is M195 (Tanimoto et al., **Leukemia** 3, 339 (1989) and Scheinberg et al., **Leukemia** 3, 440 (1989), both of which are incorporated herein by reference). The reactivity of M195...

... 9, 207 (1990)). M195 radiolabeled with iodine-131 was found to rapidly and specifically target **leukemic** cells in both the blood and bone marrow.

Unfortunately, the use of non-human monoclonal...

...needs.

The present invention provides novel compositions useful, for example, in the treatment of myeloid **leukemia**-related human disorders, the compositions containing humanized immunoglobulins specifically capable of ... form, or together with a chemotherapeutic agent such as cytosine arabinoside or daunorubicin active against **leukemia** cells, or complexed with a radionuclide such as iodine-131. All of these compounds will be particularly useful in treating **leukemia** and myeloid cell-mediated disorders. The humanized immunoglobulins or their complexes can be prepared in...

...to  $10^{10}$  M  $^{-1}$  or stronger, are capable of, e.g., destroying **leukemia** cells. The humanized immunoglobulins will have a human framework and will have one or more...

... additional agents (e.g., 6-thioguanine) well-known to those skilled in the art for **leukemia** treatment may also be utilized (...of the present invention comprises the use of the subject immunoglobulins in immunotoxins to kill **leukemia** cells. Immunotoxins are characterized by two components and are particularly useful for killing selected cells... examples are offered by way of illustration, not by limitation.

## EXPERIMENTAL

### EXAMPLE 1

#### Humanized anti-Tac antibody

Design of genes for humanized anti-Tac light and heavy chains

The sequence of the human **antibody** Eu (Sequences of Proteins of Immunological Interest, E. Kabat et al., U.S. Dept. of...

... humanized antibody, because the amino acid sequence of the heavy chain variable region of anti-Tac is more homologous to the heavy chain of this **antibody** than to any other complete heavy chain variable region

sequence in the National Biomedical Foundation...heavy chain (amino acids 30 and 67); or

(4) 3-dimensional modeling of the anti-Tac antibody suggested that the amino acid was physically close to the antigen binding region (amino acids...do not express the IL-2 receptor (FIG. 7D). As controls, the original mouse anti-Tac antibody was also used to stain these cells, giving similar results.

For the next experiments, cells...

... Laboratories, Inc., Richmond, Calif.) according to standard techniques. To determine the affinity of the humanized antibody relative to the original anti-Tac antibody, a competitive binding experiment was performed. About  $5 \times 10^5$  HUT-102 cells were incubated with known quantities (10-40 ng) of the anti-Tac antibody and the humanized anti-Tac antibody for 10 min at 4 degree(s) C. Then 100 ng of biotinylated anti-Tac...

...fluorescence on a FACSCAN cytofluorometer.

Use of increasing amounts (10-40 ng) of the anti-Tac antibody as competitor in the first step decreased the amount of biotinylated anti-Tac that could... with the biotinylated anti-Tac, thus decreasing fluorescence more.

## EXAMPLE 2

### A second humanized anti-Tac antibody

Higher level expression of the humanized anti-Tac antibody

Three new plasmid vectors were prepared for expression of the humanized antibodies. The plasmid pVg1...

... Xba I sites of the plasmid vectors pVk and pVg1. To express the humanized anti-Tac antibody, the light chain encoding plasmid was introduced by electroporation into SP2/0 mouse myeloma cells...

...supernatant of transfected cells by protein A sepharose chromatography.

### Construction of the second humanized anti-Tac antibody

To determine whether it was actually necessary to use the mouse anti-Tac amino acids in categories (2)-(4) in the humanized anti-Tac antibody to retain binding affinity, a second humanized anti-Tac antibody was constructed. In the second antibody, only mouse anti-Tac amino acids in Category (1), i.e., in the CDR's themselves, were used, with...

...coming from the human Eu framework. For purposes of this discussion, the original humanized anti-Tac antibody will be called the "PDL humanized antibody," and the second humanized antibody will be called the "CDR-only humanized antibody." The amino...detectably bind the IL-2 receptor.

Binding of the PDL and CDR-only humanized anti-Tac antibodies to the IL-2 receptor were also compared in a competitive binding assay. Approximately  $4 \times 10^5$  HUT-102 cells were incubated with 1.5 ng of radioiodinated mouse anti-Tac antibody ( $7 \times 10^6$  cpm/ug) and varying amounts of each humanized antibody (4 to 512...

... were collected by centrifugation and radioactivity was measured. The relative binding by the two humanized antibodies and by mouse anti-Tac is shown in a plot of bound/free labelled antibody versus competitor concentration (FIG. 13). The PDL humanized anti-Tac antibody affinity for IL-2 receptor is essentially equal to that of

the mouse anti-Tac antibody, because it competes about equally well. But competition by the CDR-only humanized anti-Tac antibody to IL-2 receptor was undetectable at the antibody concentrations used, indicating a binding affinity reduction of at least 100-fold as compared to the PDL humanized anti-Tac antibody. Because the sequences of the PDL and CDR humanized anti-Tac antibodies differ only at positions where mouse framework residues in categories (2)-(4) were used in...

... of herpes simplex virus (Metcalf et al., Intervirology 29, 39 (1988)), M195 (Tanimoto et al., Leukemia 3, 339 (1989)) which binds to the CD33 antigen, mik- beta 1 (Tusdo et al...of the humanized antibody, because the amino acid sequence of the heavy chain of anti-Tac is more homologous to the heavy chain of this antibody than to any other heavy chain sequence in the National Biomedical Foundation Protein Identification Resource...

...Tac heavy chain (amino acids 30 and 67).

(4) 3-dimensional modeling of the anti-Tac antibody suggested that the amino acid was physically close to the antigen binding region (amino acids...do not express the IL-2 receptor (FIG. 7D). As controls, the original mouse anti-Tac antibody was also used to stain these cells (FIG. 7B and FIG. 7C), giving similar results...

... Laboratories, Inc., Richmond, Calif.) according to standard techniques. To determine the affinity of the humanized antibody relative to the original anti-Tac antibody, a competitive binding experiment was performed. About 5X10<sup>5</sup> HUT-102 cells were incubated with known quantities (10-40 ng) of the anti-Tac antibody and the humanized anti-Tac antibody for 10 min at 4 degree(s) C. Then 100 ng of biotinylated anti-Tac...

...fluorescence on a FACSCAN cytofluorometer.

Use of increasing amounts (10-40 ng) of the anti-Tac antibody as competitor in the first step decreased the amount of biotinylated anti-Tac that could...

... if one had greater affinity, it would have more effectively competed with the biotinylated anti-Tac, thus decreasing fluorescence more.

Biological properties of the humanized antibody

For optimal use in treatment of human disease, the humanized antibody should be able to...

...cell such as a macrophage that can lyse the target. To determine whether the humanized antibody and the original mouse anti-Tac antibody can mediate ADCC, a chromium release assay was performed by standard methods. Specifically, human leukemia HUT-102 cells, which express the IL-2 receptor, were incubated with sup 51 Cr...

... this radionuclide. The HUT-102 cells were then incubated with an excess of either anti-Tac or humanized anti-Tac antibody. The HUT-102 cells were next incubated for 4 hrs with either a 30:1...is likely to be more efficacious than the original mouse antibody in treating T-cell leukemia or other T-cell mediated diseases.

TABLE 3Antibody

Anti-Tac	4%	<1%
Humanized anti-Tac	24%	23
humanized anti-Tac antibody		Higher level expression of the

Two new plasmid vectors were prepared for expression of the humanized antibody. The plasmid pVgl...

... Xba I sites of the plasmid vectors pVk and pVGl. To express the humanized anti-Tac antibody, the light chain encoding plasmid

was introduced by electroporation into SP2/0 mouse myeloma cells...

... immunoglobulins of the present invention offer numerous advantages of other human IL-2 receptor-specific **antibodies**. In comparison to anti-**Tac** mouse monoclonal **antibodies**, the present human-like immunoglobulin can be more economically produced and contain substantially less foreign... antibody was within about 2-fold of the affinity of the mouse mik- beta 1 **antibody**.

The ability of humanized mik- beta 1 plus humanized anti-**Tac antibody** to inhibit IL-2 stimulated proliferation of human lymphocytes was determined. Human mononuclear cells, collected...

... of the antibodies will have strong immunosuppressive properties. Humanized mik- beta 1 plus humanized anti-**Tac** inhibited proliferation much more strongly than did either **antibody** alone.

From the foregoing, it will be appreciated that the humanized immunoglobulins of the present...

... 6. A humanized immunoglobulin according to claim 1, wherein said donor immunoglobulin is the anti-**Tac antibody**.

7. A humanized immunoglobulin according to claim 1, wherein said acceptor immunoglobulin heavy and light...

3/K/68 (Item 66 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

... et al., "Metabolizable sup 111 In Chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of **lymphoma** in mice," J. Nucl. Med. 12:455-460, 1986.

March, Advanced Organic Chemistry, Second edition...

... including monoclonal antibodies specific for tumor-associated antigens in humans. Among the many such monoclonal **antibodies** that may be used are anti-**TAC**, or other interleukin-2 receptor **antibodies**; 9.2.27 and NR-ML-05, reactive with the 250 kilodalton human melanoma-associated... 0 degree(s) C. ice bath for 2 minutes.

The Fab fragment of a monoclonal **antibody** (10 mg in 0.5 mL of PBS) was generated by **treating** the monoclonal **antibody** with papain according to conventional techniques. The monoclonal **antibody**, designated NR-LU-10, recognizes a pancarcinoma antigen. Other proteins may be substituted for the...

3/K/70 (Item 68 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

#### OTHER REFERENCES

... et al., "Metabolizable sup 111 In chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of **lymphoma** in mice", J. Nucl. Med. 12:455-460, 1986.

Meares et al., "Chelate Radiochemistry: cleavable...

...monoclonal anti-bodies specific for tumor-associated antigens in humans. Among the many such monoclonal **antibodies** that may be used are anti-**TAC**, or other interleukin-2 receptor **antibodies**; 9. ...a 0 degree(s) ice bath for 2 minutes.

The Fab fragment of a monoclonal **antibody** (10 mg in 0.5 mL of PBS) was generated by **treating** the monoclonal **antibody** with papain according to conventional techniques. The monoclonal **antibody**, designated NR-LU-10, recognizes a pancarcinoma antigen. Other proteins may be substituted for the...

3/K/71 (Item 69 from file: 654)  
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

...81 [1987], 73).

Uchiyama et al (J. Immunol. 126[1981], 1398) described the first monoclonal **antibody** to recognize the **Tac**-antigen (epitope), the short chain of the interleukin-2 receptor.

European Application 0 241 811...

... activated T and B cells but are inactive against quiescent lymphocytes. One of these monoclonal **antibodies**, an anti-**Tac** analogue, enters into interaction with the **Tac**-antigen, the shorter chain of the receptor molecule. The other monoclonal antibody also obviously enters ...

...has not yet been demonstrated.

European Application 0 240 344 concerns anti-CD 4 monoclonal **antibodies** and anti-**Tac** analogues (CD 25). Its activity with respect to immunosuppression and specifically with respect to prevention... monoclonal antibody binds to an epitope of the human interleukin 2 receptor that is not **Tac**. The **antibody** is accordingly appropriate for the treatment of and prophylaxis against such diseases as hyperimmune syndrome...

... encephalomyelitis, arthritis, etc.), and for interleukin-2 receptor expressing tumor diseases such as T-cell **leukemia**.

The monoclonal antibody can be employed either as such, coupled with magnetic beads, radioactive substances...

... PBS) with 10  $\mu$ l of test residue or control monoclonal antibody. The control monoclonal **antibodies** in this and in the following examples were the anti-**Tac**-analogous monoclonal **antibodies** BF 2 and BG 8 (CRTS, Besancon). The bound monoclonal antibody was detected with an... cells was tested on days 0 and 4 as in Example 5a. The control monoclonal **antibodies** were the **Tac** analogues

B-F2: CRTS, Besancon (France)

33B3.1: Inserm U 110, Marseille (France)

Clonab IL...risk to infections.

In conjunction with the following clinical-emergency indications, 0.1 to 20 mg and preferably 2.5 to 5 mg per day of the monoclonal **antibody** B.B.10 were **administered** to the patients within 30 minutes in the form of an intravenous infusion. The dose...

...selected to attain a plasma level of 0.5 to 5  $\mu$ g/mL.

The **treatment** was continued for 3 to 30 days and preferably for 7 to 10 days until the interleukin-2-dependent symptoms subsided. **Treatment** beyond that point surprisingly turned out to be unnecessary.

#### EXAMPLE 8

The amounts of the monoclonal **antibody** B.B.10 (diluted in human albumin) listed in Table 5 were **administered** at the times cited in the table to a group of 4 patients 4, 11...marrow transplantation on the third one. Due to their age, the dosage of the monoclonal **antibody**

B.B.10 was only 2.5 mg per day.

Table 6 indicates the doses and duration of treatment.

TABLE 6...

? t s3/3/1,21,47,50,54,62,68,70,71

1/3/1

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0234528 DBA Accession No.: 99-04629 PATENT

Killing cells with immunotoxin - cell lysis using a Pseudomonas sp.  
exotoxin and single chain antibody scFv fragment fusion, antibody  
engineering for autoimmune disease and cancer therapy

AUTHOR: Fitzgerald D J; Chaudhary V K; Pastan I H; Waldmann T A;  
Queen C L

CORPORATE SOURCE: Washington, DC, USA.

PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1999

PATENT NUMBER: US 5863745 PATENT DATE: 990126 WPI ACCESSION NO.:  
99-131300 (9911)

PRIORITY APPLIC. NO.: US 461825 APPLIC. DATE: 950605

NATIONAL APPLIC. NO.: US 461825 APPLIC. DATE: 950605

LANGUAGE: English

1/3/2

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0220988 DBA Accession No.: 98-02585 PATENT

Fusion protein of antibody Fv fragment and Pseudomonas exotoxin fragment -  
an immunotoxin for use as e.g. an antitumor or immunosuppressive agent

AUTHOR: Fitzgerald D; Chaudhary V K; Pastan I H; Waldmann T A;  
Queen C L

CORPORATE SOURCE: Washington, DC, USA.

PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1997

PATENT NUMBER: US 5696237 PATENT DATE: 971209 WPI ACCESSION NO.:  
98-041352 (9804)

PRIORITY APPLIC. NO.: US 463163 APPLIC. DATE: 950605

NATIONAL APPLIC. NO.: US 463163 APPLIC. DATE: 950605

LANGUAGE: English

1/3/3

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0164255 DBA Accession No.: 94-06806

Genetically engineered monoclonal antibodies armed with radionuclides -  
radionuclide-carrying anti-Tac monoclonal antibody with reduced  
immunogenicity (humanized antibody engineering) for interleukin-2  
receptor-directed therapy (conference paper)

AUTHOR: Waldmann T A

CORPORATE AFFILIATE: Nat.Cancer-Inst.Bethesda Nat.Inst.Health-Bethesda

CORPORATE SOURCE: Metabolism Branch, Bldg 10, Rm 4N115, National Cancer  
Institute, National Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: BIOTECH'92 (7, 205-12) 1993

CODEN: 9999Q

LANGUAGE: English

1/3/4

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0123619 DBA Accession No.: 91-11261

Monoclonal antibodies in diagnosis and therapy - monoclonal antibody  
production; a review

AUTHOR: **Waldmann T A**

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: Science (252, 5013, 1657-62) 1991

CODEN: SCIEAS

LANGUAGE: English

1/3/5

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0110818 DBA Accession No.: 90-13509

IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated  
T-lymphocytes - human interleukin-2 gene fusion with Pseudomonas  
exotoxin mutant gene; potential use of chimeric toxin as cytostatic and  
immunosuppressive

AUTHOR: Loberboum-Galski H; Garsia R J; Gately M; Brown P S; Clark R E;  
**Waldmann T A**

CORPORATE AFFILIATE: Roche

CORPORATE SOURCE: Laboratory of Molecular Biology, Division of Cancer  
Biology and Diagnosis, National Cancer Institute, National Institutes  
of Health, Bethesda, Maryland 20892, USA.

JOURNAL: J.Biol.Chem. (265, 27, 16311-17) 1990

CODEN: JBCHA3

LANGUAGE: English

1/3/6

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0090949 DBA Accession No.: 89-08940

A recombinant immunotoxin consisting of two antibody variable domains fused  
to Pseudomonas exotoxin - monoclonal antibody anti-Tac to the p55  
subunit of human interleukin-2 receptor

AUTHOR: Chaudhary V K; Queen C; Junghans R P; **Waldmann T A**;  
FitzGerald D J; Pastan I

CORPORATE AFFILIATE: Protein-Design-Labs

CORPORATE SOURCE: Laboratory of Molecular Biology, DCBD, National Cancer  
Institute, National Institutes of Health, Bethesda, Maryland 20892,  
USA.

JOURNAL: Nature (339, 6223, 394-97) 1989

CODEN: NATUAS

LANGUAGE: English

1/3/7

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0054663 DBA Accession No.: 86-12511

Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology,  
inorganic chemistry and nuclear science - development and application  
in tumor diagnosis etc.

AUTHOR: Kozak R W; **Waldmann T A**; Atcher R W; Gansow O A

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute of NIH,  
Bethesda, MD 20892, USA.

JOURNAL: Trends Biotechnol. (4, 10, 259-64) 1986

CODEN: 8921M

LANGUAGE: English

1/3/8

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0049478 DBA Accession No.: 86-07326

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes - investigated using a monoclonal antibody

AUTHOR: **Waldmann T A**

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: Science (232, 4751, 727-32) 1986

CODEN: SCIEAS

LANGUAGE: English

1/3/9

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0005909 DBA Accession No.: 82-04909

A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor - purification of the interleukin-2 surface receptor by immunoprecipitation

AUTHOR: Leonard W J; Depper J M; Uchiyama T; Smith K A; **Waldmann T A**; Greene W C

CORPORATE SOURCE: The Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland 20205, USA.

JOURNAL: Nature (300, 5889, 267-69) 1982

CODEN: NATUAS

LANGUAGE: English

File 399:CA SEARCH(R) 1967-2000/UD=13210

(c) 2000 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see HELP RATES 399.

File 357:Derwent Biotechnology Abs 1982-2000/Mar B1

(c) 2000 Derwent Publ Ltd

\*File 357: Derwent changes DialUnit pricing from May 1, 1999. See  
HELP DERWENT for details.

Set Items Description

? e au=waldmann thomas

Ref	Items	Index-term
E1	1	AU=WALDMANN TB
E2	3	AU=WALDMANN TH.
E3	10	*AU=WALDMANN THOMAS
E4	49	AU=WALDMANN THOMAS A
E5	1	AU=WALDMANN THOMAS W
E6	1	AU=WALDMANN TODD B
E7	2	AU=WALDMANN TODD M
E8	1	AU=WALDMANN TS
E9	15	AU=WALDMANN U
E10	7	AU=WALDMANN U.
E11	1	AU=WALDMANN ULRICH
E12	30	AU=WALDMANN V

Enter P or PAGE for more

? s e3,e4

	10	AU=WALDMANN THOMAS
	49	AU=WALDMANN THOMAS A
S1	59	E3,E4

? rd s1

...examined 50 records (50)  
...completed examining records  
S2 57 RD S1 (unique items)  
? s s2 and tac

	57	S2
	9596	TAC
S3	20	S2 AND TAC

? t s3/3/all

3/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

12285286 BIOSIS NO.: 200000043153

Patients with chemotherapy-refractory hairy cell leukemia achieve major  
responses to recombinant immunotoxins containing truncated pseudomonas  
exotoxin and targeting either CD25 or CD22.

AUTHOR: Kreitman Robert J(a); Wilson Wyndham H; Margulies Inger(a);  
Stetler-Stevenson Maryalice; Raggio Miranda; FitzGerald David J(a);  
**Waldmann Thomas A**; Pastan Ira(a)

AUTHOR ADDRESS: (a)Laboratory of Molecular Biology, National Cancer  
Institute, NIH, Bethesda, MD\*\*USA

JOURNAL: Blood 94 (10 SUPPL. 1 PART 1):p96a Nov. 15, 1999

CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of  
Hematology New Orleans, Louisiana, USA December 3-7, 1999

SPONSOR: The American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Citation

LANGUAGE: English

3/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

12266169 BIOSIS NO.: 200000019671  
Responses in refractory hairy cell leukemia to a recombinant immunotoxin.  
AUTHOR: Kreitman Robert J; Wilson Wyndham H; Robbins David; Margulies Inger  
; Stetler-Stevenson Maryalice; **Waldmann Thomas A**; Pastan Ira(a  
AUTHOR ADDRESS: (a)National Cancer Institute, National Institutes of  
Health, 37 Convent Dr, 37/4E16, MSC 4255, Bethesda, MD, 20892\*\*USA  
JOURNAL: Blood 94 (10):p3340-3348 Nov. 15, 1999  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

3/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

12122210 BIOSIS NO.: 199900417059  
Methods to avoid adverse effect of circulating antigen on biodistribution  
of 125I-labeled antiTac dsFv: Preinjection of intact antibody versus  
clearance of antigen with avidin-biotin system.  
AUTHOR: Kobayashi Hisataka; Sun Bao-Fu; Yoo Tae M; Le Nhat; Kim Meyoung-Kon  
; Paik Chang H; Pastan Ira; **Waldmann Thomas A**; Carrasquillo Jorge A  
(a  
AUTHOR ADDRESS: (a)Nuclear Medicine Department, National Institutes of  
Health, 10 Center Dr., Building 10, Rm. 1C-496, Bethesda, MD, 20892-1180  
\*\*USA  
JOURNAL: Journal of Nuclear Medicine 40 (8):p1381-1391 Aug., 1999  
ISSN: 0161-5505  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

3/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11990442 BIOSIS NO.: 199900270961  
Favorable effects of glycolate conjugation on the biodistribution of  
humanized antiTac Fab fragment.  
AUTHOR: Kobayashi Hisataka; Kim In-sook; Drumm Debbie; Kim Meyoung-kon;  
Paik David S; Le Nhat; **Waldmann Thomas A**; Carrasquillo Jorge A(a);  
Paik Chang H  
AUTHOR ADDRESS: (a)Department of Nuclear Medicine, National Institutes of  
Health, 10 Center Dr., MSC 1180, Bldg. 10\*\*USA  
JOURNAL: Journal of Nuclear Medicine 40 (5):p837-845 May, 1999  
ISSN: 0161-5505  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

3/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11848859 BIOSIS NO.: 199900094968

The pharmacokinetic characteristics of glycolated humanized anti-Tac  
Fabs are determined by their isoelectric points.

AUTHOR: Kobayashi Hisataka; Le Nhat; Kim In-Sook; Kim Meyoung-Kon; Pie  
Jae-Eun; Drumm Debra; Paik David S; **Waldmann Thomas A**; Paik Chang H  
; Carrasquillo Jorge A(a)

AUTHOR ADDRESS: (a)NIH, Building 10, Room IC496, 10 Center Dr., MSC 1180,  
Bethesda, MD 20892-1180\*\*USA

JOURNAL: Cancer Research 59 (2):p422-430 Jan. 15, 1999

ISSN: 0008-5472

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

11815653 BIOSIS NO.: 199900061762

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in  
HTLV-I-associated myelopathy/tropical spastic paraparesis patients  
treated with humanized anti-Tac.

AUTHOR: Lehyk Tanya J(a); Levin Michael C; Kubota Ryuji; Bamford Richard N;  
Flerlage Alfred N; Soldan Samantha S; Leist Thomas P; Xavier Andrew;  
White Jeffrey D; Brown Margaret; Fleisher Thomas A; Top Lois E; Light  
Susan; McFarland Henry F; **Waldmann Thomas A**; Jacobson Steven

AUTHOR ADDRESS: (a)HIV Res., DAIDS, NIAID, NIH, 6003 Executive Blvd.,  
Rockville, MD 20892\*\*USA

JOURNAL: Annals of Neurology 44 (6):p942-947 Dec., 1998

ISSN: 0364-5134

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

10946921 BIOSIS NO.: 199799568066

Improved biodistribution of 125I-labeled anti-Tac  
disulfide-stabilized Fv fragment by blocking its binding to the alpha  
subunit of the interleukin 2 receptor in the circulation with preinjected  
humanized anti-Tac IgG.

AUTHOR: Kobayashi Hisataka; Yoo Tae M; Drumm Debra; Kim Meyoung-Kon; Sun  
Bao-Fu; Le Nhat; Webber Keith O; Pastan Ira; **Waldmann Thomas A**;  
Paik Chang H; Carrasquillo Jorge A(a)

AUTHOR ADDRESS: (a)Nuclear Med. Dep., Build. 10, Room 1C496, NIH, 10 Center  
Drive, Bethesda, MD 20892-1180\*\*USA

JOURNAL: Cancer Research 57 (10):p1955-1961 1997

ISSN: 0008-5472

RECORD TYPE: Abstract

LANGUAGE: English

3/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

10154496 BIOSIS NO.: 199698609414

Radioimmunotherapy of interleukin-2R-alpha-expressing adult T-cell leukemia  
with Yttrium-90-labeled anti-tac.

AUTHOR: **Waldmann Thomas A**(a); White Jeffrey D; Carrasquillo Jorge A;  
Reynolds James C; Paik Chang H; Gansow Otto A; Brechbiel Martin W; Jaffe

Elaine S; Fleisher Thomas A; Goldman Carolyn K; Top Lois E; Bamford Richard; Zaknoen Sara; Roessler Eric; Kasten-Sportes Claude; England Richard; Litou Hariklia; Johnson John A; Jackson-White Terri; Manns Angela; Hanchard Barrie; Junghans Richard P; Nelson David L  
AUTHOR ADDRESS: (a)Metabolism Branch, Natl. Cancer Inst. Health, Build. 10, Room 4N115, Bethesda, MD 20892\*\*USA  
JOURNAL: Blood 86 (11):p4063-4075 1995  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10119190 BIOSIS NO.: 199698574108  
The treatment of HAM/TSP patients with humanized anti-Tac antibody: Preliminary immunologic studies.  
AUTHOR: Lehky Tanya J; Levin Michael; Flerlage Nick; White Jeffrey; Fleisher Thomas; McFarland Henry; **Waldmann Thomas**; Jacobson Steven  
AUTHOR ADDRESS: NIH, Bethesda, MD\*\*USA  
JOURNAL: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10 (2):p285 1995  
CONFERENCE/MEETING: Seventh International Conference on Human Retrovirology HTLV and Related Viruses Paris, France October 17-21, 1995  
ISSN: 1077-9450  
RECORD TYPE: Citation  
LANGUAGE: English

3/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09775306 BIOSIS NO.: 199598230224  
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.  
AUTHOR: Richardson Jennifer H; Sodroski Joseph G; **Waldmann Thomas A**; Marasco Wayne A(a  
AUTHOR ADDRESS: (a)Dep. Med. Human Retrovirol., Dana-Farber Cancer Inst., Harvard Med. Sch., Boston, MA 02115\*\*USA  
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 92 (8):p3137-3141 1995  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09555739 BIOSIS NO.: 199598010657  
Humanized Antibody Directed to the IL-2 Receptor beta-Chain Prolongs Primate Cardiac Allograft Survival.  
AUTHOR: Tinubu Sikiru A; Hakimi John; Kondas Jo A; Bailon Pascal; Familletti Philip C; Spence Cheryl; Crittenden Michael D; Parenteau Gary L; Dirbas Fredrick M; Tsudo Mitsuro; Bacher John D; Kasten-Sportes Claude; Martinucci Jean L; Goldman Carolyn K; Clark Richard E; **Waldmann Thomas A**  
AUTHOR ADDRESS: Inq.\*\*USA  
JOURNAL: Journal of Immunology 153 (9):p4330-4338 1994

ISSN: 0022-1767  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09454744 BIOSIS NO.: 199497463114  
Treatment of acute graft-versus-host disease with humanized anti-gac: An antibody that binds to the interleukin-2 receptor.  
AUTHOR: Anasetti Claudio(a); Hansen John A; **Waldmann Thomas A**; Appelbaum Frederick R; Davis Jennifer; Deeg H Joachim; Doney Kristine; Martin Paul J; Nash Richard; et al  
AUTHOR ADDRESS: (a)Fred Hutchinson Cancer Res. Cent., 1124 Columbia St., E611, Seattle, WA 98104\*\*USA  
JOURNAL: Blood 84 (4):p1320-1327 1994  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09443625 BIOSIS NO.: 199497451995  
Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-**Tac**.  
AUTHOR: Hartmann Frank; Horak Eva M; Garmestani Kayhan; Wu Chuanchu; Brechbiel Martin W; Kozak Robert W; Tso J; Kosteiny Sheri A; Gansow Otto A; Nelson David L; **Waldmann Thomas A**(a  
AUTHOR ADDRESS: (a)Metabolic Branch, Natl. Cancer Inst., Build. 10, 4N115, NIH, Bethesda, MD 20892\*\*USA  
JOURNAL: Cancer Research 54 (16):p4362-4370 1994  
ISSN: 0008-5472  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/14 (Item 14 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09261813 BIOSIS NO.: 199497270183  
Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits.  
AUTHOR: Roessler Erich(a); Grant Angus(a); Ju Grace; Tsudo Mitsuru; Sugamura Kazuo; **Waldmann Thomas A**(a  
AUTHOR ADDRESS: (a)Metabolism Branch, Natl. Cancer Inst., Natl. Inst. Health, Bethesda, MD 20892\*\*USA  
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 91 (8):p3344-3347 1994  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/15 (Item 15 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

.(c) 2000 BIOSIS. All rts. reserv.

09039688 BIOSIS NO.: 199497048058

1992 Stohlman Memorial Lecture: Targeting the IL-2 receptor.

AUTHOR: **Waldmann Thomas A**

AUTHOR ADDRESS: Metabolism Branch, Natl. Cancer Inst., Natl. Inst. Health,  
Bethesda, MD 20892\*\*USA

JOURNAL: Leukemia (Basingstoke) 7 (SUPPL. 2):pS151-S156 1993

ISSN: 0887-6924

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/16 (Item 16 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

08974421 BIOSIS NO.: 199396125922

The interleukin-2 receptor: A target for monoclonal antibody treatment of  
human T-cell lymphotropic virus I-induced adult T-cell leukemia.

AUTHOR: **Waldmann Thomas A**(a); White Jeffrey D; Goldman Carolyn K; Top  
Lois; Grant Angus; Bamford Richard; Roessler Eric; Horak Ivan D; Zaknoen  
Sara; et al

AUTHOR ADDRESS: (a)Metabolism Branch, Natl. Cancer Inst., Build. 4N115,  
Bethesda, MD 20892\*\*USA

JOURNAL: Blood 82 (6):p1701-1712 1993

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/17 (Item 17 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

08890746 BIOSIS NO.: 199396042247

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas  
toxin or diphtheria toxin toward lymphocytes from patients with adult  
T-cell leukemia.

AUTHOR: Kreitman Robert J; Chaudhary Vijay K; **Waldmann Thomas A**;

Hanchard Barrie; Cranston Beverly; Fitzgerald David J P; Pastan Ira(a)

AUTHOR ADDRESS: (a)Lab. Mol. Biol., Div. Cancer Biol., Diagnosis Cent., NCH  
NIH, 9000 Rockville Pike, 37/4E16, Beth

JOURNAL: Leukemia (Basingstoke) 7 (4):p553-562 1993

ISSN: 0887-6924

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/18 (Item 18 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2000 BIOSIS. All rts. reserv.

08785022 BIOSIS NO.: 199395074373

Prolongation of graft survival in primate allograft transplantation by  
yttrium-90-labeled anti-**Tac** in conjunction with granulocyte  
colony-stimulating factor.

AUTHOR: Parenteau Gary L; Dirbas Frederick M; Garmestani Kayhan; Brechbiel  
Martin W; Bukowski Maria A; Goldman Carolyn K; Clark Richard; Gansow Otto  
A; **Waldmann Thomas A**(a)

AUTHOR ADDRESS: (a)Metabolism Branch, National Cancer Inst., Bldg. 10, Room  
4N115, National Inst. Health, Bethesda,

JOURNAL: Transplantation (Baltimore) 54 (6):p963-968 1992

ISSN: 0041-1337  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08751679 BIOSIS NO.: 199395041030  
Recombinant toxins containing the variable domains of the anti-Tac  
monoclonal antibody to the interleukin-2 receptor kill malignant cells  
from patients with chronic lymphocytic leukemia.  
AUTHOR: Kreitman Robert J; Chaudhary Vijay K; Kozak Robert W; Fitzgerald  
David J P; **Waldmann Thomas A**; Pastan Ira(a  
AUTHOR ADDRESS: (a)Lab. Mol. Biol., Div. Cancer Biol., Diagnosis and  
Centers, Natl. Cancer Inst., Natl. Inst. Healt  
JOURNAL: Blood 80 (9):p2344-2352 1992  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/20 (Item 20 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

08749929 BIOSIS NO.: 199395039280  
Mik-beta-1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells  
bearing the beta-chain of the IL-2 receptor.  
AUTHOR: Kreitman Robert J; Schneider William P; Queen Cary; Tsudo Mitsuru;  
Fitzgerald David J P; **Waldmann Thomas A**; Pastan Ira(a  
AUTHOR ADDRESS: (a)Lab. Mol. Biol./Div. Cancer Biol., Diagnosis and  
Centers, 37/4E16, Natl. Cancer Inst., Natl. Ins  
JOURNAL: Journal of Immunology 149 (8):p2810-2815 1992  
ISSN: 0022-1767  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

potential applications in organ transplantation and the treatment of IL-2 receptor-expressing neoplastic diseases.

2/7/3 (Item 3 from file: 5)  
DIALOG(R)File 5: Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

07421848 BIOSIS NO.: 000091027837

USE OF YTTRIUM-90-LABELED ANTI-TAC ANTIBODY IN PRIMATE XENOGRAFT TRANSPLANTATION

AUTHOR: COOPER M M; ROBBINS R C; GOLDMAN C K; MIRZADEH S; BRECHBIEL M W; STONE C D; GANSOW O A; CLARK R E; WALDMANN T A

AUTHOR ADDRESS: DEP. OF SURG., COLUMBIA UNIV. COLL. OF PHYSICIANS AND SURGEONS, 630 WEST 168TH ST., NEW YORK, N.Y. 10032.

JOURNAL: TRANSPLANTATION (BALTIMORE) 50 (5). 1990. 760-765.

FULL JOURNAL NAME: TRANSPLANTATION (Baltimore)

CODEN: TRPLA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The high-affinity interleukin-2 receptor (IL-2R) is expressed by T cell activated in response to foreign histocompatibility antigens but not by normal resting cells. Thus, blockade of the interaction of IL-2 with its receptor could achieve selective immunosuppression. Accordingly, anti-Tac, a murine IgG2a class monoclonal antibody specific to the IL-2R, was used alone or in a chelated form with yttrium-90 (90Y), a pure beta emitter, to inhibit rejection of cardiac xenografts from *Macaca fascicularis* (cynomolgus) donors transplanted to the cervical or abdominal region of *Macaca mulatta* (rhesus) recipients (n = 20). Animals received no immunosuppression (n = 3, group I, controls), unmodified anti-Tac (n = 5, 2 mg/kg q.o.d., group II), or 90Y-anti-Tac (n = 5, 16 mCi, group III). To distinguish the nonspecific immunosuppressive effect of radiation, 90Y was administered bound to UPC-10 (n = 4, 16 mCi, group IV), another murine monoclonal antibody that does not specifically recognize activated immunoresponsive cells. All immunosuppression was administered in divided doses during the first 2 weeks posttransplant. Group I animals rejected their grafts at 6.7 +/- 1 days and demonstrated a rise in soluble IL-2R levels at the time of rejection, indicating the generation of Tac-expressing and -releasing cells. Graft survival in group II was not prolonged compared with controls (mean survival 6.2 +/- 1 days; P > 0.05). In contrast, graft survival in animals that received the designed dosage of 90Y-anti-Tac was significantly prolonged to an average of 38.4 +/- 5 days compared with groups I and II (P < 0.005 and P < 0.0005, respectively). Prolongation of graft survival occurred in animals that received 90Y-UPC-10 (mean survival 21.3 +/- 5 days, P < 0.05 versus group I, P < 0.01 versus group II). However, 90Y-UPC-10 was significantly less effective in prolonging graft survival than 90Y-anti-Tac, in which one-half the per-kilogram dosage of radioactivity was delivered in specific fashion via anti-Tac (P < 0.025). Reversible nonlethal bone marrow suppression occurred without associated nephro- or hepatotoxicity, and virtually all animals developed antibodies to the urine monoclonal. Thus, the approach used in the present study, IL-2R-directed therapy with 90Y-anti-Tac, may have potential applications in organ transplantation and in the treatment of Tac-expressing neoplastic diseases.

\*\*\*

RELOADED

\*\*\*AIDSLINE (File 157)  
\*\*\*MEDLINE (File 154,155)  
\*\*\*Book in Print (File 470)  
\*\*\*Kompa Latin America (File 586)

\*\*\*

REMOVED

\*\*\*Global Mobilit (File 64). Please see 2,6,8,63,65,94,99,108,238,266,583.

>>>Get immediate new with Dialog' First Release  
new service. First Release update major newwire  
databases within 15 minutes of transmission over the  
wire. First Release provide full Dialog searchability  
and full-text feature. To search First Release file in  
OneSearch implement BEGIN FIRST for coverage from Dialog'  
broad spectrum of new wire.

>>> Enter BEGIN HOMEBASE for Dialog Announcement <<<  
>>> of new databases, price change, etc. <<<  
\*\*\*\*

□dialog

\*\*\*

\*\*\*

File 1:ERIC 1966-2000/May  
(c) format only 2000 The Dialog Corporation  
\*File 1: File has been reloaded. See HELP NEWS 1.

Set	Items	Description
---	----	-----

? b 410

>>>'IALOG' not recognized as set or accession number  
? set hi ;set hi

01jun00 08:02:31 User208760 Session D1582.1  
\$0.41 0.117 DialUnits File1  
\$0.41 Estimated cost File1  
\$0.05 TYMNET  
\$0.46 Estimated cost this search  
\$0.46 Estimated total session cost 0.117 DialUnits

File 410:Chronolog(R) 1981-2000 Mar/Apr  
(c) 2000 The Dialog Corporation plc

Set	Items	Description
---	----	-----

?

HIGHLIGHT set on as ''  
HIGHLIGHT set on as ''  
? begin 351,357

>>> 351 is unauthorized  
>>>1 of the specified files is not available  
01jun00 08:02:38 User208760 Session D1582.2  
\$0.00 0.056 DialUnits File410  
\$0.00 Estimated cost File410

\$0.00 Estimated cost this search  
\$0.46 Estimated total session cost 0.173 DialUnits

File 357:Derwent Biotechnology Abs 1982-2000/Jun B1  
(c) 2000 Derwent Publ Ltd

Set Items Description  
---  
? e au=waldmann thomas

Ref	Items	Index-term
E1	1	AU=WALDMANN R; +LOCKSLEY R M; GLAICHENHAUS N
E2	9	AU=WALDMANN T A
E3	0	*AU=WALDMANN THOMAS
E4	1	AU=WALDMANN V
E5	1	AU=WALDMEIER P
E6	1	AU=WALDNER H
E7	10	AU=WALDNER R
E8	2	AU=WALDNER-SANDER S
E9	2	AU=WALDO G S
E10	1	AU=WALDO III R H
E11	4	AU=WALDOR M K
E12	5	AU=WALDRAFF W

Enter P or PAGE for more  
? se2

S1 9 AU="WALDMANN T A"  
? t s1/3/all

1/3/1  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0234528 DBA Accession No.: 99-04629 PATENT  
Killing cells with immunotoxin - cell lysis using a Pseudomonas sp.  
exotoxin and single chain antibody scFv fragment fusion, antibody  
engineering for autoimmune disease and cancer therapy  
AUTHOR: Fitzgerald D J; Chaudhary V K; Pastan I H; **Waldmann T A**;  
Queen C L  
CORPORATE SOURCE: Washington, DC, USA.  
PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1999  
PATENT NUMBER: US 5863745 PATENT DATE: 990126 WPI ACCESSION NO.:  
99-131300 (9911)  
PRIORITY APPLIC. NO.: US 461825 APPLIC. DATE: 950605  
NATIONAL APPLIC. NO.: US 461825 APPLIC. DATE: 950605  
LANGUAGE: English

1/3/2  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0220988 DBA Accession No.: 98-02585 PATENT  
Fusion protein of antibody Fv fragment and Pseudomonas exotoxin fragment -  
an immunotoxin for use as e.g. an antitumor or immunosuppressive agent  
AUTHOR: FitzGerald D; Chaudhary V K; Pastan I H; **Waldmann T A**;  
Queen C L  
CORPORATE SOURCE: Washington, DC, USA.  
PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1997  
PATENT NUMBER: US 5696237 PATENT DATE: 971209 WPI ACCESSION NO.:  
98-041352 (9804)  
PRIORITY APPLIC. NO.: US 463163 APPLIC. DATE: 950605  
NATIONAL APPLIC. NO.: US 463163 APPLIC. DATE: 950605

LANGUAGE: English

1/3/3

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0164255 DBA Accession No.: 94-06806

Genetically engineered monoclonal antibodies armed with radionuclides -  
radionuclide-carrying anti-Tac monoclonal antibody with reduced  
immunogenicity (humanized antibody engineering) for interleukin-2  
receptor-directed therapy (conference paper)

AUTHOR: **Waldmann T A**

CORPORATE AFFILIATE: Nat.Cancer-Inst.Bethesda Nat.Inst.Health-Bethesda

CORPORATE SOURCE: Metabolism Branch, Bldg 10, Rm 4N115, National Cancer  
Institute, National Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: BIOTECH'92 (7, 205-12) 1993

CODEN: 9999Q

LANGUAGE: English

1/3/4

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0123619 DBA Accession No.: 91-11261

Monoclonal antibodies in diagnosis and therapy - monoclonal antibody  
production; a review

AUTHOR: **Waldmann T A**

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: Science (252, 5013, 1657-62) 1991

CODEN: SCIEAS

LANGUAGE: English

1/3/5

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0110818 DBA Accession No.: 90-13509

IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated  
T-lymphocytes - human interleukin-2 gene fusion with Pseudomonas  
exotoxin mutant gene; potential use of chimeric toxin as cytostatic and  
immunosuppressive

AUTHOR: Loberboum-Galski H; Garsia R J; Gately M; Brown P S; Clark R E;  
**Waldmann T A**

CORPORATE AFFILIATE: Roche

CORPORATE SOURCE: Laboratory of Molecular Biology, Division of Cancer  
Biology and Diagnosis, National Cancer Institute, National Institutes  
of Health, Bethesda, Maryland 20892, USA.

JOURNAL: J.Biol.Chem. (265, 27, 16311-17) 1990

CODEN: JBCHA3

LANGUAGE: English

1/3/6

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0090949 DBA Accession No.: 89-08940

A recombinant immunotoxin consisting of two antibody variable domains fused  
to Pseudomonas exotoxin - monoclonal antibody anti-Tac to the p55  
subunit of human interleukin-2 receptor

AUTHOR: Chaudhary V K; Queen C; Junghans R P; **Waldmann T A**;  
FitzGerald D J; Pastan I

CORPORATE AFFILIATE: Protein-Design-Labs  
CORPORATE SOURCE: Laboratory of Molecular Biology, DCBD, National Cancer  
Institute, National Institutes of Health, Bethesda, Maryland 20892,  
USA.  
JOURNAL: Nature (339, 6223, 394-97) 1989  
CODEN: NATUAS  
LANGUAGE: English

1/3/7  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0054663 DBA Accession No.: 86-12511  
Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology,  
inorganic chemistry and nuclear science - development and application  
in tumor diagnosis etc.  
AUTHOR: Kozak R W; **Waldmann T A**; Atcher R W; Gansow O A  
CORPORATE SOURCE: Metabolism Branch, National Cancer Institute of NIH,  
Bethesda, MD 20892, USA.  
JOURNAL: Trends Biotechnol. (4, 10, 259-64) 1986  
CODEN: 8921M  
LANGUAGE: English

1/3/8  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0049478 DBA Accession No.: 86-07326  
The structure, function, and expression of interleukin-2 receptors on  
normal and malignant lymphocytes - investigated using a monoclonal  
antibody  
AUTHOR: **Waldmann T A**  
CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20892, USA.  
JOURNAL: Science (232, 4751, 727-32) 1986  
CODEN: SCIEAS  
LANGUAGE: English

1/3/9  
DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0005909 DBA Accession No.: 82-04909  
A monoclonal antibody that appears to recognize the receptor for human  
T-cell growth factor; partial characterization of the receptor -  
purification of the interleukin-2 surface receptor by  
immunoprecipitation  
AUTHOR: Leonard W J; Depper J M; Uchiyama T; Smith K A; **Waldmann T  
A**; Greene W C  
CORPORATE SOURCE: The Metabolism Branch, National Cancer Institute, NIH,  
Bethesda, Maryland 20205, USA.  
JOURNAL: Nature (300, 5889, 267-69) 1982  
CODEN: NATUAS  
LANGUAGE: English

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0234528 DBA Accession No.: 99-04629 PATENT  
Killing cells with immunotoxin - cell lysis using a Pseudomonas sp.  
exotoxin and single chain antibody scFv fragment fusion, antibody  
engineering for autoimmune disease and cancer therapy  
AUTHOR: Fitzgerald D J; Chaudhary V K; Pastan I H; Waldmann T A;  
Queen C L  
CORPORATE SOURCE: Washington, DC, USA.  
PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1999  
PATENT NUMBER: US 5863745 PATENT DATE: 990126 WPI ACCESSION NO.:  
99-131300 (9911)  
PRIORITY APPLIC. NO.: US 461825 APPLIC. DATE: 950605  
NATIONAL APPLIC. NO.: US 461825 APPLIC. DATE: 950605  
LANGUAGE: English

1/3/2

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0220988 DBA Accession No.: 98-02585 PATENT  
Fusion protein of antibody Fv fragment and Pseudomonas exotoxin fragment -  
an immunotoxin for use as e.g. an antitumor or immunosuppressive agent  
AUTHOR: FitzGerald D; Chaudhary V K; Pastan I H; Waldmann T A;  
Queen C L  
CORPORATE SOURCE: Washington, DC, USA.  
PATENT ASSIGNEE: U.S.Dep.Health-Hum.Serv. 1997  
PATENT NUMBER: US 5696237 PATENT DATE: 971209 WPI ACCESSION NO.:  
98-041352 (9804)  
PRIORITY APPLIC. NO.: US 463163 APPLIC. DATE: 950605  
NATIONAL APPLIC. NO.: US 463163 APPLIC. DATE: 950605  
LANGUAGE: English

1/3/3

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0164255 DBA Accession No.: 94-06806  
Genetically engineered monoclonal antibodies armed with radionuclides -  
radionuclide-carrying anti-Tac monoclonal antibody with reduced  
immunogenicity (humanized antibody engineering) for interleukin-2  
receptor-directed therapy (conference paper)  
AUTHOR: Waldmann T A  
CORPORATE AFFILIATE: Nat.Cancer-Inst.Bethesda Nat.Inst.Health-Bethesda  
CORPORATE SOURCE: Metabolism Branch, Bldg 10, Rm 4N115, National Cancer  
Institute, National Institutes of Health, Bethesda, MD 20892, USA.  
JOURNAL: BIOTECH'92 (7, 205-12) 1993  
CODEN: 9999Q  
LANGUAGE: English

1/3/4

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0123619 DBA Accession No.: 91-11261

Monoclonal antibodies in diagnosis and therapy - monoclonal antibody  
production; a review

AUTHOR: **Waldmann T A**

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: Science (252, 5013, 1657-62) 1991

CODEN: SCIEAS

LANGUAGE: English

1/3/5

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0110818 DBA Accession No.: 90-13509

IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated  
T-lymphocytes - human interleukin-2 gene fusion with Pseudomonas  
exotoxin mutant gene; potential use of chimeric toxin as cytostatic and  
immunosuppressive

AUTHOR: Loberboum-Galski H; Garsia R J; Gately M; Brown P S; Clark R E;  
**Waldmann T A**

CORPORATE AFFILIATE: Roche

CORPORATE SOURCE: Laboratory of Molecular Biology, Division of Cancer  
Biology and Diagnosis, National Cancer Institute, National Institutes  
of Health, Bethesda, Maryland 20892, USA.

JOURNAL: J.Biol.Chem. (265, 27, 16311-17) 1990

CODEN: JBCHA3

LANGUAGE: English

1/3/6

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0090949 DBA Accession No.: 89-08940

A recombinant immunotoxin consisting of two antibody variable domains fused  
to Pseudomonas exotoxin - monoclonal antibody anti-Tac to the p55  
subunit of human interleukin-2 receptor

AUTHOR: Chaudhary V K; Queen C; Junghans R P; **Waldmann T A**;  
FitzGerald D J; Pastan I

CORPORATE AFFILIATE: Protein-Design-Labs

CORPORATE SOURCE: Laboratory of Molecular Biology, DCBD, National Cancer  
Institute, National Institutes of Health, Bethesda, Maryland 20892,  
USA.

JOURNAL: Nature (339, 6223, 394-97) 1989

CODEN: NATUAS

LANGUAGE: English

1/3/7

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2000 Derwent Publ Ltd. All rts. reserv.

0054663 DBA Accession No.: 86-12511

Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology,  
inorganic chemistry and nuclear science - development and application  
in tumor diagnosis etc.

AUTHOR: Kozak R W; **Waldmann T A**; Atcher R W; Gansow O A

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute of NIH,  
Bethesda, MD 20892, USA.

JOURNAL: Trends Biotechnol. (4, 10, 259-64) 1986

CODEN: 8921M

LANGUAGE: English

1/3/8

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0049478 DBA Accession No.: 86-07326

The structure, function, and expression of interleukin-2 receptors on  
normal and malignant lymphocytes - investigated using a monoclonal  
antibody

AUTHOR: **Waldmann T A**

CORPORATE SOURCE: Metabolism Branch, National Cancer Institute, National  
Institutes of Health, Bethesda, MD 20892, USA.

JOURNAL: Science (232, 4751, 727-32) 1986

CODEN: SCIEAS

LANGUAGE: English

1/3/9

DIALOG(R)File 357:Derwent Biotechnology Abs  
(c) 2000 Derwent Publ Ltd. All rts. reserv.

0005909 DBA Accession No.: 82-04909

A monoclonal antibody that appears to recognize the receptor for human  
T-cell growth factor; partial characterization of the receptor -  
purification of the interleukin-2 surface receptor by  
immunoprecipitation

AUTHOR: Leonard W J; Depper J M; Uchiyama T; Smith K A; **Waldmann T  
A**; Greene W C

CORPORATE SOURCE: The Metabolism Branch, National Cancer Institute, NIH,  
Bethesda, Maryland 20205, USA.

JOURNAL: Nature (300, 5889, 267-69) 1982

CODEN: NATUAS

LANGUAGE: English

7/3/42 (Item 13 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

07162127 EMBASE No: 1998050169

Clinical pharmacology and therapeutic potential of monoclonal antibody  
treatment in rheumatoid **arthritis**

Choy E.H.S.

Dr. E.H.S. Choy, Rheumatology Unit, Thomas Guy House, Guy's Hospital, St  
Thomas Street, London SE1 9RT United Kingdom

AUTHOR EMAIL: e.choy@umds.ac.uk

Drugs and Aging ( DRUGS AGING ) (New Zealand) 1998, 12/2 (139-148)

CODEN: DRAGE ISSN: 1170-229X

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

7/3/38 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

07247945 EMBASE No: 1998138658

Biological agents in rheumatoid arthritis: Which ones could be used in combination?

Lorenz H.-M.; Kalden J.R.

Dr. H.-M. Lorenz, Department of Medicine III, Inst. Clinical Immunol./Rheumatology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen Germany

AUTHOR EMAIL: Hannes.Lorenz@med3.med.uni-erlangen.de

BioDrugs ( BIODRUGS ) (New Zealand) 1998, 9/4 (303-324)

CODEN: BIDRF ISSN: 1173-8804

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 130

7/3/32 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

07932003 EMBASE No: 1999405331  
Novel biologic approaches to the treatment of rheumatoid **arthritis**  
Sany J.  
Prof. J. Sany, Service d'Immuno-Rhumatologie, Hopital Lapeyronie, 34295  
Montpellier Cedex 2 France  
Revue du Rhumatisme (English Edition) ( REV. RHUM. ENGL. ED. ) (France)  
1999, 66/11 (548-559)  
CODEN: RRHUE ISSN: 1169-8446  
DOCUMENT TYPE: Journal; Conference Paper  
LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 73

7/3/33 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2000 Elsevier Science B.V. All rts. reserv.

07768530 EMBASE No: 1999247338  
What we have learned from trials of immunomodulatory agents in rheumatoid  
**arthritis**: Future directions  
Schulze-Koops H.; Burkhardt H.; Kalden J.R.  
Dr. H. Schulze-Koops, Department of Internal Medicine III, University of  
Erlangen-Nuremberg, Krankenhausstrasse 12, D-91054 Erlangen Germany  
Drugs of Today ( DRUGS TODAY ) (Spain) 1999, 35/4-5 (327-351)  
CODEN: MDACA ISSN: 0025-7656  
DOCUMENT TYPE: Journal; Conference Paper  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 172

7/3/28 (Item 28 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

07982165 BIOSIS NO.: 000042033563  
HUMANIZED MONOCLONAL ANTIBODY TREATMENT IN RHEUMATOID **ARTHRITIS**  
AUTHOR: KYLE V; RODDY J; HALE G; HAZLEMAN B L; WALDMANN H  
AUTHOR ADDRESS: RHEUMATOLOGY RESEARCH UNIT, ADDENBROOKE'S HOSPITAL,  
CAMBRIDGE, UK.  
JOURNAL: J RHEUMATOL 18 (11). 1991. 1737-1738.  
FULL JOURNAL NAME: Journal of Rheumatology  
CODEN: JRHUA  
RECORD TYPE: Citation  
LANGUAGE: ENGLISH

7/3/29 (Item 29 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

06744219 BIOSIS NO.: 000088053649  
BENEFICIAL EFFECT OF MONOCLONAL ANTIBODY TO INTERLEUKIN 2 RECEPTOR ON  
ACTIVATED T CELLS IN RHEUMATOID **ARTHRITIS**  
AUTHOR: KYLE V; COUGHLAN R J; TIGHE H; WALDMANN H; HAZLEMAN B L  
AUTHOR ADDRESS: RHEUMATOL. RES. UNIT., UNIT E6, ADDENBROOKE'S HOSP., HILLS  
ROAD, CAMBRIDGE CB2 2QQ.  
JOURNAL: ANN RHEUM DIS 48 (5). 1989. 428-429.  
FULL JOURNAL NAME: Annals of the Rheumatic Diseases  
CODEN: ARDIA  
RECORD TYPE: Abstract